678938 678939 678940 678941 678942 678943 678944 678945 678946 678947 678948 678949 678950 678951 678952

678953 678954 678955 679370 679371 679372 679373 679374 679375 679376 679377 679378 679379 679380 679381 679382 679383 679384 679385 679386 679387 679388 679389 684458 684459 684460 684461 684462

Age >= 60 years Age Have been insured with HBA for 12 months or longer Diagnostic or Lab Results Subjects at high-risk of subsequent development of heart failure Disease, Symptom and Sig comprising at least one of: Prior myocardial infarction (MI) without known left ventricular (LV) dysfunction Sig Disease, Symptom and Current active ischemic heart disease Disease, Symptom and Sig Prior Cerebrovascular Accident (CVA) Disease, Symptom and Sig Known valvular heart disease without known LV dysfunction Disease, Symptom and Sig Atrial fibrillation Disease, Symptom and Sig Ventricular arrhythmia resulting in syncope or pre-syncope Disease, Symptom and Sig Treated hypertension, of at least 2 years duration Disease, Symptom and Sig Treated Diabetes mellitus, of at least 2 years duration Disease, Symptom and Sig Estimated Glomerular Filtration Rate (eGFR) <50ml/min Diagnostic or Lab Results Exclusion Criteria: Disease, Symptom and Sig Known systolic or diastolic heart failure Disease, Symptom and Sig Symptoms suggestive of current heart failure. Disease, Symptom and Sig LV systolic or diastolic dysfunction on echocardiography or other objective imaging modality. Pharmaceutical Substance Medications for treatment of heart failure such as ACE inhibitors, angiotensin receptorPharmaceutical Substance blockers (ARBs), beta bloc Use of such medications for approved indications such as hypertension, post-MI management (without knownSig Disease, Symptom and LV Ages Eligible for Study: 18 Years and older Age Genders Eligible for Study: Both Gender Accepts Healthy Volunteers: No Special Characteristic of Pa Principal Inclusion Criteria: Male or female > or = 18 years old. Age Symptomatic CHF corresponding to NYHA class II-IV symptoms for at least 4 weeks prior randomization. Disease Stage LVEF < or = 40% Diagnostic or Lab Results Treatment with an optimal and stable dose of ACE inhibitor for at least 4 weeks prior to enrolment in the study. Therapy or Surgery Principal Exclusion Criteria: Treatment with an ARB within 8 weeks prior to randomization. Therapy or Surgery Known hypersensitivity to ARBs or ACE inhibitors. Allergy Creatinine clearance < 30 ml/min or serum creatinine > 221 Diagnostic or Lab Results Current serum potassium > or = 5.0 mmol/L or a history of marked ACE inhibitor or ARB induced hyperkalemia. Pharmaceutical Substance Known bilateral renal artery stenosis. Disease, Symptom and Sig Current symptomatic hypotension and/or systolic B.P Disease Stage < 90 mmHg. Diagnostic or Lab Results Decompensated heart failure described as hospitalization or I.V Disease Stage administration of medication in emergency room or heart failure clinic within 4 weeks Disease, Symptom and Sig Stroke, acute coronary syndrome, PCI within the last 4 weeks before randomization. Disease, Symptom and Sig Connective tissue disease or chronic inflammatory condition Disease, Symptom and Sig Acute inflammatory process such as an infection or gout attack in the last 2 weeks. Disease, Symptom and Sig Pregnant or lactating women or women of childbearing potential who are not protected from pregnancyActivitie Pregancy Related by an ac Age <18 and >80 Age Serum creatinine level > 2.5 mg per deciliter Diagnostic or Lab Results Serum potassium level > 5.0 mmol per liter Diagnostic or Lab Results Valvular heart disease amenable to surgical treatment Disease, Symptom and Sig Congenital heart disease Disease, Symptom and Sig

684463 684464 684465 684466 684467 684468 684469 684470 684471 684472 684473 684474 684475 705728 705729 705730 705731 705732 705733 705734 705735 705736 705737 705738 705739 765653 765654 765655 765656 765657 765658 765659 765660 765661 765662 765663 765664 799597 799598 799599 799600 799601 799602 799603

Unstable angina and/or acute myocardial infarction and/or coronary revascularization procedure within three Sig Disease, Symptom and mo Intravenous therapy with inotropic drugs within three months before enrolment Pharmaceutical Substance History of resuscitated ventricular fibrillation or tachycardia, unless these occurred within 24 hours of an acute m Disease, Symptom and Sig Chronic active hepatitis or cirrhosis Disease, Symptom and Sig Malignant neoplasm or any life threatening non cardiac disease Neoplasm Status History of hypersensitivity to study drug Allergy Pregnancy or lactating or childbearing age women who are not protected by an accepted method of contraceptio Pregancy Related Activitie History of drug abuse or alcohol abuse Addictive Behavior Legal incapacity and/or other circumstances rending the patient unable to understand Capacity scope and pos the nature, Evidence of uncooperative attitude Disease, Symptom and Sig Any condition other than heart failure that does not permit an optimal participation toDisease, Symptom and Sig the trial Participation to other RCTs during the last 3 months Disease, Symptom and Sig Treatment with: Lithium salts, Potassium sparing diuretics, oral positive inotropic drugs or any investigational dru Pharmaceutical Substance Ages Eligible for Study: 18 Years and older Age Genders Eligible for Study: Both Gender Accepts Healthy Volunteers: No Special Characteristic of Pa Inclusion Criteria: Disease, Symptom and Sig Ischemic heart disease Disease, Symptom and Sig Systolic lv dysfunction Pharmaceutical Substance Mild anemia Disease, Symptom and Sig Normal renal function Disease, Symptom and Sig Stable condition Disease, Symptom and Sig Exclusion Criteria: Disease, Symptom and Sig Pregnancy Pregancy Related Activitie Unstable condition Disease, Symptom and Sig Ages Eligible for Study: 18 Years to 80 Years Age Genders Eligible for Study: Both Gender Accepts Healthy Volunteers: No Special Characteristic of Pa Inclusion Criteria: Disease, Symptom and Sig Heart failure NYHA III-IV Disease Stage LVEF<35% Diagnostic or Lab Results QRS duration>150 ms Gender Chronic atrial fibrillation. Disease, Symptom and Sig Exclusion Criteria: Disease, Symptom and Sig Heart failure not related to systolic function Disease, Symptom and Sig Unstable angina pectoris, AMI, PCI or CABG within 2 month Disease, Symptom and Sig Inclusion in other studies Enrollment in other studie Ages Eligible for Study: 18 Years and older Age Genders Eligible for Study: Both Gender Accepts Healthy Volunteers: No Special Characteristic of Pa Inclusion Criteria: Disease, Symptom and Sig Subjects of both genders with mild to severe HF as defined as NHYA Class II to IV who also have an indication for Diagnostic or Lab Results Exclusion Criteria: Disease, Symptom and Sig Subject is post heart transplant or actively listed on the transplant list and reasonable probability (as defined by in Therapy or Surgery

799604 799605 799606 799607 799608 799609 799610 799611 799612 799613 1070066 1070067 1070068 1070069 1070070 1070071 1070072 1070073 1070074 1070075 1070076 1070077 1070078 1088513 1088514 1088515 1088516 1088517 1088518 1088519 1088520 1088521 1088522 1088523 1088524 1088525 1088526 1088527 1088528 1088529 1088530 1088531

Subject received a coronary artery bypass graft or valve surgery in last 90 days Therapy or Surgery Subject with a myocardial infarction (MI) in the last 40 days. Disease, Symptom and Sig Subject's life expectancy is less than one year in the opinion of the physician Life Expectancy Subject has severe Chronic Obstructive Pulmonary Disease (COPD), as determined by physician and documented Disease, Symptom and Sig Subject is listed for valve replacement/valve repair Diagnostic or Lab Results Subject has severe, primary pulmonary hypertension as determined by physician and documented in medical rec Disease, Symptom and Sig Subject with serum creatinine 2.5 mg/dL measured within 14 days prior to enrolment Diagnostic or Lab Results Subject on chronic renal dialysis Therapy or Surgery Subject on continuous or uninterrupted ( 2 stable infusions per week) infusion (inotropic) therapy for HF Therapy or Surgery Subject has complex and uncorrected Congenital Heart Disease Disease, Symptom and Sig Ages Eligible for Study: 80 Years and older Age Genders Eligible for Study: Both Gender Accepts Healthy Volunteers: No Special Characteristic of Pa Sampling Method: Non-Probability Sample Disease, Symptom and Sig Study Population Special Characteristic of Pa Defined population Special Characteristic of Pa Inclusion Criteria: Disease, Symptom and Sig acute dyspnea Disease, Symptom and Sig crackles on lung auscultation, Diagnostic or Lab Results hypoxemia, Disease, Symptom and Sig right-sided signs. Disease, Symptom and Sig Exclusion Criteria: Disease, Symptom and Sig no exclusion criteria Disease, Symptom and Sig Ages Eligible for Study: 18 Years and older Age Genders Eligible for Study: Both Gender Accepts Healthy Volunteers: No Special Characteristic of Pa Inclusion Criteria: Disease, Symptom and Sig Patients who are in sinus rhythm Organ or Tissue Status Patients who are on stable medical therapy Therapy or Surgery Patients who exhibit signs and symptoms of heart failure, NYHA Class II or III Disease Stage Patients who have experienced a hospitalization for decompensated heart failure Disease, Symptom and Sig treatment for pulmonary congestion or volume overload Disease, Symptom and Sig chronic treatment with a loop diuretic Pharmaceutical Substance or a BNP > 125 ng/l. Diagnostic or Lab Results Left ventricular ejection fraction 50% Diagnostic or Lab Results Exclusion Criteria: Disease, Symptom and Sig Patients with persistent atrial fibrillation or atrial flutter Disease, Symptom and Sig Patients who are in complete heart block Disease, Symptom and Sig Patients who have experienced a recent MI or have unstable angina or require cardiac Disease,or other procedur surgery Symptom and Sig Patients who have severe heart valve disease or valve replacement Disease, Symptom and Sig Patients with a contraindication for a pacemaker system Device Patients who have a neuromuscular, orthopedic or other non-cardiac condition that prevents patient from exerci Exercise

1088532 1088533 1088534 1237959 1237960 1237961 1237962 1237963 1237964 1237965 1237966 1237967 1237968 1237969 1237970 1237971 1237972 1237973 1237974 1237975 1237976 1237977 1237978 1237979 1237980 1237981 1237982 1237983 1278885 1278886 1278887 1278888 1278889 1278890 1278891 1278892 1278893 1278894 1278895 1278896 1278897 1278898 1278899

Patients who have infiltrative or hypertrophic cardiomyopathy Disease, Symptom and Sig Patients who have known severe pulmonary disease Disease, Symptom and Sig Patients with uncontrolled diabetes or blood pressure (SBP > 160 mmHg or DBP > 95 mmHg) Symptom and Sig Disease, Ages Eligible for Study: 18 Years to 85 Years Age Genders Eligible for Study: Both Gender Accepts Healthy Volunteers: No Special Characteristic of Pa Inclusion Criteria: Disease, Symptom and Sig Age of 18 to 85 years Age Symptomatic heart failure, NYHA class I to III Disease Stage Left ventricular ejection fraction < 0.40 Diagnostic or Lab Results Give written informed consent Consent Exclusion Criteria: Disease, Symptom and Sig Pregnant or lactating women Pregancy Related Activitie Women in reproductive years must have an active form of contraception (oral contraceptives, IUD, diaphragm, co Pregancy Related Activitie Heart failure as the results of any of the following conditions: active myocarditis Disease, Symptom and Sig congenital heart disease Disease, Symptom and Sig uncorrected, hemodynamically significant stenotic valvular disease Disease, Symptom and Sig NYHA functional class IV symptoms Disease Stage Current or previous treatment with a statin Patients with plasma LDL-C concentrations Disease, Symptom and Sig higher than 130 mg/dL an Ischemic cardiomyopathy Disease, Symptom and Sig Previous cardiovascular event (CVA, ACS event) Therapy or Surgery Known coronary artery disease Disease, Symptom and Sig Unstable angina Disease, Symptom and Sig Presence of any progressive systemic disease that would be expected to impact the patient's outcome over the t Disease, Symptom and Sig Uncorrected endocrine disorders including primary aldosteronism, pheochromocytoma, hyperthyroidism, hypoth Neoplasm Status Inherited disorders of lipid metabolism Disease, Symptom and Sig Evidence of significant renal disease (serum creatinine > 2.5 mg/dl), or hepatic disease Diagnostic or Lab Results (transaminase levels > thre Inability or unwillingness to cooperate with study or give written informed consent Consent Ages Eligible for Study: 18 Years and older Age Genders Eligible for Study: Both Gender Accepts Healthy Volunteers: No Special Characteristic of Pa Sampling Method: Non-Probability Sample Disease, Symptom and Sig Study Population Special Characteristic of Pa Heart failure patients needing CRT therapy Disease, Symptom and Sig Inclusion Criteria: Disease, Symptom and Sig NYHA Class III/IV Disease Stage Stable medical regimen Therapy or Surgery QRS greater than or equal to 130 ms Disease, Symptom and Sig LVEF less than or equal to 35% Diagnostic or Lab Results Exclusion Criteria: Disease, Symptom and Sig VT of transient or reversible causes Special Characteristic of Pa Incessant VT Disease, Symptom and Sig Currently implanted with a lead positioned through the coronary sinus (unless it is the SITUS OTW Surgery Therapy or LV lead)

1278900 1278901 1278902 1278903 1278904 1278906 1278907 1278908 1278909 1278910 1288358 1288359 1288360 1288361 1288362 1288363 1288364 1288365 1288366 1288367 1288368 1288369 1288370 1288371 1288372 1500399 1500400 1500401 1500402 1500403 1500404 1500405 1500406 1500407 1500408 1500409 1500410 1500411 1500412 1500413 1500414 1500415 1500416

Cardiac revascularization or angioplasty within the last month Therapy or Surgery Heart failure due to correctable valve disease Disease, Symptom and Sig Chronic, medially refractory AT Disease, Symptom and Sig Enrolled in another clinical study that may confound the results of this study Enrollment in other studie Life expectancy less than 6 months Life Expectancy Inability or refusal to provide informed consent Consent Unavailable for scheduled follow-up with the implanting practice Therapy or Surgery Sensitivity to 1 mg dexamethasone sodium phosphate Allergy Less than 18 years of age Age Pregnancy Pregancy Related Activitie Genders Eligible for Study: Both Gender Accepts Healthy Volunteers: No Special Characteristic of Pa Inclusion Criteria: Disease, Symptom and Sig Patients eligible for the study had objective evidence of systolic dysfunction (ejection fraction 40%), were >18 ye Disease, Symptom and Sig Exclusion Criteria: Disease, Symptom and Sig Patients were excluded for active viral myocarditis Disease, Symptom and Sig hemodynamically significant valvular heart disease Disease, Symptom and Sig hypertrophic cardiomyopathy, peripartum cardiomyopathy Disease, Symptom and Sig contra-indications to beta blocker (asthma or obstructive airway disease requiring scheduled bronchodilators or i Disease, Symptom and Sig supine blood pressure <85/50 Diagnostic or Lab Results second or third degree heart block) Disease, Symptom and Sig concomitant use of beta agonist, beta antagonist, or antiarrhythmic Pharmaceutical Substance unstable angina Disease, Symptom and Sig myocardial infarction or bypass surgery within 3 months Disease, Symptom and Sig or significant renal insufficiency (creatinine >2.5 mg/dL), liver disease (transaminase levels > 3 fold aboveResults Diagnostic or Lab laborato Ages Eligible for Study: 18 Years and older Age Genders Eligible for Study: Both Gender Accepts Healthy Volunteers: No Special Characteristic of Pa Inclusion Criteria: Disease, Symptom and Sig The patient has signed an Informed Consent Form/Patient Information Sheet for this study approved by the gove Capacity The patient is at least 18 years old at the time of consent Consent Left ventricular ejection fraction (LVEF) 35% as determined by the Investigator withinDiagnostic or Lab enrollme 3 weeks prior to Results Treated for at least 4 weeks with a beta blocker and an ACE inhibitor (and/or an ARB) unless not tolerated Pharmaceutical Substance If prescribed, diuretics must have been administered according to a consistent regimen for at least 4 weeks. Pharmaceutical Substance Diagnosed with heart failure for 3 months prior to enrollment Disease, Symptom and Sig Patient is considered to be an appropriate candidate for study enrollment as determined by theSymptom clinical Disease, patient's and Sig For female patients only: The patient is post menopausal ( 1 year) or sterilized, or if she is of childbearing potent Pregancy Related Activitie For male patients only: Male patients agree for the duration of the study and 10 weeksPregancy Relatedthe study after the end of Activitie Exclusion Criteria: Disease, Symptom and Sig Patient has been hospitalised for heart failure, acute coronary syndrome, myocardial infarction,Symptom and Sig Disease, coronary revascu Poorly controlled hypertension defined as blood pressure > 150/95 mmHg, documented on at least 2 separate oc Diagnostic or Lab Results The patient has a supine heart rate 100 beats per minute after 10 minutes of rest Diagnostic or Lab Results Patient has a troponin I at screening that is above the upper limit of normal Diagnostic or Lab Results

1500417 1500418 1500419 1500420 1500421 1500422 1500423 1500424 1500425 1500426 1500427 1500428 1500429 1500430 1500431 1518784 1518785 1518786 1518787 1518788 1518789 1518790 1518791 1518792 1518793 1518794 1518795 1518796 1518797 1518798 1518799 1518800 1518801 1518802 1518803 1518804 1518805 1518806 1518807 1518808 1518809 1518810 1518811 1518812

The patient has severe aortic or mitral stenosis Disease, Symptom and Sig The patient has active myocarditis Disease, Symptom and Sig clinically significant restrictive, constrictive, or hypertrophic obstructive cardiomyopathy Disease, Symptom and Sig clinically significant congenital heart disease Disease, Symptom and Sig history of major organ transplantation Therapy or Surgery The patient has Canadian Cardiovascular Society Class IV angina Address Patient is on chronic antiarrhythmic therapy, with the exception of amiodarone Pharmaceutical Substance Patient has impaired renal function defined as an estimated GFR 30 ml/min/1.73 m2 Diagnostic or Lab Results calculated by the Modifica Patient is currently taking, or has taken within 14 days prior to enrollment, a potent CYP3A4 inhibitor or food as l Pharmaceutical Substance Patient is currently taking, or has taken within 28 days prior to enrollment, a potent CYP3A4 inducer orSubstance Pharmaceutical food as lis The patient has hepatic impairment defined as a total bilirubin > 3 mg/dL, or an ALT or Diagnostic or Lab Resultslim AST > 2 times the upper Concomitant non-cardiovascular disease that is expected to reduce life expectancy to less than 1 year Life Expectancy The patient has received an investigational drug or device within 30 days or 5 half-lives, whichever is greater, of e Disease, Symptom and Sig Patient has, in the opinion of the Investigator, a condition that compromises the abilityCapacity of the subject to give writ The patient has had any prior treatment with CK-1827452 Therapy or Surgery Ages Eligible for Study: 18 Years and older Age Genders Eligible for Study: Both Gender Accepts Healthy Volunteers: No Special Characteristic of Pa Sampling Method: Probability Sample Disease, Symptom and Sig Study Population Special Characteristic of Pa Acutely Decompensated Systolic HF group: patients who are admitted to Albert Einstein Medical Center on the H Diagnostic or Lab Results Chronic HF on Dialysis group: patients at the dialysis center at Albert Einstein Medical Center. or Surgery Therapy Ambulatory Chronic HF group: patients who present to the Albert Einstein Medical Center HF clinic. Lab Results Diagnostic or Acutely Decompensated Diastolic HF group: patients who are admitted to Albert Einstein Medical or Lab Results H Diagnostic Center on the ACUTELY DECOMPENSATED SYSTOLIC HEART FAILURE Disease, Symptom and Sig Inclusion Criteria: Disease, Symptom and Sig Patients over the age of 18 and able to consent Consent NYHA Class III or IV Disease Stage EF 35% Diagnostic or Lab Results Diagnosis of acute congestive heart failure exacerbation by history or physical examination Disease, Symptom and Sig Ability to understand and willing to sign informed consent Patient Preference Willingness to follow-up for clinic visits at 30 days and 6 months Patient Preference Exclusion Criteria: Disease, Symptom and Sig Pacemaker Device Patients requiring and willing to sign informed consent Consent Unwillingness to provide consent Patient Preference CHRONIC HEART FAILURE on DIALYSIS GROUP Disease, Symptom and Sig Inclusion Criteria: Disease, Symptom and Sig Patients over the age of 18 and able to consent Consent NYHA Class II, III, or IV Disease Stage EF 35% with a screening echocardiogram Diagnostic or Lab Results Ability to understand and willing to sign informed consent Patient Preference Willingness to follow up at 30 days and 6 months via phone contact Patient Preference Exclusion Criteria: Disease, Symptom and Sig

1518813 1518814 1518815 1518816 1518817 1518818 1518819 1518820 1518821 1518822 1518823 1518824 1518825 1518826 1518827 1518828 1518829 1518830 1518831 1518832 1518833 1518834 1518835 1518836 1518837 1518838 1518839 1440833 1440834 1440835 1440836 1440837 1440838 1440839 1440840 1440841 1440842 1472712 1472713 1472714 1472715 1472716 1472717

Unwillingness to provide consent Patient Preference Pacemaker Device AMBULATORY CHRONIC HEART FAILURE GROUP Disease, Symptom and Sig Inclusion Criteria: Disease, Symptom and Sig Patients over the age of 18 and able to consent Consent NYHA Class II and III with an EF 35% Disease Stage Diagnosis of chronic heart failure and currently on optimal medical therapy, including ACE, or ARB, beta-blockers Pharmaceutical Substance Ability to understand and willing to sign informed consent Patient Preference Willingness to follow up as an outpatient at 30 days and 6 months Patient Preference Exclusion Criteria: Disease, Symptom and Sig Incapable of taking the 6-minute walk test due to any condition unrelated to heart failure Disease, Symptom and Sig Patients requiring chronic inotrope therapy Therapy or Surgery Pacemaker Device Symptoms of angina limiting exercise ability Disease, Symptom and Sig Unwillingness to provide consent Patient Preference ACUTELY DECOMPENSATED DIASTOLIC HEART FAILURE GROUP Disease, Symptom and Sig Inclusion Criteria: Disease, Symptom and Sig Patients over the age of 18 and able to consent Consent NYHA Class III or IV Disease Stage EF 45% Diagnostic or Lab Results Diagnosis of acute congestive heart failure exacerbation by history or physical examination Disease, Symptom and Sig Ability to understand and willing to sign informed consent Patient Preference Willingness to follow-up for clinic visits at 30 days and 6 months Patient Preference Exclusion Criteria: Disease, Symptom and Sig Pacemaker Device Patients requiring inotrope support on admission Device Unwillingness to provide consent Patient Preference Ages Eligible for Study: 18 Years and older Age Genders Eligible for Study: Both Gender Accepts Healthy Volunteers: No Special Characteristic of Pa Inclusion Criteria: Disease, Symptom and Sig hypertension requiring drug treatment Disease, Symptom and Sig Exclusion Criteria: Disease, Symptom and Sig significantly elevated blood pressure (severe hypertension) Disease, Symptom and Sig requiring 3 or more antihypertensive drugs Pharmaceutical Substance severe kidney disease Disease, Symptom and Sig Other protocol-defined inclusion/exclusion criteria may apply Disease, Symptom and Sig Ages Eligible for Study: 18 Years to 70 Years Age Genders Eligible for Study: Both Gender Accepts Healthy Volunteers: No Special Characteristic of Pa Inclusion Criteria: Disease, Symptom and Sig Mild to moderate essential hypertension : sitting diastolic blood pressure measured at Disease, Symptom and Sig Screening and Baseline(Da Subjects who agree to participate in this sudy and give written informed consent Consent

1472718 1472719 1472720 1472721 1472722 1472723 1472724 1472725 1472726 1472727 1472728 1472729 1472730 1472731 1472732 1472733 1472734 1472735 1472736 1472737 313431 313432 313433 313434 313435 313436 313437 313438 313439 313440 313441 313442 313443 313444 313445 313446 313447 313448 313449 313450

Subjects considered to understand the study, be cooperative, and able to be followed-up until the end of the stud Capacity Exclusion Criteria: Disease, Symptom and Sig The sitting DBP is less than 94mmHg or more than 115mmHg or severe hypertensive patient with sitting systolic b Pharmaceutical Substance Patients with secondary hypertension Disease, Symptom and Sig Patients with severe renal ( Creatinine more 1.5 times than upper limit of normal ), gastrointestinal, hematologic Disease, Symptom and Sig which might affect absorption, disposition, metabolism or excretion of the drug Disease, Symptom and Sig Patients with postural hypotension Disease, Symptom and Sig Patients with sever insulin dependent diabetes mellitus or uncontrolled diabetes mellitus(HbA1c>9%, regimenSig Disease, Symptom and ch Patients with a history of myocardial infarction, severe coronary artery disease or clinically significant heart failur Disease, Symptom and Sig Patients with consumptive disease, autoimmune disease, connective tissue disease Disease, Symptom and Sig Patients with a history of type B or C hepatitis Disease Stage Patients with HIV or hepatitis Disease, Symptom and Sig Patients with clinically significant laboratory abnormality Diagnostic or Lab Results Patients receiving any drugs known to affect blood pressure or medical treatments that can influence the blood p Pharmaceutical Substance Patients with allergy or contraindication to any angiotensin II receptor antagonists Allergy Female of childbearing potential who does not undergo hysterectomy or is not post-menopausalRelated Activitie Pregancy Patients judged to have a history of alcohol or drug abuse by the investigator Addictive Behavior Patients with average weight > +35% or <-15% in Modified Metropolitan Life InsuranceDiagnostic or Lab Results table Patients participated other clinical trial 3 months before Screening Enrollment in other studie Patients judged to be inappropriate for this study by the investigator with other reasons Disease, Symptom and Sig Ages Eligible for Study: 18 Years and older Age Genders Eligible for Study: Both Gender Accepts Healthy Volunteers: No Special Characteristic of Pa Inclusion Criteria: Disease, Symptom and Sig Age 18 or above Age Acute myocardial infarction within last 1-14 days (defined by typical electrocardiogramDiagnostic or Lab Results [ECG] changes and/or ele Left ventricular systolic dysfunction (LVSD) based on echocardiographic wall motion score index (WMSI) and left v Diagnostic or Lab Results Ability to give written informed consent Consent Exclusion Criteria: Disease, Symptom and Sig Clinical or radiological heart failure Disease, Symptom and Sig Established diabetes mellitus Disease, Symptom and Sig Current use of potassium (K)-sparing diuretics, clarithromycin, nefazodone, itraconazole, ketoconazole,Substance Pharmaceutical ritonavir, Serum creatinine > 220 mol/l Diagnostic or Lab Results Serum potassium > 5.0 mmol/l Diagnostic or Lab Results Pregnancy Pregancy Related Activitie Addisons disease Disease, Symptom and Sig MRI-incompatible (ferrous) sulphate prosthesis Diagnostic or Lab Results Claustrophobia (unable to tolerate MR environment) Disease, Symptom and Sig Concurrent use of phenytoin, carbamazepine, rifampicin or St Pharmaceutical Substance Johns Wort (reduce efficacy of eplerenone). Pharmaceutical Substance

age\Age Group\AGGP\C1114365 | 60\NUMERAL\\ | years\Temporal Concept\TMCO\C1561544 | have\\\ | been\\\ | insured\Intellectual Product\INPR\C1548605 | with\\\ | hba\Biologically Active Substance\BACS\C18257 subjects\Patient or Disabled Group\PODG\C2349001 | at\\\ | high\Quantitative Concept\QNCO\C1561958 | -\SYMBOL\\ | r comprising\Organic Chemical\ORCH\ | >=\SYMBOL\\ | one\Quantitative Concept\QNCO\C0205447 | of\\\ | :\\\ | prior\Hist current\Temporal Concept\TMCO\C1705970 | active\Functional Concept\FTCN\C2347179 | ischemic heart disease\Disease prior\History\\C0332152 | cerebrovascular accident\Disease or Syndrome\DSYN\C0038454 | (\\\ | cva\Therapeutic or Preve known\Qualitative Concept\QLCO\C0205309 | valvular heart disease\Disease or Syndrome\DSYN\C1963123 | without\NO\\ atrial fibrillation\Pathologic Function\PATF\C1963067 | ventricular arrhythmia\Pathologic Function\PATF\C1963277 | resulting in\Functional Concept\FTCN\C1546471 | syncope\Sig treated\Therapeutic or Preventive Procedure\TOPP\C1522326 | hypertension\Disease or Syndrome\DSYN\C1963138 | ,\\\ | treated\Therapeutic or Preventive Procedure\TOPP\C1522326 | diabetes mellitus\Disease or Syndrome\DSYN\C0011849 | ,\ estimated\Quantitative Concept\QNCO\C0750572 | glomerular filtration rate\Diagnostic Procedure\DIAP\C1561549 | (\\\ | exclusion criteria\NO\\C0680251 | known\Qualitative Concept\QLCO\C0205309 | systolic\Temporal Concept\TMCO\C0039155 | or\\\ | diastolic heart failure\D symptoms\Sign or Symptom\SOSY\C1457887 | suggestive of\Functional Concept\FTCN\C0332299 | current\Temporal Conce lv\Pharmacologic Substance\PHSU\C1881413 | systolic\Temporal Concept\TMCO\C0039155 | or\\\ | diastolic dysfunction\P medications\Pharmacologic Substance\PHSU\C0013227 | for\\\ | treatment\Therapeutic or Preventive Procedure\TOPP\C17 use of\Functional Concept\FTCN\C1947944 | such\\\ | medications\Pharmacologic Substance\PHSU\C0013227 | for\\\ | app ages\Age Group\AGGP\C1114365 | eligible\Idea or Concept\IDCN\C1548635 | for\\\ | study\Research Activity\RESA\C26033 genders\Organism Attribute\ORGA\C0079399 | eligible\Idea or Concept\IDCN\C1548635 | for\\\ | study\Research Activity\R accepts\Qualitative Concept\QLCO\C1548601 | healthy volunteers\Healthy Population\\null | :\\\ | no\NO\\C1549444 | principal\Qualitative Concept\QLCO\C0401925 | inclusion criteria\Qualitative Concept\QLCO\C1512693 | :\\\ | male\Organi symptomatic\Functional Concept\FTCN\C0231220 | chf\Disease or Syndrome\DSYN\C0018802 | corresponding\Quantitative lvef\Laboratory or Test Result\LBTR\C0428772 | <\SYMBOL\\ | or\\\ | =\SYMBOL\\ | 40\NUMERAL\\ | %\UNIT\\ | treatment\Therapeutic or Preventive Procedure\TOPP\C1705169 | with\\\ | an\\\ | optimal\\\ | and\\\ | stable\Qualitative principal\Qualitative Concept\QLCO\C0401925 | exclusion criteria\NO\\C0680251 | :\\\ | treatment\Therapeutic or Prevent known\Qualitative Concept\QLCO\C0205309 | hypersensitivity\Allergy\\C0520946 | to\\\ | arbs\Quantitative Concept\QNC creatinine clearance\Laboratory Procedure\LBPR\C0812399 | <\SYMBOL\\ | 30\NUMERAL\\ | ml\UNIT\\C1706380 | min\UN current\Temporal Concept\TMCO\C1705970 | serum potassium\Laboratory Procedure\LBPR\C0302353 | >\SYMBOL\\ | or\\ known\Qualitative Concept\QLCO\C0205309 | bilateral renal artery stenosis\Disease or Syndrome\DSYN\C0856760 | current\Temporal Concept\TMCO\C1705970 | symptomatic\Functional Concept\FTCN\C0231220 | hypotension\Finding\FND <\SYMBOL\\ | 90\NUMERAL\\ | mmhg.\UNIT\\C0439475 | decompensated\Qualitative Concept\QLCO\C0205434 | heart failure\Disease or Syndrome\DSYN\C0018801 | described\Ide administration of medication\Health Care Activity\HLCA\C0150270 | in\\\ | emergency room\Health Care Related Organizati stroke\Disease or Syndrome\DSYN\C0038454 | ,\\\ | acute coronary syndrome\Disease or Syndrome\DSYN\C0948089 | ,\\\ connective tissue disease\Disease or Syndrome\DSYN\C0009782 | or\\\ | chronic\Temporal Concept\TMCO\C1555457 | infl acute\Temporal Concept\TMCO\C1547295 | inflammatory\Sign or Symptom\SOSY\C0333348 | process\Phenomenon or Pro pregnant\Organism Function\ORGF\C0549206 | or\\\ | lactating\Organism Function\ORGF\C0376261 | women\Population G age\Age Group\AGGP\C1114365 | <\SYMBOL\\ | 18\NUMERAL\\ | and\\\ | >\SYMBOL\\ | 80\NUMERAL\\ | serum creatinine level\Laboratory or Test Result\LBTR\C0600061 | >\SYMBOL\\ | 2.5\NUMERAL\\ | mg\UNIT\\C2348270 | p serum potassium level\Laboratory Procedure\LBPR\C0302353 | >\SYMBOL\\ | 5.0\NUMERAL\\ | mmol\Quantitative Concep valvular heart disease\Disease or Syndrome\DSYN\C1963123 | amenable\\\ | to\\\ | surgical treatment\Therapeutic or Prev congenital heart disease\Disease or Syndrome\DSYN\C0152021 |

unstable angina\Disease or Syndrome\DSYN\C0002965 | and\\\ | or\\\ | acute myocardial infarction\Disease or Syndrome\D intravenous therapy\Therapeutic or Preventive Procedure\TOPP\C0455142 | with\\\ | inotropic\\\ | drugs\Pharmacologic Su history of\History\\C2004062 | resuscitated\Finding\FNDG\C2587207 | ventricular fibrillation\Disease or Syndrome\DSYN\C chronic active hepatitis\Disease or Syndrome\DSYN\C0520463 | or\\\ | cirrhosis\Disease or Syndrome\DSYN\C1623038 | malignant neoplasm\Neoplastic Process\NEOP\C1547218 | or\\\ | any\\\ | life threatening\Finding\FNDG\C1546953 | non\F history of\History\\C2004062 | hypersensitivity\Allergy\\C0520946 | to\\\ | study\Research Activity\RESA\C2603343 | drug\ pregnancy\Organism Function\ORGF\C0032961 | or\\\ | lactating\Organism Function\ORGF\C0376261 | or\\\ | childbearing history of\History\\C2004062 | drug\Pharmacologic Substance\PHSU\C1254351 | or\\\ | alcohol abuse\Behavior Problem\\n legal\Idea or Concept\IDCN\C1550727 | incapacity\Capacity\\ | and\\\ | or\\\ | other\Qualitative Concept\QLCO\C1996846 evidence of\Functional Concept\FTCN\C0332120 | uncooperative\Individual Behavior\INBE\C0424350 | attitude\Mental Pro any\\\ | condition\Sign or Symptom\SOSY\C1705253 | other\Qualitative Concept\QLCO\C1996846 | than\\\ | heart failure\ participation\Individual Behavior\INBE\C0679823 | to\\\ | other\Qualitative Concept\QLCO\C1996846 | rcts\\\ | during\Tem treatment\Therapeutic or Preventive Procedure\TOPP\C1705169 | with\\\ | :\\\ | lithium salts\Pharmacologic Substance\PH ages\Age Group\AGGP\C1114365 | eligible\Idea or Concept\IDCN\C1548635 | for\\\ | study\Research Activity\RESA\C26033 genders\Organism Attribute\ORGA\C0079399 | eligible\Idea or Concept\IDCN\C1548635 | for\\\ | study\Research Activity\R accepts\Qualitative Concept\QLCO\C1548601 | healthy volunteers\Healthy Population\\null | :\\\ | no\NO\\C1549444 | inclusion criteria\Qualitative Concept\QLCO\C1512693 | ischemic heart disease\Disease or Syndrome\DSYN\C0151744 | systolic\Temporal Concept\TMCO\C0039155 | lv\Pharmacologic Substance\PHSU\C1881413 | dysfunction\Pathologic Functi mild anemia\Finding\FNDG\C1858586 | normal renal function\Finding\FNDG\C0232805 | stable\Qualitative Concept\QLCO\C1547311 | condition\Sign or Symptom\SOSY\C1705253 | exclusion criteria\NO\\C0680251 | pregnancy\Organism Function\ORGF\C0032961 | unstable\Phenomenon or Process\PHPR\C1883468 | condition\Sign or Symptom\SOSY\C1705253 | ages\Age Group\AGGP\C1114365 | eligible\Idea or Concept\IDCN\C1548635 | for\\\ | study\Research Activity\RESA\C26033 genders\Organism Attribute\ORGA\C0079399 | eligible\Idea or Concept\IDCN\C1548635 | for\\\ | study\Research Activity\R accepts\Qualitative Concept\QLCO\C1548601 | healthy volunteers\Healthy Population\\null | :\\\ | no\NO\\C1549444 | inclusion criteria\Qualitative Concept\QLCO\C1512693 | heart failure\Disease or Syndrome\DSYN\C0018801 | nyha\Classification\CLAS\ | iii\Classification\CLAS\C1705160 | -\SYMBO lvef\Laboratory or Test Result\LBTR\C0428772 | <\SYMBOL\\ | 35\NUMERAL\\ | %\UNIT\\ | qrs duration\Organism Attribute\ORGA\C0429025 | >\SYMBOL\\ | 150\NUMERAL\\ | ms\Disease or Syndrome\DSYN\C2349 chronic atrial fibrillation\Disease or Syndrome\DSYN\C0694539 | exclusion criteria\NO\\C0680251 | heart failure\Disease or Syndrome\DSYN\C0018801 | not related\Idea or Concept\IDCN\C1546988 | to\\\ | systolic\Tempor unstable angina pectoris\Disease or Syndrome\DSYN\C0002965 | ,\\\ | ami\Disease or Syndrome\DSYN\C0027051 | ,\\\ | pc inclusion\Qualitative Concept\QLCO\C1512693 | in\\\ | other studies\Other Study\\null | ages\Age Group\AGGP\C1114365 | eligible\Idea or Concept\IDCN\C1548635 | for\\\ | study\Research Activity\RESA\C26033 genders\Organism Attribute\ORGA\C0079399 | eligible\Idea or Concept\IDCN\C1548635 | for\\\ | study\Research Activity\R accepts\Qualitative Concept\QLCO\C1548601 | healthy volunteers\Healthy Population\\null | :\\\ | no\NO\\C1549444 | inclusion criteria\Qualitative Concept\QLCO\C1512693 | subjects\Patient or Disabled Group\PODG\C2349001 | of\\\ | both\Quantitative Concept\QNCO\C1706086 | genders\Organ exclusion criteria\NO\\C0680251 | subject\Patient or Disabled Group\PODG\C2349001 | is\\\ | post\Temporal Concept\TMCO\C1704687 | heart transplant\Th

subject\Patient or Disabled Group\PODG\C2349001 | received\Qualitative Concept\QLCO\C1709850 | a\\\ | coronary artery subject\Patient or Disabled Group\PODG\C2349001 | with\\\ | a\\\ | myocardial infarction\Disease or Syndrome\DSYN\C00 subjects\Patient or Disabled Group\PODG\C2349001 | life expectancy\Group Attribute\GRPA\C0023671 | is\\\ | <\SYMBOL\ subject\Patient or Disabled Group\PODG\C2349001 | has\Qualitative Concept\QLCO\C2348947 | severe chronic obstructive subject\Patient or Disabled Group\PODG\C2349001 | is\\\ | listed\Conceptual Entity\CNCE\C0745732 | for\\\ | valve\Medic subject\Patient or Disabled Group\PODG\C2349001 | has\Qualitative Concept\QLCO\C2348947 | severe\Qualitative Concep subject\Patient or Disabled Group\PODG\C2349001 | with\\\ | serum creatinine\Laboratory Procedure\LBPR\C0201976 | subject\Patient or Disabled Group\PODG\C2349001 | on\\\ | chronic\Temporal Concept\TMCO\C1555457 | renal dialysis\Th subject\Patient or Disabled Group\PODG\C2349001 | on\\\ | continuous\Idea or Concept\IDCN\C0549178 | or\\\ | uninterr subject\Patient or Disabled Group\PODG\C2349001 | has\Qualitative Concept\QLCO\C2348947 | complex\Qualitative Conce ages\Age Group\AGGP\C1114365 | eligible\Idea or Concept\IDCN\C1548635 | for\\\ | study\Research Activity\RESA\C26033 genders\Organism Attribute\ORGA\C0079399 | eligible\Idea or Concept\IDCN\C1548635 | for\\\ | study\Research Activity\R accepts\Qualitative Concept\QLCO\C1548601 | healthy volunteers\Healthy Population\\null | :\\\ | no\NO\\C1549444 | sampling method\Intellectual Product\INPR\C0815259 | :\\\ | non\Functional Concept\FTCN\C1518422 | -\SYMBOL\\ | prob study population\Population Group\POPG\C2348561 | defined\\\ | population\Population Group\POPG\C1257890 | inclusion criteria\Qualitative Concept\QLCO\C1512693 | acute\Temporal Concept\TMCO\C1547295 | dyspnea\Sign or Symptom\SOSY\C0013404 | crackles\Sign or Symptom\SOSY\C0034642 | on\\\ | lung\Body Part Organ or Organ Component\\C1278908 | auscultation\D hypoxemia\Finding\FNDG\C0700292 | right\Body Substance\BDSU\C1552823 | -\SYMBOL\\ | sided\Spatial Concept\SPCO\C0441987 | signs\Finding\FNDG\C15616 exclusion criteria\NO\\C0680251 | no\NO\\C1549444 | exclusion criteria\NO\\C0680251 | ages\Age Group\AGGP\C1114365 | eligible\Idea or Concept\IDCN\C1548635 | for\\\ | study\Research Activity\RESA\C26033 genders\Organism Attribute\ORGA\C0079399 | eligible\Idea or Concept\IDCN\C1548635 | for\\\ | study\Research Activity\R accepts\Qualitative Concept\QLCO\C1548601 | healthy volunteers\Healthy Population\\null | :\\\ | no\NO\\C1549444 | inclusion criteria\Qualitative Concept\QLCO\C1512693 | patients\Patient or Disabled Group\PODG\C1705908 | who\\\ | are\\\ | in\\\ | sinus rhythm\Organ or Tissue Function\ORTF patients\Patient or Disabled Group\PODG\C1705908 | who\\\ | are\\\ | on\\\ | stable\Qualitative Concept\QLCO\C1547311 patients\Patient or Disabled Group\PODG\C1705908 | who\\\ | exhibit\Intellectual Product\INPR\C0015272 | signs and sym patients\Patient or Disabled Group\PODG\C1705908 | who\\\ | have\\\ | experienced\Mental Process\MENP\C0596545 | a treatment\Therapeutic or Preventive Procedure\TOPP\C1705169 | for\\\ | pulmonary congestion\Disease or Syndrome\DSY chronic\Temporal Concept\TMCO\C1555457 | treatment\Therapeutic or Preventive Procedure\TOPP\C1705169 | with\\\ | or\\\ | a\\\ | bnp\Gene or Genome\GNGM\C1417808 | >\SYMBOL\\ | 125\NUMERAL\\ | ng\UNIT\\C0694637 | l\UNIT\\C17 left ventricular ejection fraction\Laboratory or Test Result\LBTR\C0428772 | \\\ | 50\NUMERAL\\ | %\UNIT\\ | exclusion criteria\NO\\C0680251 | patients\Patient or Disabled Group\PODG\C1705908 | with\\\ | persistent atrial fibrillation\Pathologic Function\PATF\C2585 patients\Patient or Disabled Group\PODG\C1705908 | who\\\ | are\\\ | in\\\ | complete heart block\Disease or Syndrome\D patients\Patient or Disabled Group\PODG\C1705908 | who\\\ | have\\\ | experienced\Mental Process\MENP\C0596545 | a patients\Patient or Disabled Group\PODG\C1705908 | who\\\ | have\\\ | severe\Qualitative Concept\QLCO\C1561581 | hea patients\Patient or Disabled Group\PODG\C1705908 | with\\\ | a\\\ | contraindication\Qualitative Concept\QLCO\C154731 patients\Patient or Disabled Group\PODG\C1705908 | who\\\ | have\\\ | a\\\ | neuromuscular\Qualitative Concept\QLCO\C

patients\Patient or Disabled Group\PODG\C1705908 | who\\\ | have\\\ | infiltrative\Sign or Symptom\SOSY\ | or\\\ | hyper patients\Patient or Disabled Group\PODG\C1705908 | who\\\ | have\\\ | known\Qualitative Concept\QLCO\C0205309 | sev patients\Patient or Disabled Group\PODG\C1705908 | with\\\ | uncontrolled\Qualitative Concept\QLCO\C0205318 | diabet ages\Age Group\AGGP\C1114365 | eligible\Idea or Concept\IDCN\C1548635 | for\\\ | study\Research Activity\RESA\C26033 genders\Organism Attribute\ORGA\C0079399 | eligible\Idea or Concept\IDCN\C1548635 | for\\\ | study\Research Activity\R accepts\Qualitative Concept\QLCO\C1548601 | healthy volunteers\Healthy Population\\null | :\\\ | no\NO\\C1549444 | inclusion criteria\Qualitative Concept\QLCO\C1512693 | age\Age Group\AGGP\C1114365 | of\\\ | 18\NUMERAL\\ | to\\\ | 85\NUMERAL\\ | years\Temporal Concept\TMCO\C1561 symptomatic\Functional Concept\FTCN\C0231220 | heart failure\Disease or Syndrome\DSYN\C0018801 | ,\\\ | nyha class i\ left ventricular ejection fraction\Laboratory or Test Result\LBTR\C0428772 | <\SYMBOL\\ | 0.40\NUMERAL\\ | give\Functional Concept\FTCN\C1947972 | written\Finding\FNDG\C2584304 | informed consent\Regulation or Law\RNLW\C exclusion criteria\NO\\C0680251 | pregnant\Organism Function\ORGF\C0549206 | or\\\ | lactating\Organism Function\ORGF\C0376261 | women\Population G women\Population Group\POPG\C1555916 | in\\\ | reproductive\Organism Function\ORGF\C0748342 | years\Temporal Co heart failure\Disease or Syndrome\DSYN\C0018801 | as\\\ | the\\\ | results\Functional Concept\FTCN\C1546471 | of\\\ | a congenital heart disease\Disease or Syndrome\DSYN\C0152021 | uncorrected\\\ | ,\\\ | hemodynamically\Organ or Tissue Function\ORTF\ | significant\Qualitative Concept\QLCO\C1546944 nyha\Classification\CLAS\ | functional\Functional Concept\FTCN\C0542341 | class iv\Intellectual Product\INPR\C0441888 | s current\Temporal Concept\TMCO\C1705970 | or\\\ | previous\Temporal Concept\TMCO\C1552607 | treatment\Therapeut ischemic cardiomyopathy\Disease or Syndrome\DSYN\C0349782 | previous\Temporal Concept\TMCO\C1552607 | cardiovascular event\Finding\FNDG\C1320716 | (\\\ | cva\Therapeutic or Pr known\Qualitative Concept\QLCO\C0205309 | coronary artery disease\Disease or Syndrome\DSYN\C1956346 | unstable angina\Disease or Syndrome\DSYN\C0002965 | presence of\Finding\FNDG\C0392148 | any\\\ | progressive\Functional Concept\FTCN\C0205329 | systemic disease\Disease uncorrected\\\ | endocrine disorders\Disease or Syndrome\DSYN\C0014130 | including\Functional Concept\FTCN\C1552866 inherited\Functional Concept\FTCN\C0439660 | disorders of lipid metabolism\Disease or Syndrome\DSYN\C0154251 | evidence of\Functional Concept\FTCN\C0332120 | significant\Qualitative Concept\QLCO\C1546944 | renal disease\Disease o inability\Clinical Attribute\CLNA\ | or\\\ | unwillingness\Willing\\ | to\\\ | cooperate\Activity\ACTY\ | with\\\ | study\Resea ages\Age Group\AGGP\C1114365 | eligible\Idea or Concept\IDCN\C1548635 | for\\\ | study\Research Activity\RESA\C26033 genders\Organism Attribute\ORGA\C0079399 | eligible\Idea or Concept\IDCN\C1548635 | for\\\ | study\Research Activity\R accepts\Qualitative Concept\QLCO\C1548601 | healthy volunteers\Healthy Population\\null | :\\\ | no\NO\\C1549444 | sampling method\Intellectual Product\INPR\C0815259 | :\\\ | non\Functional Concept\FTCN\C1518422 | -\SYMBOL\\ | prob study population\Population Group\POPG\C2348561 | heart failure\Disease or Syndrome\DSYN\C0018801 | patients\Patient or Disabled Group\PODG\C1705908 | needing\Qualita inclusion criteria\Qualitative Concept\QLCO\C1512693 | nyha class iii\Classification\CLAS\C1882086 | iv\Classification\CLAS\C1706303 | stable\Qualitative Concept\QLCO\C1547311 | medical\Professional or Occupational Group\PROG\C1561579 | regimen\Ther qrs\\\ | >\SYMBOL\\ | or\\\ | =\SYMBOL\\ | 130\NUMERAL\\ | ms\Disease or Syndrome\DSYN\C2349943 | lvef\Laboratory or Test Result\LBTR\C0428772 | <\SYMBOL\\ | or\\\ | =\SYMBOL\\ | 35\NUMERAL\\ | %\UNIT\\ | exclusion criteria\NO\\C0680251 | vt\Pathologic Function\PATF\C0042537 | of\\\ | transient\Population Group\POPG\C1550450 | or\\\ | reversible\Functiona incessant\\\ | vt\Pathologic Function\PATF\C0042537 | currently\Temporal Concept\TMCO\C0521116 | implanted\Therapeutic or Preventive Procedure\TOPP\C1705604 | with\\\ |

cardiac\Body Part Organ or Organ Component\\C1522601 | revascularization\Therapeutic or Preventive Procedure\TOPP\C0 heart failure\Disease or Syndrome\DSYN\C0018801 | due to\Functional Concept\FTCN\C0678226 | correctable\\\ | valve\M chronic\Temporal Concept\TMCO\C1555457 | ,\\\ | medially\\\ | refractory\Functional Concept\FTCN\C0205269 | enrolled in another\Other Study\\null | clinical study\Research Activity\RESA\C0008972 | that\\\ | may\\\ | confound\\\ | th life expectancy\Group Attribute\GRPA\C0023671 | <\SYMBOL\\ | 6\NUMERAL\\ | months\Temporal Concept\TMCO\C1561 inability\Clinical Attribute\CLNA\ | or\\\ | refusal\Idea or Concept\IDCN\C1569452 | to\\\ | provide\Functional Concept\FTC unavailable\Functional Concept\FTCN\C0686905 | for\\\ | scheduled\Health Care Activity\HLCA\C1571999 | follow\Tempor sensitivity\Allergy\\C2349185 | to\\\ | 1\NUMERAL\\ | mg\UNIT\\C2348270 | dexamethasone sodium phosphate\Pharmaco <\SYMBOL\\ | 18\NUMERAL\\ | years\Temporal Concept\TMCO\C1561544 | of\\\ | age\Age Group\AGGP\C1114365 | pregnancy\Organism Function\ORGF\C0032961 | genders\Organism Attribute\ORGA\C0079399 | eligible\Idea or Concept\IDCN\C1548635 | for\\\ | study\Research Activity\R accepts\Qualitative Concept\QLCO\C1548601 | healthy volunteers\Healthy Population\\null | :\\\ | no\NO\\C1549444 | inclusion criteria\Qualitative Concept\QLCO\C1512693 | patients\Patient or Disabled Group\PODG\C1705908 | eligible\Idea or Concept\IDCN\C1548635 | for\\\ | the\\\ | study\Res exclusion criteria\NO\\C0680251 | patients\Patient or Disabled Group\PODG\C1705908 | were\\\ | excluded\NO\\C1554077 | for\\\ | active\Functional Conce hemodynamically\Organ or Tissue Function\ORTF\ | significant\Qualitative Concept\QLCO\C1546944 | valvular heart disease hypertrophic cardiomyopathy\Disease or Syndrome\DSYN\C0007194 | ,\\\ | peripartum cardiomyopathy\Pathologic Functio contra\\\ | -\SYMBOL\\ | indications\Idea or Concept\IDCN\C0392360 | to\\\ | beta\Qualitative Concept\QLCO\C2004068 | supine\Spatial Concept\SPCO\C0038846 | blood pressure\Clinical Attribute\CLNA\C1272641 | <\SYMBOL\\ | 85\NUMERAL\\ second\Idea or Concept\IDCN\C2348168 | or\\\ | third degree heart block\Disease or Syndrome\DSYN\C0151517 | concomitant\Temporal Concept\TMCO\C0521115 | use of\Functional Concept\FTCN\C1947944 | beta\Qualitative Concept\ unstable angina\Disease or Syndrome\DSYN\C0002965 | myocardial infarction\Disease or Syndrome\DSYN\C0027051 | or\\\ | bypass surgery\Therapeutic or Preventive Procedure\T or\\\ | significant\Qualitative Concept\QLCO\C1546944 | renal insufficiency\Disease or Syndrome\DSYN\C1565489 | (\\\ | c ages\Age Group\AGGP\C1114365 | eligible\Idea or Concept\IDCN\C1548635 | for\\\ | study\Research Activity\RESA\C26033 genders\Organism Attribute\ORGA\C0079399 | eligible\Idea or Concept\IDCN\C1548635 | for\\\ | study\Research Activity\R accepts\Qualitative Concept\QLCO\C1548601 | healthy volunteers\Healthy Population\\null | :\\\ | no\NO\\C1549444 | inclusion criteria\Qualitative Concept\QLCO\C1512693 | the\\\ | patient\Patient or Disabled Group\PODG\C1705908 | has\Qualitative Concept\QLCO\C2348947 | signed\Finding\FN the\\\ | patient\Patient or Disabled Group\PODG\C1705908 | is\\\ | >=\SYMBOL\\ | 18\NUMERAL\\ | years\Temporal Conc left ventricular ejection fraction\Laboratory or Test Result\LBTR\C0428772 | (\\\ | lvef\Laboratory or Test Result\LBTR\C042 treated for\Therapeutic or Preventive Procedure\TOPP\C1522326 | >=\SYMBOL\\ | 4\NUMERAL\\ | weeks\Temporal Conce if\\\ | prescribed\Health Care Activity\HLCA\C0278329 | ,\\\ | diuretics\Pharmacologic Substance\PHSU\C0012798 | must\\ diagnosed\Diagnostic Procedure\DIAP\C0011900 | with\\\ | heart failure\Disease or Syndrome\DSYN\C0018801 | for\\\ | patient\Patient or Disabled Group\PODG\C1705908 | is\\\ | considered\Idea or Concept\IDCN\ | to\\\ | be\\\ | an\\\ | appr for\\\ | female\Organism Attribute\ORGA\C1705498 | patients\Patient or Disabled Group\PODG\C1705908 | only\Quantita for\\\ | male\Organism Attribute\ORGA\C1706429 | patients\Patient or Disabled Group\PODG\C1705908 | only\Quantitativ exclusion criteria\NO\\C0680251 | patient\Patient or Disabled Group\PODG\C1705908 | has\Qualitative Concept\QLCO\C2348947 | been\\\ | hospitalised\Hea poorly\Qualitative Concept\QLCO\C0205169 | controlled\Functional Concept\FTCN\C2587213 | hypertension\Disease or Syn the\\\ | patient\Patient or Disabled Group\PODG\C1705908 | has\Qualitative Concept\QLCO\C2348947 | a\\\ | supine\Spat patient\Patient or Disabled Group\PODG\C1705908 | has\Qualitative Concept\QLCO\C2348947 | a\\\ | troponin i\Biological

the\\\ | patient\Patient or Disabled Group\PODG\C1705908 | has\Qualitative Concept\QLCO\C2348947 | severe\Qualitative the\\\ | patient\Patient or Disabled Group\PODG\C1705908 | has\Qualitative Concept\QLCO\C2348947 | active\Functional clinically\Qualitative Concept\QLCO\ | significant\Qualitative Concept\QLCO\C1546944 | restrictive\\\ | ,\\\ | constrictive\\\ clinically\Qualitative Concept\QLCO\ | significant\Qualitative Concept\QLCO\C1546944 | congenital heart disease\Disease o history of\History\\C2004062 | major\Qualitative Concept\QLCO\C0205164 | organ transplantation\Therapeutic or Preventi the\\\ | patient\Patient or Disabled Group\PODG\C1705908 | has\Qualitative Concept\QLCO\C2348947 | canadian\Geograp patient\Patient or Disabled Group\PODG\C1705908 | is\\\ | on\\\ | chronic\Temporal Concept\TMCO\C1555457 | anti\Ther patient\Patient or Disabled Group\PODG\C1705908 | has\Qualitative Concept\QLCO\C2348947 | impaired renal function\Di patient\Patient or Disabled Group\PODG\C1705908 | is\\\ | currently\Temporal Concept\TMCO\C0521116 | taking\Activity\ patient\Patient or Disabled Group\PODG\C1705908 | is\\\ | currently\Temporal Concept\TMCO\C0521116 | taking\Activity\ the\\\ | patient\Patient or Disabled Group\PODG\C1705908 | has\Qualitative Concept\QLCO\C2348947 | hepatic impairmen concomitant\Temporal Concept\TMCO\C0521115 | non\Functional Concept\FTCN\C1518422 | -\SYMBOL\\ | cardiovascular the\\\ | patient\Patient or Disabled Group\PODG\C1705908 | has\Qualitative Concept\QLCO\C2348947 | received\Qualitati patient\Patient or Disabled Group\PODG\C1705908 | has\Qualitative Concept\QLCO\C2348947 | ,\\\ | in\\\ | the\\\ | opinio the\\\ | patient\Patient or Disabled Group\PODG\C1705908 | has\Qualitative Concept\QLCO\C2348947 | had\\\ | any\\\ | p ages\Age Group\AGGP\C1114365 | eligible\Idea or Concept\IDCN\C1548635 | for\\\ | study\Research Activity\RESA\C26033 genders\Organism Attribute\ORGA\C0079399 | eligible\Idea or Concept\IDCN\C1548635 | for\\\ | study\Research Activity\R accepts\Qualitative Concept\QLCO\C1548601 | healthy volunteers\Healthy Population\\null | :\\\ | no\NO\\C1549444 | sampling method\Intellectual Product\INPR\C0815259 | :\\\ | probability sample\Quantitative Concept\QNCO\C0033206 | study population\Population Group\POPG\C2348561 | acutely\Temporal Concept\TMCO\ | decompensated\Qualitative Concept\QLCO\C0205434 | systolic\Temporal Concept\TM chronic\Temporal Concept\TMCO\C1555457 | hf\Gene or Genome\GNGM\C1538440 | on\\\ | dialysis\Therapeutic or Preve ambulatory\Biomedical Occupation or Discipline\BMOD\C1561561 | chronic\Temporal Concept\TMCO\C1555457 | hf\Gene acutely\Temporal Concept\TMCO\ | decompensated\Qualitative Concept\QLCO\C0205434 | diastolic\Clinical Attribute\CLN acutely\Temporal Concept\TMCO\ | decompensated\Qualitative Concept\QLCO\C0205434 | systolic heart failure\Disease o inclusion criteria\Qualitative Concept\QLCO\C1512693 | patients\Patient or Disabled Group\PODG\C1705908 | over\Spatial Concept\SPCO\C0205136 | the\\\ | age\Age Group\AGG nyha class iii\Classification\CLAS\C1882086 | or\\\ | iv\Classification\CLAS\C1706303 | ef\\\ | 35\NUMERAL\\ | %\UNIT\\ | diagnosis\Health Care Activity\HLCA\C1704656 | of\\\ | acute congestive heart failure\Disease or Syndrome\DSYN\C026471 ability to understand\Mental Process\MENP\C1273101 | and\\\ | willing\Willing\\ | to\\\ | sign\Finding\FNDG\C1561610 | i willingness\Willing\\ | to\\\ | follow\Temporal Concept\TMCO\C1719822 | -\SYMBOL\\ | up\Spatial Concept\SPCO\C128291 exclusion criteria\NO\\C0680251 | pacemaker\Medical Device\MEDD\C1546728 | patients\Patient or Disabled Group\PODG\C1705908 | requiring\Functional Concept\FTCN\C1619636 | and\\\ | willing\Willi unwillingness\Willing\\ | to\\\ | provide\Functional Concept\FTCN\C0359589 | consent\Regulation or Law\RNLW\C1554192 chronic heart failure\Disease or Syndrome\DSYN\C0264716 | on\\\ | dialysis\Therapeutic or Preventive Procedure\TOPP\C1 inclusion criteria\Qualitative Concept\QLCO\C1512693 | patients\Patient or Disabled Group\PODG\C1705908 | over\Spatial Concept\SPCO\C0205136 | the\\\ | age\Age Group\AGG nyha class ii\Finding\FNDG\C1882085 | ,\\\ | iii\Classification\CLAS\C1705160 | ,\\\ | or\\\ | iv\Classification\CLAS\C170630 ef\\\ | \\\ | 35\NUMERAL\\ | %\UNIT\\ | with\\\ | a\\\ | screening\Laboratory Procedure\LBPR\C1710031 | echocardio ability to understand\Mental Process\MENP\C1273101 | and\\\ | willing\Willing\\ | to\\\ | sign\Finding\FNDG\C1561610 | i willingness\Willing\\ | to\\\ | follow up\Health Care Activity\HLCA\null | at\\\ | 30\NUMERAL\\ | days\Temporal Concept\TM exclusion criteria\NO\\C0680251 |

unwillingness\Willing\\ | to\\\ | provide\Functional Concept\FTCN\C0359589 | consent\Regulation or Law\RNLW\C1554192 pacemaker\Medical Device\MEDD\C1546728 | ambulatory\Biomedical Occupation or Discipline\BMOD\C1561561 | chronic heart failure\Disease or Syndrome\DSYN\C0264 inclusion criteria\Qualitative Concept\QLCO\C1512693 | patients\Patient or Disabled Group\PODG\C1705908 | over\Spatial Concept\SPCO\C0205136 | the\\\ | age\Age Group\AGG nyha class ii\Finding\FNDG\C1882085 | and\\\ | iii\Classification\CLAS\C1705160 | with\\\ | an\\\ | ef\\\ | \\\ | 35\NU diagnosis\Health Care Activity\HLCA\C1704656 | of\\\ | chronic heart failure\Disease or Syndrome\DSYN\C0264716 | and\\\ ability to understand\Mental Process\MENP\C1273101 | and\\\ | willing\Willing\\ | to\\\ | sign\Finding\FNDG\C1561610 | i willingness\Willing\\ | to\\\ | follow up\Health Care Activity\HLCA\null | as\\\ | an\\\ | outpatient\Patient or Disabled Group exclusion criteria\NO\\C0680251 | incapable\Idea or Concept\IDCN\C1550518 | of\\\ | taking\Activity\ACTY\C1883727 | the\\\ | 6\NUMERAL\\ | -\SYMBOL\\ | patients\Patient or Disabled Group\PODG\C1705908 | requiring\Functional Concept\FTCN\C1619636 | chronic\Temporal Co pacemaker\Medical Device\MEDD\C1546728 | symptoms\Sign or Symptom\SOSY\C1457887 | of\\\ | angina\Disease or Syndrome\DSYN\C0002962 | limiting\Functional Co unwillingness\Willing\\ | to\\\ | provide\Functional Concept\FTCN\C0359589 | consent\Regulation or Law\RNLW\C1554192 acutely\Temporal Concept\TMCO\ | decompensated\Qualitative Concept\QLCO\C0205434 | diastolic heart failure\Disease o inclusion criteria\Qualitative Concept\QLCO\C1512693 | patients\Patient or Disabled Group\PODG\C1705908 | over\Spatial Concept\SPCO\C0205136 | the\\\ | age\Age Group\AGG nyha class iii\Classification\CLAS\C1882086 | or\\\ | iv\Classification\CLAS\C1706303 | ef\\\ | \\\ | 45\NUMERAL\\ | %\UNIT\\ | diagnosis\Health Care Activity\HLCA\C1704656 | of\\\ | acute congestive heart failure\Disease or Syndrome\DSYN\C026471 ability to understand\Mental Process\MENP\C1273101 | and\\\ | willing\Willing\\ | to\\\ | sign\Finding\FNDG\C1561610 | i willingness\Willing\\ | to\\\ | follow\Temporal Concept\TMCO\C1719822 | -\SYMBOL\\ | up\Spatial Concept\SPCO\C128291 exclusion criteria\NO\\C0680251 | pacemaker\Medical Device\MEDD\C1546728 | patients\Patient or Disabled Group\PODG\C1705908 | requiring\Functional Concept\FTCN\C1619636 | inotrope\\\ | suppor unwillingness\Willing\\ | to\\\ | provide\Functional Concept\FTCN\C0359589 | consent\Regulation or Law\RNLW\C1554192 ages\Age Group\AGGP\C1114365 | eligible\Idea or Concept\IDCN\C1548635 | for\\\ | study\Research Activity\RESA\C26033 genders\Organism Attribute\ORGA\C0079399 | eligible\Idea or Concept\IDCN\C1548635 | for\\\ | study\Research Activity\R accepts\Qualitative Concept\QLCO\C1548601 | healthy volunteers\Healthy Population\\null | :\\\ | no\NO\\C1549444 | inclusion criteria\Qualitative Concept\QLCO\C1512693 | hypertension\Disease or Syndrome\DSYN\C1963138 | requiring\Functional Concept\FTCN\C1619636 | drug\Pharmacologic S exclusion criteria\NO\\C0680251 | significantly\Qualitative Concept\QLCO\ | elevated blood pressure\Finding\FNDG\C0497247 | (\\\ | severe\Qualitative Conc requiring\Functional Concept\FTCN\C1619636 | 3\NUMERAL\\ | or\\\ | more\\\ | antihypertensive drugs\Pharmacologic Su severe\Qualitative Concept\QLCO\C1561581 | kidney disease\Disease or Syndrome\DSYN\C0022658 | other\Qualitative Concept\QLCO\C1996846 | protocol\Qualitative Concept\QLCO\C2349977 | -\SYMBOL\\ | defined\\\ | inc ages\Age Group\AGGP\C1114365 | eligible\Idea or Concept\IDCN\C1548635 | for\\\ | study\Research Activity\RESA\C26033 genders\Organism Attribute\ORGA\C0079399 | eligible\Idea or Concept\IDCN\C1548635 | for\\\ | study\Research Activity\R accepts\Qualitative Concept\QLCO\C1548601 | healthy volunteers\Healthy Population\\null | :\\\ | no\NO\\C1549444 | inclusion criteria\Qualitative Concept\QLCO\C1512693 | mild to moderate\Qualitative Concept\QLCO\C1299392 | essential hypertension\Disease or Syndrome\DSYN\C0085580 | :\\ subjects\Patient or Disabled Group\PODG\C2349001 | who\\\ | agree\Willing\\ | to\\\ | participate\Functional Concept\FTC

subjects\Patient or Disabled Group\PODG\C2349001 | considered\Idea or Concept\IDCN\ | to\\\ | understand\Mental Proce exclusion criteria\NO\\C0680251 | the\\\ | sitting\Educational Activity\EDAC\C1705188 | dbp\Pharmacologic Substance\PHSU\C1704663 | is\\\ | <\SYMBOL\\ patients\Patient or Disabled Group\PODG\C1705908 | with\\\ | secondary hypertension\Disease or Syndrome\DSYN\C0155 patients\Patient or Disabled Group\PODG\C1705908 | with\\\ | severe\Qualitative Concept\QLCO\C1561581 | renal\Body P which\\\ | might\\\ | affect\Functional Concept\FTCN\C1314939 | absorption\Natural Phenomenon or Process\NPOP\C2347 patients\Patient or Disabled Group\PODG\C1705908 | with\\\ | postural hypotension\Finding\FNDG\C0020651 | patients\Patient or Disabled Group\PODG\C1705908 | with\\\ | sever\Activity\ACTY\ | insulin dependent diabetes mellitus\D patients\Patient or Disabled Group\PODG\C1705908 | with\\\ | a\\\ | history of\History\\C2004062 | myocardial infarction\ patients\Patient or Disabled Group\PODG\C1705908 | with\\\ | consumptive\\\ | disease\Disease or Syndrome\DSYN\C001 patients\Patient or Disabled Group\PODG\C1705908 | with\\\ | a\\\ | history of\History\\C2004062 | type\Health Care Acti patients\Patient or Disabled Group\PODG\C1705908 | with\\\ | hiv\Virus\VIRS\C0086413 | or\\\ | hepatitis\Disease or Synd patients\Patient or Disabled Group\PODG\C1705908 | with\\\ | clinically\Qualitative Concept\QLCO\ | significant\Qualitativ patients\Patient or Disabled Group\PODG\C1705908 | receiving\Qualitative Concept\QLCO\C1709850 | any\\\ | drugs\Phar patients\Patient or Disabled Group\PODG\C1705908 | with\\\ | allergy\Allergy\\C1611280 | or\\\ | contraindication to\Qua female\Organism Attribute\ORGA\C1705498 | of\\\ | childbearing\Organism Function\ORGF\ | potential\Qualitative Concep patients\Patient or Disabled Group\PODG\C1705908 | judged\Professional or Occupational Group\PROG\C0221191 | to\\\ | patients\Patient or Disabled Group\PODG\C1705908 | with\\\ | average\Quantitative Concept\QNCO\C1510992 | weight\C patients\Patient or Disabled Group\PODG\C1705908 | participated\Functional Concept\FTCN\C0679823 | other clinical trial\ patients\Patient or Disabled Group\PODG\C1705908 | judged\Professional or Occupational Group\PROG\C0221191 | to\\\ | ages\Age Group\AGGP\C1114365 | eligible\Idea or Concept\IDCN\C1548635 | for\\\ | study\Research Activity\RESA\C26033 genders\Organism Attribute\ORGA\C0079399 | eligible\Idea or Concept\IDCN\C1548635 | for\\\ | study\Research Activity\R accepts\Qualitative Concept\QLCO\C1548601 | healthy volunteers\Healthy Population\\null | :\\\ | no\NO\\C1549444 | inclusion criteria\Qualitative Concept\QLCO\C1512693 | age\Age Group\AGGP\C1114365 | 18\NUMERAL\\ | or\\\ | above\Spatial Concept\SPCO\C1552828 | acute myocardial infarction\Disease or Syndrome\DSYN\C1521999 | within\Quantitative Concept\QNCO\C0332285 | last\Qu left ventricular systolic dysfunction\Pathologic Function\PATF\C1963159 | (\\\ | lvsd\\\ | )\\\ | based\Functional Concept\FT ability\Capacity\\C0085732 | to\\\ | give\Functional Concept\FTCN\C1947972 | written\Finding\FNDG\C2584304 | informed exclusion criteria\NO\\C0680251 | clinical\Qualitative Concept\QLCO\C1611832 | or\\\ | radiological\Therapeutic or Preventive Procedure\TOPP\ | heart failur established\Qualitative Concept\QLCO\C1272684 | diabetes mellitus\Disease or Syndrome\DSYN\C0011849 | current\Temporal Concept\TMCO\C1705970 | use of\Functional Concept\FTCN\C1947944 | potassium\Laboratory Procedur serum creatinine\Laboratory Procedure\LBPR\C0201976 | >\SYMBOL\\ | 220\NUMERAL\\ | mol\\\ | l\UNIT\\C1706496 | serum potassium\Laboratory Procedure\LBPR\C0302353 | >\SYMBOL\\ | 5.0\NUMERAL\\ | mmol\Quantitative Concept\QN pregnancy\Organism Function\ORGF\C0032961 | addisons\\\ | disease\Disease or Syndrome\DSYN\C0012634 | mri\Diagnostic Procedure\DIAP\C0881820 | -\SYMBOL\\ | incompatible\Qualitative Concept\QLCO\ | (\\\ | ferrous\Element claustrophobia\Mental or Behavioral Dysfunction\MOBD\C0008909 | (\\\ | unable\Capacity\\C1299582 | to\\\ | tolerate\\\ concurrent\Temporal Concept\TMCO\C0205420 | use of\Functional Concept\FTCN\C1947944 | phenytoin\Pharmacologic Su johns\\\ | wort\\\ | (\\\ | reduce\Qualitative Concept\QLCO\C0392756 | efficacy\\\ | of\\\ | eplerenone\Pharmacologic

age >=60 years Inclusion http://ClinicalTrials.gov/show/NCT00400257 Evaluation ofNo Results Available Heart Fail 47941 NCT00400257 Screening Recruiting the Evolution of New have been insured with hba for 12 http://ClinicalTrials.gov/show/NCT00400257 Evaluation ofNo Results Available Heart Fail Inclusion months or longer 47941 NCT00400257 Screening Recruiting the Evolution of New subjects at high-risk of subsequenthttp://ClinicalTrials.gov/show/NCT00400257 Evaluation ofNo Results Available Heart Fail Inclusion development of47941 failure heart NCT00400257 Screening Recruiting the Evolution of New comprising Inclusion prior myocardial infarction (mi) without known Screening Evaluation ofNo Results Available Heart Fail >= one of: http://ClinicalTrials.gov/show/NCT00400257 Recruiting the Evolution of New 47941 NCT00400257 ventricular (lv) dysfunction left current active ischemic heart disease Inclusion http://ClinicalTrials.gov/show/NCT00400257 Evaluation ofNo Results Available Heart Fail 47941 NCT00400257 Screening Recruiting the Evolution of New prior cerebrovascular accident (cva) Inclusion http://ClinicalTrials.gov/show/NCT00400257 Evaluation ofNo Results Available Heart Fail 47941 NCT00400257 Screening Recruiting the Evolution of New known valvular heart disease without known lv dysfunction Inclusion http://ClinicalTrials.gov/show/NCT00400257 Evaluation ofNo Results Available Heart Fail 47941 NCT00400257 Screening Recruiting the Evolution of New atrial fibrillation Inclusion http://ClinicalTrials.gov/show/NCT00400257 Evaluation ofNo Results Available Heart Fail 47941 NCT00400257 Screening Recruiting the Evolution of New ventricular arrhythmia resulting in http://ClinicalTrials.gov/show/NCT00400257 Evaluation ofNo Results Available Heart Fail Inclusion syncope or pre-syncope 47941 NCT00400257 Screening Recruiting the Evolution of New treated hypertension, of >= 2 years duration Inclusion http://ClinicalTrials.gov/show/NCT00400257 Evaluation ofNo Results Available Heart Fail 47941 NCT00400257 Screening Recruiting the Evolution of New treated diabetes mellitus, of >= 2 years duration 47941 NCT00400257 Inclusion http://ClinicalTrials.gov/show/NCT00400257 Evaluation ofNo Results Available Heart Fail Screening Recruiting the Evolution of New estimated glomerular filtration rate (egfr) <50 ml / 47941 NCT00400257 Inclusion http://ClinicalTrials.gov/show/NCT00400257 Evaluation ofNo Results Available Heart Fail min Screening Recruiting the Evolution of New exclusion criteria: Exclusion http://ClinicalTrials.gov/show/NCT00400257 Evaluation ofNo Results Available Heart Fail 47941 NCT00400257 Screening Recruiting the Evolution of New known systolic or diastolic heart failure Exclusion http://ClinicalTrials.gov/show/NCT00400257 Evaluation ofNo Results Available Heart Fail 47941 NCT00400257 Screening Recruiting the Evolution of New symptoms suggestive of current heart failure. Exclusion http://ClinicalTrials.gov/show/NCT00400257 Evaluation ofNo Results Available Heart Fail 47941 NCT00400257 Screening Recruiting the Evolution of New lv systolic or diastolic dysfunction on echocardiography or NCT00400257 imaging modality. No Results Available Heart Fail Exclusion http://ClinicalTrials.gov/show/NCT00400257 Evaluation of the Evolution of New 47941 other objective Screening Recruiting medications for treatment of heart failure such as ace inhibitors, angiotensin receptor blockers (arbs), beta-blockers or aldost Exclusion http://ClinicalTrials.gov/show/NCT00400257 Evaluation ofNo Results Available Heart Fail 47941 NCT00400257 Screening Recruiting the Evolution of New use of such Exclusion medications for approved indications such as hypertension, post-mi Evaluation ofNo Resultsknown New Heart Fail http://ClinicalTrials.gov/show/NCT00400257 management the Evolution of lv dysfunction) 47941 NCT00400257 Screening Recruiting (without Available ages eligible for study: 18 years and older NoInEx Age http://ClinicalTrials.gov/show/NCT00400582 RecruitingStudyResults Availablein Heart Fail 68820 NCT00400582 A Pharmacogenomic No of Candesartan genders eligible for study: both http://ClinicalTrials.gov/show/NCT00400582 RecruitingStudyResults Availablein Heart Fail NoInEx Gender 68820 NCT00400582 A Pharmacogenomic No of Candesartan accepts healthy volunteers: no NoInEx Healthy http://ClinicalTrials.gov/show/NCT00400582 RecruitingStudyResults Availablein Heart Fail 68820 NCT00400582 A Pharmacogenomic No of Candesartan principal inclusion criteria: male orhttp://ClinicalTrials.gov/show/NCT00400582 RecruitingStudyResults Availablein Heart Fail Inclusion female > or = 18 years old. 68820 NCT00400582 A Pharmacogenomic No of Candesartan symptomatic chf corresponding to http://ClinicalTrials.gov/show/NCT00400582 RecruitingStudyResults Availablein Heart Fail Inclusion nyha class ii-iv symptoms for >= 4 weeks prior randomization. of Candesartan 68820 NCT00400582 A Pharmacogenomic No lvef < or = 40% Inclusion http://ClinicalTrials.gov/show/NCT00400582 RecruitingStudyResults Availablein Heart Fail 68820 NCT00400582 A Pharmacogenomic No of Candesartan treatment with an optimal and stable dose of ace inhibitorNCT00400582 prior to enrolmentNo the Candesartan in Heart Fail Inclusion http://ClinicalTrials.gov/show/NCT00400582 RecruitingStudyResults Available 68820 for >= 4 weeks A Pharmacogenomic in of study. principal exclusion criteria: treatment with an arb within 8NCT00400582 randomization. StudyResults Availablein Heart Fail Exclusion http://ClinicalTrials.gov/show/NCT00400582 Recruiting No of Candesartan 68820 weeks prior to A Pharmacogenomic known hypersensitivity to arbs or ace inhibitors. 68820 NCT00400582 Exclusion http://ClinicalTrials.gov/show/NCT00400582 RecruitingStudyResults Availablein Heart Fail A Pharmacogenomic No of Candesartan creatinine clearance < 30 ml / min http://ClinicalTrials.gov/show/NCT00400582 RecruitingStudyResults Availablein Heart Fail Exclusion or serum creatinine > 221 68820 NCT00400582 A Pharmacogenomic No of Candesartan current serum potassium > or = 5.0 mmol / l or a history of marked ace inhibitor or arb induced hyperkalemia. in Heart Fail Exclusion http://ClinicalTrials.gov/show/NCT00400582 RecruitingStudyResults Available 68820 NCT00400582 A Pharmacogenomic No of Candesartan known bilateral renal artery stenosis. Exclusion http://ClinicalTrials.gov/show/NCT00400582 RecruitingStudyResults Availablein Heart Fail 68820 NCT00400582 A Pharmacogenomic No of Candesartan current symptomatic hypotension http://ClinicalTrials.gov/show/NCT00400582 RecruitingStudyResults Availablein Heart Fail Exclusion and / or systolic 68820 NCT00400582 b. p A Pharmacogenomic No of Candesartan < 90 mmhg.Exclusion http://ClinicalTrials.gov/show/NCT00400582 RecruitingStudyResults Availablein Heart Fail 68820 NCT00400582 A Pharmacogenomic No of Candesartan decompensated heart failure described as hospitalization or i. v Exclusion http://ClinicalTrials.gov/show/NCT00400582 RecruitingStudyResults Availablein Heart Fail 68820 NCT00400582 A Pharmacogenomic No of Candesartan administration of medication in emergency room or heart NCT00400582 Exclusion http://ClinicalTrials.gov/show/NCT00400582 weeks 68820 failure clinic within 4 RecruitingStudyResults Availablein Heart Fail A Pharmacogenomic No of Candesartan stroke, acute coronary syndrome, pci within the last 4 weeks before randomization. Exclusion http://ClinicalTrials.gov/show/NCT00400582 RecruitingStudyResults Availablein Heart Fail 68820 NCT00400582 A Pharmacogenomic No of Candesartan connective tissue disease or chronic inflammatory condition Exclusion http://ClinicalTrials.gov/show/NCT00400582 RecruitingStudyResults Availablein Heart Fail 68820 NCT00400582 A Pharmacogenomic No of Candesartan acute inflammatory process such as an infection or68820 NCT00400582 2 weeks. Exclusion http://ClinicalTrials.gov/show/NCT00400582 RecruitingStudyResults Availablein Heart Fail gout attack in the A Pharmacogenomic No of Candesartan last pregnant orExclusion women or women of childbearing potential whoAare not protected from pregnancy by an accepted met lactating http://ClinicalTrials.gov/show/NCT00400582 RecruitingStudyResults Availablein Heart Fail 68820 NCT00400582 Pharmacogenomic No of Candesartan age <18 and >80 Exclusion http://ClinicalTrials.gov/show/NCT00403910 CompletedOf Aldosterone Receptors Blocka 8691 NCT00403910 Antiremodeling Effect No Results Available serum creatinine level > 2.5 mg per deciliter Exclusion http://ClinicalTrials.gov/show/NCT00403910 CompletedOf Aldosterone Receptors Blocka 8691 NCT00403910 Antiremodeling Effect No Results Available serum potassium level > 5.0 mmol http://ClinicalTrials.gov/show/NCT00403910 CompletedOf Aldosterone Receptors Blocka Exclusion per liter 8691 NCT00403910 Antiremodeling Effect No Results Available valvular heart disease amenable tohttp://ClinicalTrials.gov/show/NCT00403910 CompletedOf Aldosterone Receptors Blocka Exclusion surgical treatment 8691 NCT00403910 Antiremodeling Effect No Results Available congenital heart disease Exclusion http://ClinicalTrials.gov/show/NCT00403910 CompletedOf Aldosterone Receptors Blocka 8691 NCT00403910 Antiremodeling Effect No Results Available

unstable angina and / or acute myocardial infarction8691/NCT00403910 Exclusion http://ClinicalTrials.gov/show/NCT00403910 CompletedOf Aldosterone Receptors Blocka and or coronary revascularization procedure within three months befo Antiremodeling Effect No Results Available intravenousExclusionwith inotropichttp://ClinicalTrials.gov/show/NCT00403910 CompletedOf Aldosterone Receptors Blocka therapy drugs within three months before Antiremodeling Effect No Results Available 8691 NCT00403910 enrolment history of resuscitated ventricular fibrillation or tachycardia, unless these occurred within 24Of Aldosterone Receptors Blocka Exclusion http://ClinicalTrials.gov/show/NCT00403910 Completed No Results Available 8691 NCT00403910 Antiremodeling Effect hours of an acute myocardial inf chronic active hepatitis or cirrhosishttp://ClinicalTrials.gov/show/NCT00403910 CompletedOf Aldosterone Receptors Blocka Exclusion 8691 NCT00403910 Antiremodeling Effect No Results Available malignant neoplasm or any life threatening non cardiac disease Exclusion http://ClinicalTrials.gov/show/NCT00403910 CompletedOf Aldosterone Receptors Blocka 8691 NCT00403910 Antiremodeling Effect No Results Available history of hypersensitivity to studyhttp://ClinicalTrials.gov/show/NCT00403910 CompletedOf Aldosterone Receptors Blocka Exclusion drug 8691 NCT00403910 Antiremodeling Effect No Results Available pregnancy or lactating or childbearing age women who are not protected by an accepted method of contraception Exclusion http://ClinicalTrials.gov/show/NCT00403910 CompletedOf Aldosterone Receptors Blocka 8691 NCT00403910 Antiremodeling Effect No Results Available history of drug or alcohol abuse http://ClinicalTrials.gov/show/NCT00403910 CompletedOf Aldosterone Receptors Blocka Exclusion 8691 NCT00403910 Antiremodeling Effect No Results Available legal incapacity and / or other circumstances rending the patient unable to understand the nature, scope and possible Blocka Exclusion http://ClinicalTrials.gov/show/NCT00403910 CompletedOf Aldosterone Receptors conseq 8691 NCT00403910 Antiremodeling Effect No Results Available evidence ofExclusion uncooperative attitude http://ClinicalTrials.gov/show/NCT00403910 CompletedOf Aldosterone Receptors Blocka 8691 NCT00403910 Antiremodeling Effect No Results Available any condition other than heart failure that does not 8691 NCT00403910 Exclusion http://ClinicalTrials.gov/show/NCT00403910 CompletedOf Aldosterone Receptors Blocka permit an optimal participation to the trial Results Available Antiremodeling Effect No participation to other rcts during the last 3 months 8691 NCT00403910 Exclusion http://ClinicalTrials.gov/show/NCT00403910 CompletedOf Aldosterone Receptors Blocka Antiremodeling Effect No Results Available treatment with: lithium salts, potassium sparing diuretics, NCT00403910 Exclusion http://ClinicalTrials.gov/show/NCT00403910 drugs or any investigational drug 8691 oral positive inotropic CompletedOf Aldosterone Receptors Blocka Antiremodeling Effect No Results Available ages eligible for study: 18 years and older NoInEx Age http://ClinicalTrials.gov/show/NCT00418119 NotTreatment in Patients With Systolic Left 16211 NCT00418119 Erythropoietin yet recruiting No Results Available genders eligible for study: both http://ClinicalTrials.gov/show/NCT00418119 NotTreatment in Patients With Systolic Left NoInEx Gender 16211 NCT00418119 Erythropoietin yet recruiting No Results Available accepts healthy volunteers: no NoInEx Healthy http://ClinicalTrials.gov/show/NCT00418119 NotTreatment in Patients With Systolic Left 16211 NCT00418119 Erythropoietin yet recruiting No Results Available inclusion criteria: Inclusion http://ClinicalTrials.gov/show/NCT00418119 NotTreatment in Patients With Systolic Left 16211 NCT00418119 Erythropoietin yet recruiting No Results Available ischemic heart disease Inclusion http://ClinicalTrials.gov/show/NCT00418119 NotTreatment in Patients With Systolic Left 16211 NCT00418119 Erythropoietin yet recruiting No Results Available systolic lv dysfunction Inclusion http://ClinicalTrials.gov/show/NCT00418119 NotTreatment in Patients With Systolic Left 16211 NCT00418119 Erythropoietin yet recruiting No Results Available mild anemia Inclusion http://ClinicalTrials.gov/show/NCT00418119 NotTreatment in Patients With Systolic Left 16211 NCT00418119 Erythropoietin yet recruiting No Results Available normal renal function Inclusion http://ClinicalTrials.gov/show/NCT00418119 NotTreatment in Patients With Systolic Left 16211 NCT00418119 Erythropoietin yet recruiting No Results Available stable condition Inclusion http://ClinicalTrials.gov/show/NCT00418119 NotTreatment in Patients With Systolic Left 16211 NCT00418119 Erythropoietin yet recruiting No Results Available exclusion criteria: Exclusion http://ClinicalTrials.gov/show/NCT00418119 NotTreatment in Patients With Systolic Left 16211 NCT00418119 Erythropoietin yet recruiting No Results Available pregnancy Exclusion http://ClinicalTrials.gov/show/NCT00418119 NotTreatment in Patients With Systolic Left 16211 NCT00418119 Erythropoietin yet recruiting No Results Available unstable condition Exclusion http://ClinicalTrials.gov/show/NCT00418119 NotTreatment in Patients With Systolic Left 16211 NCT00418119 Erythropoietin yet recruiting No Results Available ages eligible for study: 18 years to http://ClinicalTrials.gov/show/NCT00457834 Active, not recruitingWith Atrial Fibrillation a NoInEx Age 80 years 28757 NCT00457834 Bi-Ventricular Pacing inNo Results Available Patients genders eligible for study: both http://ClinicalTrials.gov/show/NCT00457834 Active, not recruitingWith Atrial Fibrillation a NoInEx Gender 28757 NCT00457834 Bi-Ventricular Pacing inNo Results Available Patients accepts healthy volunteers: no NoInEx Healthy http://ClinicalTrials.gov/show/NCT00457834 Active, not recruitingWith Atrial Fibrillation a 28757 NCT00457834 Bi-Ventricular Pacing inNo Results Available Patients inclusion criteria: Inclusion http://ClinicalTrials.gov/show/NCT00457834 Active, not recruitingWith Atrial Fibrillation a 28757 NCT00457834 Bi-Ventricular Pacing inNo Results Available Patients heart failure nyha iii-iv Inclusion http://ClinicalTrials.gov/show/NCT00457834 Active, not recruitingWith Atrial Fibrillation a 28757 NCT00457834 Bi-Ventricular Pacing inNo Results Available Patients lvef<35% Inclusion http://ClinicalTrials.gov/show/NCT00457834 Active, not recruitingWith Atrial Fibrillation a 28757 NCT00457834 Bi-Ventricular Pacing inNo Results Available Patients qrs duration>150 ms Inclusion http://ClinicalTrials.gov/show/NCT00457834 Active, not recruitingWith Atrial Fibrillation a 28757 NCT00457834 Bi-Ventricular Pacing inNo Results Available Patients chronic atrial fibrillation. Inclusion http://ClinicalTrials.gov/show/NCT00457834 Active, not recruitingWith Atrial Fibrillation a 28757 NCT00457834 Bi-Ventricular Pacing inNo Results Available Patients exclusion criteria: Exclusion http://ClinicalTrials.gov/show/NCT00457834 Active, not recruitingWith Atrial Fibrillation a 28757 NCT00457834 Bi-Ventricular Pacing inNo Results Available Patients heart failure not related to systolichttp://ClinicalTrials.gov/show/NCT00457834 Active, not recruitingWith Atrial Fibrillation a Exclusion function 28757 NCT00457834 Bi-Ventricular Pacing inNo Results Available Patients unstable angina pectoris, ami, pci or cabg within 2 month NCT00457834 Exclusion http://ClinicalTrials.gov/show/NCT00457834 Active, not recruitingWith Atrial Fibrillation a 28757 Bi-Ventricular Pacing inNo Results Available Patients inclusion in Exclusion other studies http://ClinicalTrials.gov/show/NCT00457834 Active, not recruitingWith Atrial Fibrillation a 28757 NCT00457834 Bi-Ventricular Pacing inNo Results Available Patients ages eligible for study: 18 years and older NoInEx Age http://ClinicalTrials.gov/show/NCT00480077 Outcome Trial in Heart Available 64702 NCT00480077 Diagnostic Active, not recruiting Failure (DOT-HF Trial No Results genders eligible for study: both http://ClinicalTrials.gov/show/NCT00480077 Outcome Trial in Heart Available NoInEx Gender 64702 NCT00480077 Diagnostic Active, not recruiting Failure (DOT-HF Trial No Results accepts healthy volunteers: no NoInEx Healthy http://ClinicalTrials.gov/show/NCT00480077 Outcome Trial in Heart Available 64702 NCT00480077 Diagnostic Active, not recruiting Failure (DOT-HF Trial No Results inclusion criteria: Inclusion http://ClinicalTrials.gov/show/NCT00480077 Outcome Trial in Heart Available 64702 NCT00480077 Diagnostic Active, not recruiting Failure (DOT-HF Trial No Results subjects of both genders with mildhttp://ClinicalTrials.gov/show/NCT00480077 Outcome Trial in Heart Available Exclusion to severe hf as defined NCT00480077ii to iv who also haverecruiting Failuredevice implant 64702 as nhya class Diagnostic Active, not No Results an indication for (DOT-HF Trial exclusion criteria: Exclusion http://ClinicalTrials.gov/show/NCT00480077 Outcome Trial in Heart Available 64702 NCT00480077 Diagnostic Active, not recruiting Failure (DOT-HF Trial No Results subject is post heart transplant or actively listed on64702 NCT00480077 reasonable probability (as defined by(DOT-HF Trial Exclusion http://ClinicalTrials.gov/show/NCT00480077 Outcome Trial in Heart Available the transplant list Diagnostic Active, not recruiting Failure investigator) and No Results

subject received a coronary artery http://ClinicalTrials.gov/show/NCT00480077 Outcome Trial in Heart Available Exclusion bypass graft or valve surgery in lastDiagnostic Active, not recruiting Failure (DOT-HF Trial 64702 NCT00480077 days 90 No Results subject with a myocardial infarction (mi) in the last 64702 NCT00480077 Exclusion http://ClinicalTrials.gov/show/NCT00480077 Outcome Trial in Heart Available 40 days. Diagnostic Active, not recruiting Failure (DOT-HF Trial No Results subject's life expectancy is < one year in the opinion of theNCT00480077 Exclusion http://ClinicalTrials.gov/show/NCT00480077 Outcome Trial in Heart Available 64702 physician Diagnostic Active, not recruiting Failure (DOT-HF Trial No Results subject has Exclusion severe chronic obstructive pulmonary disease NCT00480077 http://ClinicalTrials.gov/show/NCT00480077 Outcome Trial in Heart Available medical rec 64702 (copd), as determined by physicianNo Results Failure in Diagnostic Active, not recruiting and documented (DOT-HF Trial subject is listed for valve replacement / valve repair Exclusion http://ClinicalTrials.gov/show/NCT00480077 Outcome Trial in Heart Available 64702 NCT00480077 Diagnostic Active, not recruiting Failure (DOT-HF Trial No Results subject has Exclusion severe, primary pulmonary hypertension as determined by physicianOutcome Trial in Heart Available http://ClinicalTrials.gov/show/NCT00480077 and documented in medical records Trial 64702 NCT00480077 Diagnostic Active, not recruiting Failure (DOT-HF No Results subject with serum creatinine >= 2.5 mg / dl measured within 14 daysDiagnostic Outcome Trial in Heart Available Exclusion http://ClinicalTrials.gov/show/NCT00480077 Active, not recruiting Failure (DOT-HF Trial 64702 NCT00480077 to enrolment prior No Results subject on chronic renal dialysis http://ClinicalTrials.gov/show/NCT00480077 Outcome Trial in Heart Available Exclusion 64702 NCT00480077 Diagnostic Active, not recruiting Failure (DOT-HF Trial No Results subject on continuous or uninterrupted (>= 2 stable infusions per week) infusion Outcome Trial in Heart Available Exclusion http://ClinicalTrials.gov/show/NCT00480077 (inotropic) therapy for hf 64702 NCT00480077 Diagnostic Active, not recruiting Failure (DOT-HF Trial No Results subject has Exclusionand uncorrected congenital heart disease complex http://ClinicalTrials.gov/show/NCT00480077 Outcome Trial in Heart Available 64702 NCT00480077 Diagnostic Active, not recruiting Failure (DOT-HF Trial No Results ages eligible for study: 80 years and older NoInEx Age http://ClinicalTrials.gov/show/NCT00658216 Recruiting No(BNP) Usefulness In Elderly Dy 13900 NCT00658216 Natriuretic Peptide Results Available Brain genders eligible for study: both http://ClinicalTrials.gov/show/NCT00658216 Recruiting No(BNP) Usefulness In Elderly Dy NoInEx Gender 13900 NCT00658216 Natriuretic Peptide Results Available Brain accepts healthy volunteers: no NoInEx Healthy http://ClinicalTrials.gov/show/NCT00658216 Recruiting No(BNP) Usefulness In Elderly Dy 13900 NCT00658216 Natriuretic Peptide Results Available Brain sampling method: non-probability http://ClinicalTrials.gov/show/NCT00658216 Recruiting No(BNP) Usefulness In Elderly Dy NoInEx sample 13900 NCT00658216 Natriuretic Peptide Results Available Brain study population NoInEx http://ClinicalTrials.gov/show/NCT00658216 Recruiting No(BNP) Usefulness In Elderly Dy 13900 NCT00658216 Natriuretic Peptide Results Available Brain defined population NoInEx http://ClinicalTrials.gov/show/NCT00658216 Recruiting No(BNP) Usefulness In Elderly Dy 13900 NCT00658216 Natriuretic Peptide Results Available Brain inclusion criteria: Inclusion http://ClinicalTrials.gov/show/NCT00658216 Recruiting No(BNP) Usefulness In Elderly Dy 13900 NCT00658216 Natriuretic Peptide Results Available Brain acute dyspnea Inclusion http://ClinicalTrials.gov/show/NCT00658216 Recruiting No(BNP) Usefulness In Elderly Dy 13900 NCT00658216 Natriuretic Peptide Results Available Brain crackles on Inclusion lung auscultation, http://ClinicalTrials.gov/show/NCT00658216 Recruiting No(BNP) Usefulness In Elderly Dy 13900 NCT00658216 Natriuretic Peptide Results Available Brain hypoxemia,Inclusion http://ClinicalTrials.gov/show/NCT00658216 Recruiting No(BNP) Usefulness In Elderly Dy 13900 NCT00658216 Natriuretic Peptide Results Available Brain right-sided signs. Inclusion http://ClinicalTrials.gov/show/NCT00658216 Recruiting No(BNP) Usefulness In Elderly Dy 13900 NCT00658216 Natriuretic Peptide Results Available Brain exclusion criteria: Exclusion http://ClinicalTrials.gov/show/NCT00658216 Recruiting No(BNP) Usefulness In Elderly Dy 13900 NCT00658216 Natriuretic Peptide Results Available Brain no exclusion criteria Exclusion http://ClinicalTrials.gov/show/NCT00658216 Recruiting No(BNP) Usefulness In Elderly Dy 13900 NCT00658216 Natriuretic Peptide Results Available Brain ages eligible for study: 18 years and older NoInEx Age http://ClinicalTrials.gov/show/NCT00670111 Recruiting No Results Available Heart Failu 9726 NCT00670111 Restoration of Chronotropic Competence in genders eligible for study: both http://ClinicalTrials.gov/show/NCT00670111 Recruiting No Results Available Heart Failu NoInEx Gender 9726 NCT00670111 Restoration of Chronotropic Competence in accepts healthy volunteers: no NoInEx Healthy http://ClinicalTrials.gov/show/NCT00670111 Recruiting No Results Available Heart Failu 9726 NCT00670111 Restoration of Chronotropic Competence in inclusion criteria: Inclusion http://ClinicalTrials.gov/show/NCT00670111 Recruiting No Results Available Heart Failu 9726 NCT00670111 Restoration of Chronotropic Competence in patients who are in sinus rhythm http://ClinicalTrials.gov/show/NCT00670111 Recruiting No Results Available Heart Failu Inclusion 9726 NCT00670111 Restoration of Chronotropic Competence in patients who are on stable medical therapy Inclusion http://ClinicalTrials.gov/show/NCT00670111 Recruiting No Results Available Heart Failu 9726 NCT00670111 Restoration of Chronotropic Competence in patients who exhibit signs and symptoms of heart failure, nyha class iiRestorationRecruiting No Results Available Heart Failu Inclusion http://ClinicalTrials.gov/show/NCT00670111 of Chronotropic Competence in 9726 NCT00670111 iii or patients who have experienced a hospitalization for 9726 NCT00670111 failureRecruiting No Results Available Heart Failu Inclusion http://ClinicalTrials.gov/show/NCT00670111 of Chronotropic Competence in decompensated heart Restoration treatment for pulmonary congestion or volume overload NCT00670111 Inclusion http://ClinicalTrials.gov/show/NCT00670111 Recruiting No Results Available Heart Failu 9726 Restoration of Chronotropic Competence in chronic treatment with a loop diuretic Inclusion http://ClinicalTrials.gov/show/NCT00670111 Recruiting No Results Available Heart Failu 9726 NCT00670111 Restoration of Chronotropic Competence in or a bnp > 125 ng / l. Inclusion http://ClinicalTrials.gov/show/NCT00670111 Recruiting No Results Available Heart Failu 9726 NCT00670111 Restoration of Chronotropic Competence in left ventricular ejection fraction >=http://ClinicalTrials.gov/show/NCT00670111 Recruiting No Results Available Heart Failu Inclusion 50% 9726 NCT00670111 Restoration of Chronotropic Competence in exclusion criteria: Exclusion http://ClinicalTrials.gov/show/NCT00670111 Recruiting No Results Available Heart Failu 9726 NCT00670111 Restoration of Chronotropic Competence in patients with persistent atrial fibrillation or atrial flutter NCT00670111 Exclusion http://ClinicalTrials.gov/show/NCT00670111 Recruiting No Results Available Heart Failu 9726 Restoration of Chronotropic Competence in patients who are in complete heart block Exclusion http://ClinicalTrials.gov/show/NCT00670111 Recruiting No Results Available Heart Failu 9726 NCT00670111 Restoration of Chronotropic Competence in patients who have experienced a recent mi or have unstable angina or require cardiac surgery or other procedures Exclusion http://ClinicalTrials.gov/show/NCT00670111 Recruiting No Results Available Heart Failu 9726 NCT00670111 Restoration of Chronotropic Competence in patients who have severe heart valve disease or valve replacement RestorationRecruiting No Results Available Heart Failu Exclusion http://ClinicalTrials.gov/show/NCT00670111 of Chronotropic Competence in 9726 NCT00670111 patients with a contraindication for a pacemaker system NCT00670111 Exclusion http://ClinicalTrials.gov/show/NCT00670111 Recruiting No Results Available Heart Failu 9726 Restoration of Chronotropic Competence in patients who have a neuromuscular, orthopedic or other non-cardiac RestorationRecruiting No Results Available Heart Failu Exclusion http://ClinicalTrials.gov/show/NCT00670111 that prevents patient from exercise testing 9726 NCT00670111 condition of Chronotropic Competence in

patients who have infiltrative or hypertrophic cardiomyopathy Exclusion http://ClinicalTrials.gov/show/NCT00670111 Recruiting No Results Available Heart Failu 9726 NCT00670111 Restoration of Chronotropic Competence in patients who have known severe pulmonary disease9726 NCT00670111 Exclusion http://ClinicalTrials.gov/show/NCT00670111 Recruiting No Results Available Heart Failu Restoration of Chronotropic Competence in patients with uncontrolled diabetes or blood pressure (sbp > 160 mmhg or dbp > Recruiting No Results Available Heart Failu Exclusion http://ClinicalTrials.gov/show/NCT00670111 95 mmhg) 9726 NCT00670111 Restoration of Chronotropic Competence in ages eligible for study: 18 years to http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on the Expression of NoInEx Age 85 years 8969 NCT00769210 Effect Completed No Results Available The genders eligible for study: both http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on the Expression of NoInEx Gender 8969 NCT00769210 Effect Completed No Results Available The accepts healthy volunteers: no NoInEx Healthy http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on the Expression of 8969 NCT00769210 Effect Completed No Results Available The inclusion criteria: Inclusion http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on the Expression of 8969 NCT00769210 Effect Completed No Results Available The age of 18 toInclusion 85 years http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on the Expression of 8969 NCT00769210 Effect Completed No Results Available The symptomatic heart failure, nyha class i to iii Inclusion http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on the Expression of 8969 NCT00769210 Effect Completed No Results Available The left ventricular ejection fraction < 0.40 Inclusion http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on the Expression of 8969 NCT00769210 Effect Completed No Results Available The give writtenInclusion consent informed http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on the Expression of 8969 NCT00769210 Effect Completed No Results Available The exclusion criteria: Exclusion http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on the Expression of 8969 NCT00769210 Effect Completed No Results Available The pregnant orExclusion women lactating http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on the Expression of 8969 NCT00769210 Effect Completed No Results Available The women in reproductive years musthttp://ClinicalTrials.gov/show/NCT00769210 of Simvastatiniud, diaphragm, condoms orof Exclusion have an active form of NCT00769210 (oral contraceptives, Therapy on the Expression su 8969 contraception Effect Completed No Results Available The heart failure as the results of any of the following conditions: active myocarditis of Simvastatin Therapy on the Expression of Exclusion http://ClinicalTrials.gov/show/NCT00769210 Completed No Results Available 8969 NCT00769210 Effect The congenital heart disease Exclusion http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on the Expression of 8969 NCT00769210 Effect Completed No Results Available The uncorrected, hemodynamically significant stenotic valvular disease The Effect of Simvastatin Therapy on the Expression of Exclusion http://ClinicalTrials.gov/show/NCT00769210 Completed No Results Available 8969 NCT00769210 nyha functional class iv symptoms http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on the Expression of Exclusion 8969 NCT00769210 Effect Completed No Results Available The current or previous treatment with a statin patients 8969 plasma ldl-c The Effect of Simvastatin Therapy anythethe following c Exclusion http://ClinicalTrials.gov/show/NCT00769210 Completed No/Results on of Expression of with NCT00769210 concentrations > 130 mg dl and Available ischemic cardiomyopathy Exclusion http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on the Expression of 8969 NCT00769210 Effect Completed No Results Available The previous cardiovascular event (cva, acs event) Exclusion http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on the Expression of 8969 NCT00769210 Effect Completed No Results Available The known coronary artery disease http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on the Expression of Exclusion 8969 NCT00769210 Effect Completed No Results Available The unstable angina Exclusion http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on the Expression of 8969 NCT00769210 Effect Completed No Results Available The presence ofExclusion any progressive systemic disease that would be expected The Effect the patient'sNoTherapyover the time course o http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Results on the Expression of 8969 NCT00769210 impact Completed outcome Available to uncorrected endocrine disorders including primary aldosteronism, pheochromocytoma, hyperthyroidism, hypothyroidism,of Exclusion http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on the Expression br 8969 NCT00769210 Effect Completed No Results Available The inherited disorders of lipid metabolism Exclusion http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on the Expression of 8969 NCT00769210 Effect Completed No Results Available The evidence ofExclusion renal disease (serum creatinine > 2.5 mg / dl), or hepatic disease (transaminase levels > three fold >of significant http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on the Expression la 8969 NCT00769210 Effect Completed No Results Available The inability or unwillingness to cooperate with study or 8969written informed consentSimvastatin Therapy on the Expression of Exclusion http://ClinicalTrials.gov/show/NCT00769210 of give NCT00769210 Effect Completed No Results Available The ages eligible for study: 18 years and older NoInEx Age http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Stud genders eligible for study: both http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available NoInEx Gender 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Stud accepts healthy volunteers: no NoInEx Healthy http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Stud sampling method: non-probability http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available NoInEx sample 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Stud study population NoInEx http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Stud heart failure patients needing crt therapy NoInEx http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Stud inclusion criteria: Inclusion http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Stud nyha class iii / iv Inclusion http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Stud stable medical regimen Inclusion http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Stud qrs > or = 130 ms Inclusion http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Stud lvef < or = 35% Inclusion http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Stud exclusion criteria: Exclusion http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Stud vt of transient or reversible causeshttp://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available Exclusion 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Stud incessant vtExclusion http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Stud currently implanted with a lead positioned through61604 NCT00795873 Exclusion http://ClinicalTrials.gov/show/NCT00795873 is the situs otw lv lead) Available the coronary sinus (unless CRT and SITUS No Results Post Approval Stud OVATIO it Recruiting OTW LV Lead

cardiac revascularization or angioplasty within the last month Exclusion http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Stud heart failure due to correctable valve disease Exclusion http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Stud chronic, medially refractory at Exclusion http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Stud enrolled in another clinical study that may confound the results of this study CRT and SITUS No Results Available Exclusion http://ClinicalTrials.gov/show/NCT00795873 Recruiting OTW LV Lead Post Approval Stud 61604 NCT00795873 OVATIO life expectancy < 6 months Exclusion http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Stud inability or refusal to provide informed consent 61604 NCT00795873 Exclusion http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available OVATIO CRT and SITUS OTW LV Lead Post Approval Stud unavailable Exclusion for scheduled follow-up with the implanting practice http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Stud sensitivity to 1 mg dexamethasonehttp://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available Exclusion sodium phosphate 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Stud < 18 years of age Exclusion http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Stud pregnancy Exclusion http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Stud genders eligible for study: both http://ClinicalTrials.gov/show/NCT00802230 Completed No Results Available Metoprol NoInEx Gender 25665 NCT00802230 Pharmacodynamic Study of Carvedilol Versus accepts healthy volunteers: no NoInEx Healthy http://ClinicalTrials.gov/show/NCT00802230 Completed No Results Available Metoprol 25665 NCT00802230 Pharmacodynamic Study of Carvedilol Versus inclusion criteria: Inclusion http://ClinicalTrials.gov/show/NCT00802230 Completed No Results Available Metoprol 25665 NCT00802230 Pharmacodynamic Study of Carvedilol Versus patients eligible for the study had objective evidence of systolic dysfunction (ejection fraction <=40%), were Versus Metoprol Inclusion http://ClinicalTrials.gov/show/NCT00802230 Completed No Results Availableyears of age 25665 NCT00802230 Pharmacodynamic Study of Carvedilol >18 exclusion criteria: Exclusion http://ClinicalTrials.gov/show/NCT00802230 Completed No Results Available Metoprol 25665 NCT00802230 Pharmacodynamic Study of Carvedilol Versus patients were excluded for active viral myocarditis 25665 NCT00802230 Exclusion http://ClinicalTrials.gov/show/NCT00802230 Completed No Results Available Metoprol Pharmacodynamic Study of Carvedilol Versus hemodynamically significant valvular heart disease 25665 NCT00802230 Exclusion http://ClinicalTrials.gov/show/NCT00802230 Completed No Results Available Metoprol Pharmacodynamic Study of Carvedilol Versus hypertrophic cardiomyopathy, peripartum cardiomyopathy Exclusion http://ClinicalTrials.gov/show/NCT00802230 Completed No Results Available Metoprol 25665 NCT00802230 Pharmacodynamic Study of Carvedilol Versus contra-indications to beta-blockers (asthma or obstructiveNCT00802230 requiring scheduled bronchodilators or inhaled ster Exclusion http://ClinicalTrials.gov/show/NCT00802230 Completed No Results Available Metoprol 25665 airway disease Pharmacodynamic Study of Carvedilol Versus supine blood pressure <85 / 50 http://ClinicalTrials.gov/show/NCT00802230 Completed No Results Available Metoprol Exclusion 25665 NCT00802230 Pharmacodynamic Study of Carvedilol Versus second or third degree heart block) Exclusion http://ClinicalTrials.gov/show/NCT00802230 Completed No Results Available Metoprol 25665 NCT00802230 Pharmacodynamic Study of Carvedilol Versus concomitant use of beta-agonists, http://ClinicalTrials.gov/show/NCT00802230 Completed No Results Available Metoprol Exclusion beta-antagonists, or anti-arrhythmics 25665 NCT00802230 Pharmacodynamic Study of Carvedilol Versus unstable angina Exclusion http://ClinicalTrials.gov/show/NCT00802230 Completed No Results Available Metoprol 25665 NCT00802230 Pharmacodynamic Study of Carvedilol Versus myocardial Exclusion or bypass surgery within 3 months NCT00802230 infarction http://ClinicalTrials.gov/show/NCT00802230 Completed No Results Available Metoprol 25665 Pharmacodynamic Study of Carvedilol Versus or significant renal insufficiency (creatinine >2.5 mg / dl), liver diseasePharmacodynamic Study fold above laboratory normal) Exclusion http://ClinicalTrials.gov/show/NCT00802230 Completed No Results Available Metoprol 25665 NCT00802230 (transaminase levels > 3 of Carvedilol Versus ages eligible for study: 18 years and older NoInEx Age http://ClinicalTrials.gov/show/NCT00941681 Recruiting NoCK-1827452 in Patients With S 68404 NCT00941681 Pharmacokinetics of Oral Results Available genders eligible for study: both http://ClinicalTrials.gov/show/NCT00941681 Recruiting NoCK-1827452 in Patients With S NoInEx Gender 68404 NCT00941681 Pharmacokinetics of Oral Results Available accepts healthy volunteers: no NoInEx Healthy http://ClinicalTrials.gov/show/NCT00941681 Recruiting NoCK-1827452 in Patients With S 68404 NCT00941681 Pharmacokinetics of Oral Results Available inclusion criteria: Inclusion http://ClinicalTrials.gov/show/NCT00941681 Recruiting NoCK-1827452 in Patients With S 68404 NCT00941681 Pharmacokinetics of Oral Results Available the patient Inclusion an informedhttp://ClinicalTrials.gov/show/NCT00941681 this studyOral CK-1827452 in PatientsinstituS has signed consent form / 68404 NCT00941681 patient information sheet for Recruitingapproved by Available Pharmacokinetics of No Results the governing With the patient Inclusion is >= 18 years old at the time of consent http://ClinicalTrials.gov/show/NCT00941681 Recruiting NoCK-1827452 in Patients With S 68404 NCT00941681 Pharmacokinetics of Oral Results Available left ventricular ejection fraction (lvef) <= 35% as determined by the investigator within 3of Oral CK-1827452 in Patients With S Inclusion http://ClinicalTrials.gov/show/NCT00941681 Recruiting No prior to Available 68404 NCT00941681 Pharmacokinetics weeks Results enrollment treated for >= 4 weeks with a beta http://ClinicalTrials.gov/show/NCT00941681 unless notOral CK-1827452 in Patients With S Inclusion blocker and an ace inhibitor (and / Pharmacokinetics of tolerated Available 68404 NCT00941681 an arb) Recruiting No Results or if prescribed, diuretics must have been administered according to a consistent regimen forOral CK-1827452 in Patients With S Inclusion http://ClinicalTrials.gov/show/NCT00941681 Recruiting>= 4 weeks. Available 68404 NCT00941681 Pharmacokinetics of No Results diagnosed with heart failure for >=http://ClinicalTrials.gov/show/NCT00941681 Recruiting NoCK-1827452 in Patients With S Inclusion 3 months prior to enrollment 68404 NCT00941681 Pharmacokinetics of Oral Results Available patient is considered to be an appropriate candidate for study enrollment as determined by theCK-1827452 in Patients Withfi Inclusion http://ClinicalTrials.gov/show/NCT00941681 Recruiting No Results Availablelaboratory S 68404 NCT00941681 Pharmacokinetics of Oral patient's clinical for female patients only: the patient is post-menopausal (>= 1 year) or sterilized, Recruiting of childbearing potential, she is nS Inclusion http://ClinicalTrials.gov/show/NCT00941681 or if she is NoCK-1827452 in Patients With 68404 NCT00941681 Pharmacokinetics of Oral Results Available for male patients only: male patients agree for the 68404 NCT00941681 and 10 weeks after the Results the study to useWith S Inclusion http://ClinicalTrials.gov/show/NCT00941681 Recruiting NoCK-1827452 in Patients a con duration of the study Pharmacokinetics of Oral end of Available exclusion criteria: Exclusion http://ClinicalTrials.gov/show/NCT00941681 Recruiting NoCK-1827452 in Patients With S 68404 NCT00941681 Pharmacokinetics of Oral Results Available patient has Exclusion been hospitalised for heart failure, acute coronary syndrome, myocardial infarction,CK-1827452 in Patients WithtS http://ClinicalTrials.gov/show/NCT00941681 Recruiting No Results Available 68404 NCT00941681 Pharmacokinetics of Oral coronary revascularisation, poorly controlled hypertension defined as blood pressure > 150 / 95 mmhg, documented on NoCK-1827452occasions prior toS Exclusion http://ClinicalTrials.gov/show/NCT00941681 Recruiting >= 2 separate in Patients With 68404 NCT00941681 Pharmacokinetics of Oral Results Available the patient Exclusion has a supine heart ratehttp://ClinicalTrials.gov/show/NCT00941681 rest >= 100 beats per minute after 10 minutes of Recruiting NoCK-1827452 in Patients With S 68404 NCT00941681 Pharmacokinetics of Oral Results Available patient has Exclusion i at screening that is above the upper limit of normal a troponin http://ClinicalTrials.gov/show/NCT00941681 Recruiting NoCK-1827452 in Patients With S 68404 NCT00941681 Pharmacokinetics of Oral Results Available

the patient Exclusion aortic or mitral stenosis has severe http://ClinicalTrials.gov/show/NCT00941681 Recruiting NoCK-1827452 in Patients With S 68404 NCT00941681 Pharmacokinetics of Oral Results Available the patient Exclusion myocarditis http://ClinicalTrials.gov/show/NCT00941681 Recruiting NoCK-1827452 in Patients With S has active 68404 NCT00941681 Pharmacokinetics of Oral Results Available clinically significant restrictive, constrictive, or hypertrophic obstructive cardiomyopathyof Oral CK-1827452 in Patients With S Exclusion http://ClinicalTrials.gov/show/NCT00941681 Recruiting No Results Available 68404 NCT00941681 Pharmacokinetics clinically significant congenital heart disease Exclusion http://ClinicalTrials.gov/show/NCT00941681 Recruiting NoCK-1827452 in Patients With S 68404 NCT00941681 Pharmacokinetics of Oral Results Available history of major organ transplantation Exclusion http://ClinicalTrials.gov/show/NCT00941681 Recruiting NoCK-1827452 in Patients With S 68404 NCT00941681 Pharmacokinetics of Oral Results Available the patient Exclusion has canadian cardiovascular society class iv angina http://ClinicalTrials.gov/show/NCT00941681 Recruiting NoCK-1827452 in Patients With S 68404 NCT00941681 Pharmacokinetics of Oral Results Available patient is on chronic anti-arrhythmic therapy, with 68404 NCT00941681 Exclusion http://ClinicalTrials.gov/show/NCT00941681 Recruiting NoCK-1827452 in Patients With S the exception of amiodarone Pharmacokinetics of Oral Results Available patient has Exclusion renal function defined as an estimated gfr <= 30 Pharmacokinetics of Oral CK-1827452 in Patients With S impaired http://ClinicalTrials.gov/show/NCT00941681 1.73 m2 calculated by the modification of die 68404 NCT00941681 / min / Recruiting No Results Available ml patient is currently taking, or has taken within 14 days prior to enrollment, a potent cyp3a4 inhibitor or foodin Patients With S Exclusion http://ClinicalTrials.gov/show/NCT00941681 Recruiting NoCK-1827452 as listed in appe 68404 NCT00941681 Pharmacokinetics of Oral Results Available patient is currently taking, or has taken within 28 days prior to enrollment, a potent cyp3a4 inducer or food in Patients appen Exclusion http://ClinicalTrials.gov/show/NCT00941681 Recruiting NoCK-1827452 as listed in With S 68404 NCT00941681 Pharmacokinetics of Oral Results Available the patient Exclusion impairment defined as a total bilirubin > 3 mg Pharmacokinetics of>Oral CK-1827452 inlimit of normalS has hepatic http://ClinicalTrials.gov/show/NCT00941681 alt or ast 2No Resultsupper Patients With 68404 NCT00941681 or an Recruiting times the Available / dl, concomitant non-cardiovascular disease that is expected to reduce life expectancy to < 1 year CK-1827452 in Patients With S Exclusion http://ClinicalTrials.gov/show/NCT00941681 Recruiting No Results Available 68404 NCT00941681 Pharmacokinetics of Oral the patient Exclusion has received an investigational drug or device within 30 days or 5 half-lives, whichever is greater, of enrollment S http://ClinicalTrials.gov/show/NCT00941681 Recruiting NoCK-1827452 in Patients With 68404 NCT00941681 Pharmacokinetics of Oral Results Available patient has,Exclusion in the opinion of the investigator, a condition NCT00941681 http://ClinicalTrials.gov/show/NCT00941681 ability of the subject toAvailable 68404 that compromises the Recruiting NoCK-1827452 in Patients With S Pharmacokinetics of Oral Results give written informe the patient Exclusion prior treatment with ck-1827452 NCT00941681 has had any http://ClinicalTrials.gov/show/NCT00941681 Recruiting NoCK-1827452 in Patients With S 68404 Pharmacokinetics of Oral Results Available ages eligible for study: 18 years and older NoInEx Age http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Study genders eligible for study: both http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available NoInEx Gender 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Study accepts healthy volunteers: no NoInEx Healthy http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Study sampling method: probability sample NoInEx http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Study study population NoInEx http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Study acutely decompensated systolic hfhttp://ClinicalTrials.gov/show/NCT00953953 Recruiting Nocenter on thein Heart Failure NoInEx group: patients who are admitted to albert Left Ventricular Dyssynchrony hf service. 45024 NCT00953953 of einstein medical Results Available Study chronic hf on dialysis group: patients at the dialysis45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure NoInEx http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available center at albert einstein medical center. Study ambulatoryNoInEx hf group: patients who present45024 NCT00953953 medicalRecruiting clinic. chronic http://ClinicalTrials.gov/show/NCT00953953 center hf No Results Available to the albert einstein of Left Ventricular Dyssynchrony in Heart Failure Study acutely decompensated diastolic hf group: patients45024 NCT00953953 albert einstein medical Results on the hf service. NoInEx http://ClinicalTrials.gov/show/NCT00953953 Recruiting No center Available who are admittedStudy of Left Ventricular Dyssynchrony in Heart Failure to acutely decompensated systolic heart failure NoInEx http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Study inclusion criteria: Inclusion http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Study patients over the age of 18 and able to consent 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Inclusion http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available Study nyha class iii or iv Inclusion http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Study ef<= 35% Inclusion http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Study diagnosis ofInclusion acute congestive heart failure exacerbation by history or physical examination No Results Available http://ClinicalTrials.gov/show/NCT00953953 Recruiting Dyssynchrony in Heart Failure 45024 NCT00953953 of Left Ventricular Study ability to understand and willing tohttp://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available Inclusion sign informed consent NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure 45024 Study willingness to follow-up for clinic visits at 30 days and 6 months Inclusion http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Study exclusion criteria: Exclusion http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Study pacemaker Exclusion http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Study patients requiring and willing to sign informed consent NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Exclusion http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available 45024 Study unwillingness to provide consent http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available Exclusion 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Study chronic heart failure on dialysis group Exclusion http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Study inclusion criteria: Inclusion http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Study patients over the age of 18 and able to consent 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Inclusion http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available Study nyha class ii, iii, or iv Inclusion http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Study ef <= 35% with a screening echocardiogram Inclusion http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Study ability to understand and willing tohttp://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available Inclusion sign informed consent NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure 45024 Study willingness to follow up at 30 days http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available Inclusion and 6 months via phone contact Study of Left Ventricular Dyssynchrony in Heart Failure 45024 NCT00953953 exclusion criteria: Exclusion http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Study

unwillingness to provide consent http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available Exclusion 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Study pacemaker Exclusion http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Study ambulatoryExclusion chronic heart failure group http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Study inclusion criteria: Inclusion http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Study patients over the age of 18 and able to consent 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Inclusion http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available Study nyha class iiInclusion an ef <= 35% and iii with http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Study diagnosis ofInclusionheart failure and currently on optimalNCT00953953 of Left Ventricular Dyssynchrony in Heart Failure chronic http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available diuretics 45024 medical therapy, including ace, or arb, beta-blockers and Study ability to understand and willing tohttp://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available Inclusion sign informed consent NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure 45024 Study willingness to follow up as an outpatient at 30 days45024 months Inclusion http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available and 6 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Study exclusion criteria: Exclusion http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Study incapable of taking the 6-minute walk test due to any condition unrelated to heart Ventricular Dyssynchrony in Heart Failure Exclusion http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available 45024 NCT00953953 of Left failure Study patients requiring chronic inotropehttp://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available Exclusion therapy 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Study pacemaker Exclusion http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Study symptoms of angina limiting exercise ability Exclusion http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Study unwillingness to provide consent http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available Exclusion 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Study acutely decompensated diastolic heart failure group Exclusion http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Study inclusion criteria: Inclusion http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Study patients over the age of 18 and able to consent 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Inclusion http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available Study nyha class iii or iv Inclusion http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Study ef >= 45% Inclusion http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Study diagnosis ofInclusion acute congestive heart failure exacerbation by history or physical examination No Results Available http://ClinicalTrials.gov/show/NCT00953953 Recruiting Dyssynchrony in Heart Failure 45024 NCT00953953 of Left Ventricular Study ability to understand and willing tohttp://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available Inclusion sign informed consent NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure 45024 Study willingness to follow-up for clinic visits at 30 days and 6 months Inclusion http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Study exclusion criteria: Exclusion http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Study pacemaker Exclusion http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Study patients requiring inotrope support on admission 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Exclusion http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available Study unwillingness to provide consent http://ClinicalTrials.gov/show/NCT00953953 Recruiting No Results Available Exclusion 45024 NCT00953953 of Left Ventricular Dyssynchrony in Heart Failure Study ages eligible for study: 18 years and older NoInEx Age http://ClinicalTrials.gov/show/NCT00902304 Intensified Primary Care Available of Blood P 4076 NCT00902304 Valsartan Not yet recruiting No Results Reduction genders eligible for study: both http://ClinicalTrials.gov/show/NCT00902304 Intensified Primary Care Available of Blood P NoInEx Gender 4076 NCT00902304 Valsartan Not yet recruiting No Results Reduction accepts healthy volunteers: no NoInEx Healthy http://ClinicalTrials.gov/show/NCT00902304 Intensified Primary Care Available of Blood P 4076 NCT00902304 Valsartan Not yet recruiting No Results Reduction inclusion criteria: Inclusion http://ClinicalTrials.gov/show/NCT00902304 Intensified Primary Care Available of Blood P 4076 NCT00902304 Valsartan Not yet recruiting No Results Reduction hypertension requiring drug treatment Inclusion http://ClinicalTrials.gov/show/NCT00902304 Intensified Primary Care Available of Blood P 4076 NCT00902304 Valsartan Not yet recruiting No Results Reduction exclusion criteria: Exclusion http://ClinicalTrials.gov/show/NCT00902304 Intensified Primary Care Available of Blood P 4076 NCT00902304 Valsartan Not yet recruiting No Results Reduction significantlyExclusion blood pressure (severe hypertension) elevated http://ClinicalTrials.gov/show/NCT00902304 Intensified Primary Care Available of Blood P 4076 NCT00902304 Valsartan Not yet recruiting No Results Reduction requiring 3 or more antihypertensive drugs Exclusion http://ClinicalTrials.gov/show/NCT00902304 Intensified Primary Care Available of Blood P 4076 NCT00902304 Valsartan Not yet recruiting No Results Reduction severe kidney disease Exclusion http://ClinicalTrials.gov/show/NCT00902304 Intensified Primary Care Available of Blood P 4076 NCT00902304 Valsartan Not yet recruiting No Results Reduction other protocol-defined inclusion / exclusion criteria may apply Exclusion http://ClinicalTrials.gov/show/NCT00902304 Intensified Primary Care Available of Blood P 4076 NCT00902304 Valsartan Not yet recruiting No Results Reduction ages eligible for study: 18 years to http://ClinicalTrials.gov/show/NCT00923611 Completed Noand Tolerability and Determin NoInEx Age 70 years 9921 NCT00923611 Antihypertensive Efficacy Results Available genders eligible for study: both http://ClinicalTrials.gov/show/NCT00923611 Completed Noand Tolerability and Determin NoInEx Gender 9921 NCT00923611 Antihypertensive Efficacy Results Available accepts healthy volunteers: no NoInEx Healthy http://ClinicalTrials.gov/show/NCT00923611 Completed Noand Tolerability and Determin 9921 NCT00923611 Antihypertensive Efficacy Results Available inclusion criteria: Inclusion http://ClinicalTrials.gov/show/NCT00923611 Completed Noand Tolerability and Determin 9921 NCT00923611 Antihypertensive Efficacy Results Available mild to moderate essential hypertension : sitting diastolic NCT00923611 measured at screeningResults Available Determin Inclusion http://ClinicalTrials.gov/show/NCT00923611 Completed Noand Tolerability and are 95~1 9921 blood pressure Antihypertensive Efficacy and baseline(day1) subjects who agree to participate in this sudy and give written informed consent Completed Noand Tolerability and Determin Inclusion http://ClinicalTrials.gov/show/NCT00923611 9921 NCT00923611 Antihypertensive Efficacy Results Available

subjects considered to understandhttp://ClinicalTrials.gov/show/NCT00923611 Completed Noand Tolerability and Determin Inclusion the study, be cooperative, and able to be followed-up until the end of the study 9921 NCT00923611 Antihypertensive Efficacy Results Available exclusion criteria: Exclusion http://ClinicalTrials.gov/show/NCT00923611 Completed Noand Tolerability and Determin 9921 NCT00923611 Antihypertensive Efficacy Results Available the sitting dbp is < 94 mmhg or > 115 mmhg or severe hypertensive patient with sittingEfficacy and Tolerability over Determin Exclusion http://ClinicalTrials.gov/show/NCT00923611 Completed No blood pressure and 200 mmh 9921 NCT00923611 Antihypertensive systolic Results Available patients with secondary hypertension Exclusion http://ClinicalTrials.gov/show/NCT00923611 Completed Noand Tolerability and Determin 9921 NCT00923611 Antihypertensive Efficacy Results Available patients with severe renal(creatinine more 1.5 times9921 NCT00923611 normal), Completed Noand Tolerability and hepatic(a Exclusion http://ClinicalTrials.gov/show/NCT00923611 gastrointestinal, hematological or Determin than upper limit Antihypertensive Efficacy Results Available of which might affect absorption, disposition, metabolism or NCT00923611 drug Completed Noand Tolerability and Determin Exclusion http://ClinicalTrials.gov/show/NCT00923611 9921 excretion of the Antihypertensive Efficacy Results Available patients with postural hypotension Exclusion http://ClinicalTrials.gov/show/NCT00923611 Completed Noand Tolerability and Determin 9921 NCT00923611 Antihypertensive Efficacy Results Available patients with sever insulin dependent diabetes mellitus orNCT00923611diabetes Completed Noand Tolerability and Determin Exclusion http://ClinicalTrials.gov/show/NCT00923611 mellitus(hba1c>9%, regimen change of oral 9921 uncontrolled Antihypertensive Efficacy Results Available patients with a history of myocardial infarction, severe coronary artery disease orCompleted Noand Tolerability and Determin Exclusion http://ClinicalTrials.gov/show/NCT00923611 clinically significant heart failure or valvular 9921 NCT00923611 Antihypertensive Efficacy Results Available patients with consumptive disease, autoimmune disease, connective tissue disease Exclusion http://ClinicalTrials.gov/show/NCT00923611 Completed Noand Tolerability and Determin 9921 NCT00923611 Antihypertensive Efficacy Results Available patients with a history of type b orhttp://ClinicalTrials.gov/show/NCT00923611 Completed Noand Tolerability and Determin Exclusion c hepatitis 9921 NCT00923611 Antihypertensive Efficacy Results Available patients with hiv or hepatitis Exclusion http://ClinicalTrials.gov/show/NCT00923611 Completed Noand Tolerability and Determin 9921 NCT00923611 Antihypertensive Efficacy Results Available patients with clinically significant laboratory abnormality NCT00923611 Exclusion http://ClinicalTrials.gov/show/NCT00923611 Completed Noand Tolerability and Determin 9921 Antihypertensive Efficacy Results Available patients receiving any drugs known to affect blood pressure or medical treatments thatEfficacy and Tolerability and Determin Exclusion http://ClinicalTrials.gov/show/NCT00923611 Completedinfluence the blood pressure 9921 NCT00923611 Antihypertensive can No Results Available patients with allergy or contraindication to any angiotensin ii receptorAntihypertensive Efficacy and Tolerability and Determin Exclusion http://ClinicalTrials.gov/show/NCT00923611 Completed No Results Available 9921 NCT00923611 antagonists female of childbearing potential who does not undergo hysterectomyAntihypertensive Efficacy and Tolerability and Determin Exclusion http://ClinicalTrials.gov/show/NCT00923611post-menopausalResults Available 9921 NCT00923611 is not Completed No or patients judged to have a history of alcohol or drug abuse NCT00923611 Exclusion http://ClinicalTrials.gov/show/NCT00923611 Completed Noand Tolerability and Determin 9921 by the investigator Antihypertensive Efficacy Results Available patients with average weight > +35% or <-15% in modifiedNCT00923611 life insurance table Noand Tolerability and Determin Exclusion http://ClinicalTrials.gov/show/NCT00923611 Completed 9921 metropolitan Antihypertensive Efficacy Results Available patients participated other clinical http://ClinicalTrials.gov/show/NCT00923611 Completed Noand Tolerability and Determin Exclusion trial 3 months before screening Antihypertensive Efficacy Results Available 9921 NCT00923611 patients judged to be inappropriate for this study by9921investigator with other reasons Exclusion http://ClinicalTrials.gov/show/NCT00923611 Completed Noand Tolerability and Determin the NCT00923611 Antihypertensive Efficacy Results Available ages eligible for study: 18 years and older NoInEx Age http://ClinicalTrials.gov/show/NCT00132093 Eplerenone on Left Ventricular Remodelling F 77803 NCT00132093 Effects of Completed No Results Available genders eligible for study: both http://ClinicalTrials.gov/show/NCT00132093 Eplerenone on Left Ventricular Remodelling F NoInEx Gender 77803 NCT00132093 Effects of Completed No Results Available accepts healthy volunteers: no NoInEx Healthy http://ClinicalTrials.gov/show/NCT00132093 Eplerenone on Left Ventricular Remodelling F 77803 NCT00132093 Effects of Completed No Results Available inclusion criteria: Inclusion http://ClinicalTrials.gov/show/NCT00132093 Eplerenone on Left Ventricular Remodelling F 77803 NCT00132093 Effects of Completed No Results Available age 18 or above Inclusion http://ClinicalTrials.gov/show/NCT00132093 Eplerenone on Left Ventricular Remodelling F 77803 NCT00132093 Effects of Completed No Results Available acute myocardial infarction within http://ClinicalTrials.gov/show/NCT00132093 Eplerenone on Left Ventricularelevated cardia Inclusion last 1-14 days (defined by typical electrocardiogram [ecg] No Results Available 77803 NCT00132093 Effects of Completed changes and / or Remodelling F left ventricular systolic dysfunctionhttp://ClinicalTrials.gov/show/NCT00132093 Eplerenone on (wmsi) and left ventricular ejec Inclusion (lvsd) based on 77803 NCT00132093 motion score index Left Ventricular Remodelling F echocardiographicEffects of Completed No Results Available wall ability to give written informed consent Inclusion http://ClinicalTrials.gov/show/NCT00132093 Eplerenone on Left Ventricular Remodelling F 77803 NCT00132093 Effects of Completed No Results Available exclusion criteria: Exclusion http://ClinicalTrials.gov/show/NCT00132093 Eplerenone on Left Ventricular Remodelling F 77803 NCT00132093 Effects of Completed No Results Available clinical or radiological heart failurehttp://ClinicalTrials.gov/show/NCT00132093 Eplerenone on Left Ventricular Remodelling F Exclusion 77803 NCT00132093 Effects of Completed No Results Available established Exclusion mellitus diabetes http://ClinicalTrials.gov/show/NCT00132093 Eplerenone on Left Ventricular Remodelling F 77803 NCT00132093 Effects of Completed No Results Available current use Exclusion of potassium (k)-sparing diuretics, clarithromycin, nefazodone, itraconazole, ketoconazole, ritonavir, nelfinavir, ta http://ClinicalTrials.gov/show/NCT00132093 Eplerenone on Left Ventricular Remodelling F 77803 NCT00132093 Effects of Completed No Results Available serum creatinine > 220 mol / l http://ClinicalTrials.gov/show/NCT00132093 Eplerenone on Left Ventricular Remodelling F Exclusion 77803 NCT00132093 Effects of Completed No Results Available serum potassium > 5.0 mmol / l http://ClinicalTrials.gov/show/NCT00132093 Eplerenone on Left Ventricular Remodelling F Exclusion 77803 NCT00132093 Effects of Completed No Results Available pregnancy Exclusion http://ClinicalTrials.gov/show/NCT00132093 Eplerenone on Left Ventricular Remodelling F 77803 NCT00132093 Effects of Completed No Results Available addisons disease Exclusion http://ClinicalTrials.gov/show/NCT00132093 Eplerenone on Left Ventricular Remodelling F 77803 NCT00132093 Effects of Completed No Results Available mri-incompatible (ferrous) sulphate prosthesis Exclusion http://ClinicalTrials.gov/show/NCT00132093 Eplerenone on Left Ventricular Remodelling F 77803 NCT00132093 Effects of Completed No Results Available claustrophobia (unable to tolerate http://ClinicalTrials.gov/show/NCT00132093 Eplerenone on Left Ventricular Remodelling F Exclusion mr environment) 77803 NCT00132093 Effects of Completed No Results Available concurrent Exclusion use of phenytoin, carbamazepine, rifampicin or st http://ClinicalTrials.gov/show/NCT00132093 Eplerenone on Left Ventricular Remodelling F 77803 NCT00132093 Effects of Completed No Results Available johns wort Exclusion (reduce efficacy of eplerenone). http://ClinicalTrials.gov/show/NCT00132093 Eplerenone on Left Ventricular Remodelling F 77803 NCT00132093 Effects of Completed No Results Available

Heart Failureehavioral: The Alfred|HBA of heart failure B Early detection Both Adult|Senior Heart Failureehavioral: The Alfred|HBA of heart failure B Early detection Both Adult|Senior Heart Failureehavioral: The Alfred|HBA of heart failure B Early detection Both Adult|Senior Heart Failureehavioral: The Alfred|HBA of heart failure B Early detection Both Adult|Senior Heart Failureehavioral: The Alfred|HBA of heart failure B Early detection Both Adult|Senior Heart Failureehavioral: The Alfred|HBA of heart failure B Early detection Both Adult|Senior Heart Failureehavioral: The Alfred|HBA of heart failure B Early detection Both Adult|Senior Heart Failureehavioral: The Alfred|HBA of heart failure B Early detection Both Adult|Senior Heart Failureehavioral: The Alfred|HBA of heart failure B Early detection Both Adult|Senior Heart Failureehavioral: The Alfred|HBA of heart failure B Early detection Both Adult|Senior Heart Failureehavioral: The Alfred|HBA of heart failure B Early detection Both Adult|Senior Heart Failureehavioral: The Alfred|HBA of heart failure B Early detection Both Adult|Senior Heart Failureehavioral: The Alfred|HBA of heart failure B Early detection Both Adult|Senior Heart Failureehavioral: The Alfred|HBA of heart failure B Early detection Both Adult|Senior Heart Failureehavioral: The Alfred|HBA of heart failure B Early detection Both Adult|Senior Heart Failureehavioral: The Alfred|HBA of heart failure B Early detection Both Adult|Senior Heart Failureehavioral: The Alfred|HBA of heart failure B Early detection Both Adult|Senior Heart Failureehavioral: The Alfred|HBA of heart failure B Early detection Both Adult|Senior Heart Failurerug: Candesartan upHeart Institute|AstraZeneca IV D Montreal to 32 mg daily Both Adult|Senior Phase Heart Failurerug: Candesartan upHeart Institute|AstraZeneca IV D Montreal to 32 mg daily Both Adult|Senior Phase Heart Failurerug: Candesartan upHeart Institute|AstraZeneca IV D Montreal to 32 mg daily Both Adult|Senior Phase Heart Failurerug: Candesartan upHeart Institute|AstraZeneca IV D Montreal to 32 mg daily Both Adult|Senior Phase Heart Failurerug: Candesartan upHeart Institute|AstraZeneca IV D Montreal to 32 mg daily Both Adult|Senior Phase Heart Failurerug: Candesartan upHeart Institute|AstraZeneca IV D Montreal to 32 mg daily Both Adult|Senior Phase Heart Failurerug: Candesartan upHeart Institute|AstraZeneca IV D Montreal to 32 mg daily Both Adult|Senior Phase Heart Failurerug: Candesartan upHeart Institute|AstraZeneca IV D Montreal to 32 mg daily Both Adult|Senior Phase Heart Failurerug: Candesartan upHeart Institute|AstraZeneca IV D Montreal to 32 mg daily Both Adult|Senior Phase Heart Failurerug: Candesartan upHeart Institute|AstraZeneca IV D Montreal to 32 mg daily Both Adult|Senior Phase Heart Failurerug: Candesartan upHeart Institute|AstraZeneca IV D Montreal to 32 mg daily Both Adult|Senior Phase Heart Failurerug: Candesartan upHeart Institute|AstraZeneca IV D Montreal to 32 mg daily Both Adult|Senior Phase Heart Failurerug: Candesartan upHeart Institute|AstraZeneca IV D Montreal to 32 mg daily Both Adult|Senior Phase Heart Failurerug: Candesartan upHeart Institute|AstraZeneca IV D Montreal to 32 mg daily Both Adult|Senior Phase Heart Failurerug: Candesartan upHeart Institute|AstraZeneca IV D Montreal to 32 mg daily Both Adult|Senior Phase Heart Failurerug: Candesartan upHeart Institute|AstraZeneca IV D Montreal to 32 mg daily Both Adult|Senior Phase Heart Failurerug: Candesartan upHeart Institute|AstraZeneca IV D Montreal to 32 mg daily Both Adult|Senior Phase Heart Failurerug: Candesartan upHeart Institute|AstraZeneca IV D Montreal to 32 mg daily Both Adult|Senior Phase Heart Failurerug: Candesartan upHeart Institute|AstraZeneca IV D Montreal to 32 mg daily Both Adult|Senior Phase Heart Failurerug: Candesartan upHeart Institute|AstraZeneca IV D Montreal to 32 mg daily Both Adult|Senior Phase Heart Failurerug: Canrenone Care Foundation Adult|Senior D Heart Both Phase III Heart Failurerug: Canrenone Care Foundation Adult|Senior D Heart Both Phase III Heart Failurerug: Canrenone Care Foundation Adult|Senior D Heart Both Phase III Heart Failurerug: Canrenone Care Foundation Adult|Senior D Heart Both Phase III Heart Failurerug: Canrenone Care Foundation Adult|Senior D Heart Both Phase III

3500 3500 3500 3500 3500 3500 3500 3500 3500 3500 3500 3500 3500 3500 3500 3500 3500 3500 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 500 500 500 500 500

OTHER|UNKNOWN Observational OTHER|UNKNOWN Observational OTHER|UNKNOWN Observational OTHER|UNKNOWN Observational OTHER|UNKNOWN Observational OTHER|UNKNOWN Observational OTHER|UNKNOWN Observational OTHER|UNKNOWN Observational OTHER|UNKNOWN Observational OTHER|UNKNOWN Observational OTHER|UNKNOWN Observational OTHER|UNKNOWN Observational OTHER|UNKNOWN Observational OTHER|UNKNOWN Observational OTHER|UNKNOWN Observational OTHER|UNKNOWN Observational OTHER|UNKNOWN Observational OTHER|UNKNOWN Observational OTHER|INDUSTRY Interventional OTHER|INDUSTRY Interventional OTHER|INDUSTRY Interventional OTHER|INDUSTRY Interventional OTHER|INDUSTRY Interventional OTHER|INDUSTRY Interventional OTHER|INDUSTRY Interventional OTHER|INDUSTRY Interventional OTHER|INDUSTRY Interventional OTHER|INDUSTRY Interventional OTHER|INDUSTRY Interventional OTHER|INDUSTRY Interventional OTHER|INDUSTRY Interventional OTHER|INDUSTRY Interventional OTHER|INDUSTRY Interventional OTHER|INDUSTRY Interventional OTHER|INDUSTRY Interventional OTHER|INDUSTRY Interventional OTHER|INDUSTRY Interventional OTHER|INDUSTRY Interventional OTHER Interventional OTHER Interventional OTHER Interventional OTHER Interventional OTHER Interventional

Heart Failurerug: Canrenone Care Foundation Adult|Senior D Heart Both Phase III 500 OTHER Heart Failurerug: Canrenone Care Foundation Adult|Senior D Heart Both Phase III 500 OTHER Heart Failurerug: Canrenone Care Foundation Adult|Senior D Heart Both Phase III 500 OTHER Heart Failurerug: Canrenone Care Foundation Adult|Senior D Heart Both Phase III 500 OTHER Heart Failurerug: Canrenone Care Foundation Adult|Senior D Heart Both Phase III 500 OTHER Heart Failurerug: Canrenone Care Foundation Adult|Senior D Heart Both Phase III 500 OTHER Heart Failurerug: Canrenone Care Foundation Adult|Senior D Heart Both Phase III 500 OTHER Heart Failurerug: Canrenone Care Foundation Adult|Senior D Heart Both Phase III 500 OTHER Heart Failurerug: Canrenone Care Foundation Adult|Senior D Heart Both Phase III 500 OTHER Heart Failurerug: Canrenone Care Foundation Adult|Senior D Heart Both Phase III 500 OTHER Heart Failurerug: Canrenone Care Foundation Adult|Senior D Heart Both Phase III 500 OTHER Heart Failurerug: Canrenone Care Foundation Adult|Senior D Heart Both Phase III 500 OTHER Heart Failurerug: Canrenone Care Foundation Adult|Senior D Heart Both Phase III 500 OTHER Heart Failurerug: erythropoietin Both D Rabin Medical Center Adult|Senior Phase IV 10 OTHER Heart Failurerug: erythropoietin Both D Rabin Medical Center Adult|Senior Phase IV 10 OTHER Heart Failurerug: erythropoietin Both D Rabin Medical Center Adult|Senior Phase IV 10 OTHER Heart Failurerug: erythropoietin Both D Rabin Medical Center Adult|Senior Phase IV 10 OTHER Heart Failurerug: erythropoietin Both D Rabin Medical Center Adult|Senior Phase IV 10 OTHER Heart Failurerug: erythropoietin Both D Rabin Medical Center Adult|Senior Phase IV 10 OTHER Heart Failurerug: erythropoietin Both D Rabin Medical Center Adult|Senior Phase IV 10 OTHER Heart Failurerug: erythropoietin Both D Rabin Medical Center Adult|Senior Phase IV 10 OTHER Heart Failurerug: erythropoietin Both D Rabin Medical Center Adult|Senior Phase IV 10 OTHER Heart Failurerug: erythropoietin Both D Rabin Medical Center Adult|Senior Phase IV 10 OTHER Heart Failurerug: erythropoietin Both D Rabin Medical Center Adult|Senior Phase IV 10 OTHER Heart Failurerug: erythropoietin Both D Rabin Medical Center Adult|Senior Phase IV 10 OTHER Heart Failureevice: InSync III University D Ume Both Adult|Senior Phase II 40 OTHER Heart Failureevice: InSync III University D Ume Both Adult|Senior Phase II 40 OTHER Heart Failureevice: InSync III University D Ume Both Adult|Senior Phase II 40 OTHER Heart Failureevice: InSync III University D Ume Both Adult|Senior Phase II 40 OTHER Heart Failureevice: InSync III University D Ume Both Adult|Senior Phase II 40 OTHER Heart Failureevice: InSync III University D Ume Both Adult|Senior Phase II 40 OTHER Heart Failureevice: InSync III University D Ume Both Adult|Senior Phase II 40 OTHER Heart Failureevice: InSync III University D Ume Both Adult|Senior Phase II 40 OTHER Heart Failureevice: InSync III University D Ume Both Adult|Senior Phase II 40 OTHER Heart Failureevice: InSync III University D Ume Both Adult|Senior Phase II 40 OTHER Heart Failureevice: InSync III University D Ume Both Adult|Senior Phase II 40 OTHER Heart Failureevice: InSync III University D Ume Both Adult|Senior Phase II 40 OTHER Heart Failureevice: Programming (CRT-D, CRT,Adult|Senior and Cardiac Compass ) D Medtronic Bakken ResearchOptiVol III Both ICD Center Phase 2300 INDUSTRY Heart Failureevice: Programming (CRT-D, CRT,Adult|Senior and Cardiac Compass ) D Medtronic Bakken ResearchOptiVol III Both ICD Center Phase 2300 INDUSTRY Heart Failureevice: Programming (CRT-D, CRT,Adult|Senior and Cardiac Compass ) D Medtronic Bakken ResearchOptiVol III Both ICD Center Phase 2300 INDUSTRY Heart Failureevice: Programming (CRT-D, CRT,Adult|Senior and Cardiac Compass ) D Medtronic Bakken ResearchOptiVol III Both ICD Center Phase 2300 INDUSTRY Heart Failureevice: Programming (CRT-D, CRT,Adult|Senior and Cardiac Compass ) D Medtronic Bakken ResearchOptiVol III Both ICD Center Phase 2300 INDUSTRY Heart Failureevice: Programming (CRT-D, CRT,Adult|Senior and Cardiac Compass ) D Medtronic Bakken ResearchOptiVol III Both ICD Center Phase 2300 INDUSTRY Heart Failureevice: Programming (CRT-D, CRT,Adult|Senior and Cardiac Compass ) D Medtronic Bakken ResearchOptiVol III Both ICD Center Phase 2300 INDUSTRY

Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional

Heart Failureevice: Programming (CRT-D, CRT,Adult|Senior and Cardiac Compass ) D Medtronic Bakken ResearchOptiVol III Both ICD Center Phase 2300 INDUSTRY Heart Failureevice: Programming (CRT-D, CRT,Adult|Senior and Cardiac Compass ) D Medtronic Bakken ResearchOptiVol III Both ICD Center Phase 2300 INDUSTRY Heart Failureevice: Programming (CRT-D, CRT,Adult|Senior and Cardiac Compass ) D Medtronic Bakken ResearchOptiVol III Both ICD Center Phase 2300 INDUSTRY Heart Failureevice: Programming (CRT-D, CRT,Adult|Senior and Cardiac Compass ) D Medtronic Bakken ResearchOptiVol III Both ICD Center Phase 2300 INDUSTRY Heart Failureevice: Programming (CRT-D, CRT,Adult|Senior and Cardiac Compass ) D Medtronic Bakken ResearchOptiVol III Both ICD Center Phase 2300 INDUSTRY Heart Failureevice: Programming (CRT-D, CRT,Adult|Senior and Cardiac Compass ) D Medtronic Bakken ResearchOptiVol III Both ICD Center Phase 2300 INDUSTRY Heart Failureevice: Programming (CRT-D, CRT,Adult|Senior and Cardiac Compass ) D Medtronic Bakken ResearchOptiVol III Both ICD Center Phase 2300 INDUSTRY Heart Failureevice: Programming (CRT-D, CRT,Adult|Senior and Cardiac Compass ) D Medtronic Bakken ResearchOptiVol III Both ICD Center Phase 2300 INDUSTRY Heart Failureevice: Programming (CRT-D, CRT,Adult|Senior and Cardiac Compass ) D Medtronic Bakken ResearchOptiVol III Both ICD Center Phase 2300 INDUSTRY Heart Failureevice: Programming (CRT-D, CRT,Adult|Senior and Cardiac Compass ) D Medtronic Bakken ResearchOptiVol III Both ICD Center Phase 2300 INDUSTRY Heart Failure Assistance Publique - Hpitaux de Paris Both Senior 300 OTHER Heart Failure Assistance Publique - Hpitaux de Paris Both Senior 300 OTHER Heart Failure Assistance Publique - Hpitaux de Paris Both Senior 300 OTHER Heart Failure Assistance Publique - Hpitaux de Paris Both Senior 300 OTHER Heart Failure Assistance Publique - Hpitaux de Paris Both Senior 300 OTHER Heart Failure Assistance Publique - Hpitaux de Paris Both Senior 300 OTHER Heart Failure Assistance Publique - Hpitaux de Paris Both Senior 300 OTHER Heart Failure Assistance Publique - Hpitaux de Paris Both Senior 300 OTHER Heart Failure Assistance Publique - Hpitaux de Paris Both Senior 300 OTHER Heart Failure Assistance Publique - Hpitaux de Paris Both Senior 300 OTHER Heart Failure Assistance Publique - Hpitaux de Paris Both Senior 300 OTHER Heart Failure Assistance Publique - Hpitaux de Paris Both Senior 300 OTHER Heart Failure Assistance Publique - Hpitaux de Paris Both Senior 300 OTHER Heart Failureevice: Insignia Plus / Ultra (Guidant/Boston Scientific) D Boston Scientific Corporation Both Adult|Senior 400 INDUSTRY Heart Failureevice: Insignia Plus / Ultra (Guidant/Boston Scientific) D Boston Scientific Corporation Both Adult|Senior 400 INDUSTRY Heart Failureevice: Insignia Plus / Ultra (Guidant/Boston Scientific) D Boston Scientific Corporation Both Adult|Senior 400 INDUSTRY Heart Failureevice: Insignia Plus / Ultra (Guidant/Boston Scientific) D Boston Scientific Corporation Both Adult|Senior 400 INDUSTRY Heart Failureevice: Insignia Plus / Ultra (Guidant/Boston Scientific) D Boston Scientific Corporation Both Adult|Senior 400 INDUSTRY Heart Failureevice: Insignia Plus / Ultra (Guidant/Boston Scientific) D Boston Scientific Corporation Both Adult|Senior 400 INDUSTRY Heart Failureevice: Insignia Plus / Ultra (Guidant/Boston Scientific) D Boston Scientific Corporation Both Adult|Senior 400 INDUSTRY Heart Failureevice: Insignia Plus / Ultra (Guidant/Boston Scientific) D Boston Scientific Corporation Both Adult|Senior 400 INDUSTRY Heart Failureevice: Insignia Plus / Ultra (Guidant/Boston Scientific) D Boston Scientific Corporation Both Adult|Senior 400 INDUSTRY Heart Failureevice: Insignia Plus / Ultra (Guidant/Boston Scientific) D Boston Scientific Corporation Both Adult|Senior 400 INDUSTRY Heart Failureevice: Insignia Plus / Ultra (Guidant/Boston Scientific) D Boston Scientific Corporation Both Adult|Senior 400 INDUSTRY Heart Failureevice: Insignia Plus / Ultra (Guidant/Boston Scientific) D Boston Scientific Corporation Both Adult|Senior 400 INDUSTRY Heart Failureevice: Insignia Plus / Ultra (Guidant/Boston Scientific) D Boston Scientific Corporation Both Adult|Senior 400 INDUSTRY Heart Failureevice: Insignia Plus / Ultra (Guidant/Boston Scientific) D Boston Scientific Corporation Both Adult|Senior 400 INDUSTRY Heart Failureevice: Insignia Plus / Ultra (Guidant/Boston Scientific) D Boston Scientific Corporation Both Adult|Senior 400 INDUSTRY Heart Failureevice: Insignia Plus / Ultra (Guidant/Boston Scientific) D Boston Scientific Corporation Both Adult|Senior 400 INDUSTRY Heart Failureevice: Insignia Plus / Ultra (Guidant/Boston Scientific) D Boston Scientific Corporation Both Adult|Senior 400 INDUSTRY Heart Failureevice: Insignia Plus / Ultra (Guidant/Boston Scientific) D Boston Scientific Corporation Both Adult|Senior 400 INDUSTRY Heart Failureevice: Insignia Plus / Ultra (Guidant/Boston Scientific) D Boston Scientific Corporation Both Adult|Senior 400 INDUSTRY

Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Observational Observational Observational Observational Observational Observational Observational Observational Observational Observational Observational Observational Observational Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional

Heart Failureevice: Insignia Plus / Ultra (Guidant/Boston Scientific) D Boston Scientific Corporation Both Adult|Senior Heart Failureevice: Insignia Plus / Ultra (Guidant/Boston Scientific) D Boston Scientific Corporation Both Adult|Senior Heart Failureevice: Insignia Plus / Ultra (Guidant/Boston Scientific) D Boston Scientific Corporation Both Adult|Senior Heart Failurerug: Simvastatin D University of Utah Both Adult|Senior Heart Failurerug: Simvastatin D University of Utah Both Adult|Senior Heart Failurerug: Simvastatin D University of Utah Both Adult|Senior Heart Failurerug: Simvastatin D University of Utah Both Adult|Senior Heart Failurerug: Simvastatin D University of Utah Both Adult|Senior Heart Failurerug: Simvastatin D University of Utah Both Adult|Senior Heart Failurerug: Simvastatin D University of Utah Both Adult|Senior Heart Failurerug: Simvastatin D University of Utah Both Adult|Senior Heart Failurerug: Simvastatin D University of Utah Both Adult|Senior Heart Failurerug: Simvastatin D University of Utah Both Adult|Senior Heart Failurerug: Simvastatin D University of Utah Both Adult|Senior Heart Failurerug: Simvastatin D University of Utah Both Adult|Senior Heart Failurerug: Simvastatin D University of Utah Both Adult|Senior Heart Failurerug: Simvastatin D University of Utah Both Adult|Senior Heart Failurerug: Simvastatin D University of Utah Both Adult|Senior Heart Failurerug: Simvastatin D University of Utah Both Adult|Senior Heart Failurerug: Simvastatin D University of Utah Both Adult|Senior Heart Failurerug: Simvastatin D University of Utah Both Adult|Senior Heart Failurerug: Simvastatin D University of Utah Both Adult|Senior Heart Failurerug: Simvastatin D University of Utah Both Adult|Senior Heart Failurerug: Simvastatin D University of Utah Both Adult|Senior Heart Failurerug: Simvastatin D University of Utah Both Adult|Senior Heart Failurerug: Simvastatin D University of Utah Both Adult|Senior Heart Failurerug: Simvastatin D University of Utah Both Adult|Senior Heart Failurerug: Simvastatin D University of Utah Both Adult|Senior Heart Failure ELA Medical, Inc. Both Adult|Senior Heart Failure ELA Medical, Inc. Both Adult|Senior Heart Failure ELA Medical, Inc. Both Adult|Senior Heart Failure ELA Medical, Inc. Both Adult|Senior Heart Failure ELA Medical, Inc. Both Adult|Senior Heart Failure ELA Medical, Inc. Both Adult|Senior Heart Failure ELA Medical, Inc. Both Adult|Senior Heart Failure ELA Medical, Inc. Both Adult|Senior Heart Failure ELA Medical, Inc. Both Adult|Senior Heart Failure ELA Medical, Inc. Both Adult|Senior Heart Failure ELA Medical, Inc. Both Adult|Senior Heart Failure ELA Medical, Inc. Both Adult|Senior Heart Failure ELA Medical, Inc. Both Adult|Senior Heart Failure ELA Medical, Inc. Both Adult|Senior Heart Failure ELA Medical, Inc. Both Adult|Senior

400 400 400 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 2260 2260 2260 2260 2260 2260 2260 2260 2260 2260 2260 2260 2260 2260 2260

INDUSTRY INDUSTRY INDUSTRY OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER INDUSTRY INDUSTRY INDUSTRY INDUSTRY INDUSTRY INDUSTRY INDUSTRY INDUSTRY INDUSTRY INDUSTRY INDUSTRY INDUSTRY INDUSTRY INDUSTRY INDUSTRY

Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Observational Observational Observational Observational Observational Observational Observational Observational Observational Observational Observational Observational Observational Observational Observational

Heart Failure ELA Medical, Inc. Both Adult|Senior Heart Failure ELA Medical, Inc. Both Adult|Senior Heart Failure ELA Medical, Inc. Both Adult|Senior Heart Failure ELA Medical, Inc. Both Adult|Senior Heart Failure ELA Medical, Inc. Both Adult|Senior Heart Failure ELA Medical, Inc. Both Adult|Senior Heart Failure ELA Medical, Inc. Both Adult|Senior Heart Failure ELA Medical, Inc. Both Adult|Senior Heart Failure ELA Medical, Inc. Both Adult|Senior Heart Failure ELA Medical, Inc. Both Adult|Senior Heart Failurerug: Terbutaline Infusion D University of Utah|GlaxoSmithKline Both Child|Adult|Senior Phase IV Heart Failurerug: Terbutaline Infusion D University of Utah|GlaxoSmithKline Both Child|Adult|Senior Phase IV Heart Failurerug: Terbutaline Infusion D University of Utah|GlaxoSmithKline Both Child|Adult|Senior Phase IV Heart Failurerug: Terbutaline Infusion D University of Utah|GlaxoSmithKline Both Child|Adult|Senior Phase IV Heart Failurerug: Terbutaline Infusion D University of Utah|GlaxoSmithKline Both Child|Adult|Senior Phase IV Heart Failurerug: Terbutaline Infusion D University of Utah|GlaxoSmithKline Both Child|Adult|Senior Phase IV Heart Failurerug: Terbutaline Infusion D University of Utah|GlaxoSmithKline Both Child|Adult|Senior Phase IV Heart Failurerug: Terbutaline Infusion D University of Utah|GlaxoSmithKline Both Child|Adult|Senior Phase IV Heart Failurerug: Terbutaline Infusion D University of Utah|GlaxoSmithKline Both Child|Adult|Senior Phase IV Heart Failurerug: Terbutaline Infusion D University of Utah|GlaxoSmithKline Both Child|Adult|Senior Phase IV Heart Failurerug: Terbutaline Infusion D University of Utah|GlaxoSmithKline Both Child|Adult|Senior Phase IV Heart Failurerug: Terbutaline Infusion D University of Utah|GlaxoSmithKline Both Child|Adult|Senior Phase IV Heart Failurerug: Terbutaline Infusion D University of Utah|GlaxoSmithKline Both Child|Adult|Senior Phase IV Heart Failurerug: Terbutaline Infusion D University of Utah|GlaxoSmithKline Both Child|Adult|Senior Phase IV Heart Failurerug: Terbutaline Infusion D University of Utah|GlaxoSmithKline Both Child|Adult|Senior Phase IV Heart Failurerug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452 D Cytokinetics Both Adult|Senior Phase II Heart Failurerug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452 D Cytokinetics Both Adult|Senior Phase II Heart Failurerug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452 D Cytokinetics Both Adult|Senior Phase II Heart Failurerug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452 D Cytokinetics Both Adult|Senior Phase II Heart Failurerug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452 D Cytokinetics Both Adult|Senior Phase II Heart Failurerug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452 D Cytokinetics Both Adult|Senior Phase II Heart Failurerug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452 D Cytokinetics Both Adult|Senior Phase II Heart Failurerug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452 D Cytokinetics Both Adult|Senior Phase II Heart Failurerug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452 D Cytokinetics Both Adult|Senior Phase II Heart Failurerug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452 D Cytokinetics Both Adult|Senior Phase II Heart Failurerug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452 D Cytokinetics Both Adult|Senior Phase II Heart Failurerug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452 D Cytokinetics Both Adult|Senior Phase II Heart Failurerug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452 D Cytokinetics Both Adult|Senior Phase II Heart Failurerug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452 D Cytokinetics Both Adult|Senior Phase II Heart Failurerug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452 D Cytokinetics Both Adult|Senior Phase II Heart Failurerug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452 D Cytokinetics Both Adult|Senior Phase II Heart Failurerug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452 D Cytokinetics Both Adult|Senior Phase II Heart Failurerug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452 D Cytokinetics Both Adult|Senior Phase II

2260 2260 2260 2260 2260 2260 2260 2260 2260 2260 25 25 25 25 25 25 25 25 25 25 25 25 25 25 25 32 32 32 32 32 32 32 32 32 32 32 32 32 32 32 32 32 32

INDUSTRY Observational INDUSTRY Observational INDUSTRY Observational INDUSTRY Observational INDUSTRY Observational INDUSTRY Observational INDUSTRY Observational INDUSTRY Observational INDUSTRY Observational INDUSTRY Observational OTHER|INDUSTRY Interventional OTHER|INDUSTRY Interventional OTHER|INDUSTRY Interventional OTHER|INDUSTRY Interventional OTHER|INDUSTRY Interventional OTHER|INDUSTRY Interventional OTHER|INDUSTRY Interventional OTHER|INDUSTRY Interventional OTHER|INDUSTRY Interventional OTHER|INDUSTRY Interventional OTHER|INDUSTRY Interventional OTHER|INDUSTRY Interventional OTHER|INDUSTRY Interventional OTHER|INDUSTRY Interventional OTHER|INDUSTRY Interventional INDUSTRY Interventional INDUSTRY Interventional INDUSTRY Interventional INDUSTRY Interventional INDUSTRY Interventional INDUSTRY Interventional INDUSTRY Interventional INDUSTRY Interventional INDUSTRY Interventional INDUSTRY Interventional INDUSTRY Interventional INDUSTRY Interventional INDUSTRY Interventional INDUSTRY Interventional INDUSTRY Interventional INDUSTRY Interventional INDUSTRY Interventional INDUSTRY Interventional

Heart Failurerug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452 D Cytokinetics Both Adult|Senior Phase II Heart Failurerug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452 D Cytokinetics Both Adult|Senior Phase II Heart Failurerug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452 D Cytokinetics Both Adult|Senior Phase II Heart Failurerug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452 D Cytokinetics Both Adult|Senior Phase II Heart Failurerug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452 D Cytokinetics Both Adult|Senior Phase II Heart Failurerug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452 D Cytokinetics Both Adult|Senior Phase II Heart Failurerug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452 D Cytokinetics Both Adult|Senior Phase II Heart Failurerug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452 D Cytokinetics Both Adult|Senior Phase II Heart Failurerug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452 D Cytokinetics Both Adult|Senior Phase II Heart Failurerug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452 D Cytokinetics Both Adult|Senior Phase II Heart Failurerug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452 D Cytokinetics Both Adult|Senior Phase II Heart Failurerug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452 D Cytokinetics Both Adult|Senior Phase II Heart Failurerug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452 D Cytokinetics Both Adult|Senior Phase II Heart Failurerug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452 D Cytokinetics Both Adult|Senior Phase II Heart Failurerug: CK-1827452|Drug: CK-1827452|Drug: CK-1827452 D Cytokinetics Both Adult|Senior Phase II Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both

32 32 32 32 32 32 32 32 32 32 32 32 32 32 32 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120 120

INDUSTRY INDUSTRY INDUSTRY INDUSTRY INDUSTRY INDUSTRY INDUSTRY INDUSTRY INDUSTRY INDUSTRY INDUSTRY INDUSTRY INDUSTRY INDUSTRY INDUSTRY OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER

Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Interventional Observational Observational Observational Observational Observational Observational Observational Observational Observational Observational Observational Observational Observational Observational Observational Observational Observational Observational Observational Observational Observational Observational Observational Observational Observational Observational Observational Observational Observational

Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both 120 OTHER Observational Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both 120 OTHER Observational Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both 120 OTHER Observational Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both 120 OTHER Observational Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both 120 OTHER Observational Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both 120 OTHER Observational Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both 120 OTHER Observational Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both 120 OTHER Observational Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both 120 OTHER Observational Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both 120 OTHER Observational Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both 120 OTHER Observational Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both 120 OTHER Observational Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both 120 OTHER Observational Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both 120 OTHER Observational Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both 120 OTHER Observational Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both 120 OTHER Observational Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both 120 OTHER Observational Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both 120 OTHER Observational Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both 120 OTHER Observational Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both 120 OTHER Observational Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both 120 OTHER Observational Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both 120 OTHER Observational Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both 120 OTHER Observational Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both 120 OTHER Observational Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both 120 OTHER Observational Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both 120 OTHER Observational Heart Failureevice: Phillips ultrasound Healthcare Network D Albert Einstein system Adult|Senior Both 120 OTHER Observational Hypertension Drug: Valsartan, hydrochlorothiazide|Drug: Valsartan, amlodipine, hydrochlorothiazide|Drug: usual care Novartis Both Adult|Senior Phase IV 2700 INDUSTRY Interventional Hypertension Drug: Valsartan, hydrochlorothiazide|Drug: Valsartan, amlodipine, hydrochlorothiazide|Drug: usual care Novartis Both Adult|Senior Phase IV 2700 INDUSTRY Interventional Hypertension Drug: Valsartan, hydrochlorothiazide|Drug: Valsartan, amlodipine, hydrochlorothiazide|Drug: usual care Novartis Both Adult|Senior Phase IV 2700 INDUSTRY Interventional Hypertension Drug: Valsartan, hydrochlorothiazide|Drug: Valsartan, amlodipine, hydrochlorothiazide|Drug: usual care Novartis Both Adult|Senior Phase IV 2700 INDUSTRY Interventional Hypertension Drug: Valsartan, hydrochlorothiazide|Drug: Valsartan, amlodipine, hydrochlorothiazide|Drug: usual care Novartis Both Adult|Senior Phase IV 2700 INDUSTRY Interventional Hypertension Drug: Valsartan, hydrochlorothiazide|Drug: Valsartan, amlodipine, hydrochlorothiazide|Drug: usual care Novartis Both Adult|Senior Phase IV 2700 INDUSTRY Interventional Hypertension Drug: Valsartan, hydrochlorothiazide|Drug: Valsartan, amlodipine, hydrochlorothiazide|Drug: usual care Novartis Both Adult|Senior Phase IV 2700 INDUSTRY Interventional Hypertension Drug: Valsartan, hydrochlorothiazide|Drug: Valsartan, amlodipine, hydrochlorothiazide|Drug: usual care Novartis Both Adult|Senior Phase IV 2700 INDUSTRY Interventional Hypertension Drug: Valsartan, hydrochlorothiazide|Drug: Valsartan, amlodipine, hydrochlorothiazide|Drug: usual care Novartis Both Adult|Senior Phase IV 2700 INDUSTRY Interventional Hypertension Drug: Valsartan, hydrochlorothiazide|Drug: Valsartan, amlodipine, hydrochlorothiazide|Drug: usual care Novartis Both Adult|Senior Phase IV 2700 INDUSTRY Interventional Hypertension Drug: Fimasartan Pharmaceutical Co., Ltd|Seoul National University Hospital|Samsung Medical Center|Asan M Boryung Both Adult|Senior Phase II 182 INDUSTRY|OTHER|UNKNOWN Interventional Hypertension Drug: Fimasartan Pharmaceutical Co., Ltd|Seoul National University Hospital|Samsung Medical Center|Asan M Boryung Both Adult|Senior Phase II 182 INDUSTRY|OTHER|UNKNOWN Interventional Hypertension Drug: Fimasartan Pharmaceutical Co., Ltd|Seoul National University Hospital|Samsung Medical Center|Asan M Boryung Both Adult|Senior Phase II 182 INDUSTRY|OTHER|UNKNOWN Interventional Hypertension Drug: Fimasartan Pharmaceutical Co., Ltd|Seoul National University Hospital|Samsung Medical Center|Asan M Boryung Both Adult|Senior Phase II 182 INDUSTRY|OTHER|UNKNOWN Interventional Hypertension Drug: Fimasartan Pharmaceutical Co., Ltd|Seoul National University Hospital|Samsung Medical Center|Asan M Boryung Both Adult|Senior Phase II 182 INDUSTRY|OTHER|UNKNOWN Interventional Hypertension Drug: Fimasartan Pharmaceutical Co., Ltd|Seoul National University Hospital|Samsung Medical Center|Asan M Boryung Both Adult|Senior Phase II 182 INDUSTRY|OTHER|UNKNOWN Interventional

Hypertension Drug: Fimasartan Pharmaceutical Co., Ltd|Seoul National University Hospital|Samsung Medical Center|Asan M Boryung Both Adult|Senior Phase II 182 INDUSTRY|OTHER|UNKNOWN Interventional Hypertension Drug: Fimasartan Pharmaceutical Co., Ltd|Seoul National University Hospital|Samsung Medical Center|Asan M Boryung Both Adult|Senior Phase II 182 INDUSTRY|OTHER|UNKNOWN Interventional Hypertension Drug: Fimasartan Pharmaceutical Co., Ltd|Seoul National University Hospital|Samsung Medical Center|Asan M Boryung Both Adult|Senior Phase II 182 INDUSTRY|OTHER|UNKNOWN Interventional Hypertension Drug: Fimasartan Pharmaceutical Co., Ltd|Seoul National University Hospital|Samsung Medical Center|Asan M Boryung Both Adult|Senior Phase II 182 INDUSTRY|OTHER|UNKNOWN Interventional Hypertension Drug: Fimasartan Pharmaceutical Co., Ltd|Seoul National University Hospital|Samsung Medical Center|Asan M Boryung Both Adult|Senior Phase II 182 INDUSTRY|OTHER|UNKNOWN Interventional Hypertension Drug: Fimasartan Pharmaceutical Co., Ltd|Seoul National University Hospital|Samsung Medical Center|Asan M Boryung Both Adult|Senior Phase II 182 INDUSTRY|OTHER|UNKNOWN Interventional Hypertension Drug: Fimasartan Pharmaceutical Co., Ltd|Seoul National University Hospital|Samsung Medical Center|Asan M Boryung Both Adult|Senior Phase II 182 INDUSTRY|OTHER|UNKNOWN Interventional Hypertension Drug: Fimasartan Pharmaceutical Co., Ltd|Seoul National University Hospital|Samsung Medical Center|Asan M Boryung Both Adult|Senior Phase II 182 INDUSTRY|OTHER|UNKNOWN Interventional Hypertension Drug: Fimasartan Pharmaceutical Co., Ltd|Seoul National University Hospital|Samsung Medical Center|Asan M Boryung Both Adult|Senior Phase II 182 INDUSTRY|OTHER|UNKNOWN Interventional Hypertension Drug: Fimasartan Pharmaceutical Co., Ltd|Seoul National University Hospital|Samsung Medical Center|Asan M Boryung Both Adult|Senior Phase II 182 INDUSTRY|OTHER|UNKNOWN Interventional Hypertension Drug: Fimasartan Pharmaceutical Co., Ltd|Seoul National University Hospital|Samsung Medical Center|Asan M Boryung Both Adult|Senior Phase II 182 INDUSTRY|OTHER|UNKNOWN Interventional Hypertension Drug: Fimasartan Pharmaceutical Co., Ltd|Seoul National University Hospital|Samsung Medical Center|Asan M Boryung Both Adult|Senior Phase II 182 INDUSTRY|OTHER|UNKNOWN Interventional Hypertension Drug: Fimasartan Pharmaceutical Co., Ltd|Seoul National University Hospital|Samsung Medical Center|Asan M Boryung Both Adult|Senior Phase II 182 INDUSTRY|OTHER|UNKNOWN Interventional Hypertension Drug: Fimasartan Pharmaceutical Co., Ltd|Seoul National University Hospital|Samsung Medical Center|Asan M Boryung Both Adult|Senior Phase II 182 INDUSTRY|OTHER|UNKNOWN Interventional Hypertension Drug: Fimasartan Pharmaceutical Co., Ltd|Seoul National University Hospital|Samsung Medical Center|Asan M Boryung Both Adult|Senior Phase II 182 INDUSTRY|OTHER|UNKNOWN Interventional Hypertension Drug: Fimasartan Pharmaceutical Co., Ltd|Seoul National University Hospital|Samsung Medical Center|Asan M Boryung Both Adult|Senior Phase II 182 INDUSTRY|OTHER|UNKNOWN Interventional Hypertension Drug: Fimasartan Pharmaceutical Co., Ltd|Seoul National University Hospital|Samsung Medical Center|Asan M Boryung Both Adult|Senior Phase II 182 INDUSTRY|OTHER|UNKNOWN Interventional Hypertension Drug: Fimasartan Pharmaceutical Co., Ltd|Seoul National University Hospital|Samsung Medical Center|Asan M Boryung Both Adult|Senior Phase II 182 INDUSTRY|OTHER|UNKNOWN Interventional Hypertension Drug: Fimasartan Pharmaceutical Co., Ltd|Seoul National University Hospital|Samsung Medical Center|Asan M Boryung Both Adult|Senior Phase II 182 INDUSTRY|OTHER|UNKNOWN Interventional Hypertension Drug: Fimasartan Pharmaceutical Co., Ltd|Seoul National University Hospital|Samsung Medical Center|Asan M Boryung Both Adult|Senior Phase II 182 INDUSTRY|OTHER|UNKNOWN Interventional Myocardial Drug: Eplerenone Infarction NHS Greater Glasgow and Clyde Phase IV Both Adult|Senior 100 OTHER Interventional Myocardial Drug: Eplerenone Infarction NHS Greater Glasgow and Clyde Phase IV Both Adult|Senior 100 OTHER Interventional Myocardial Drug: Eplerenone Infarction NHS Greater Glasgow and Clyde Phase IV Both Adult|Senior 100 OTHER Interventional Myocardial Drug: Eplerenone Infarction NHS Greater Glasgow and Clyde Phase IV Both Adult|Senior 100 OTHER Interventional Myocardial Drug: Eplerenone Infarction NHS Greater Glasgow and Clyde Phase IV Both Adult|Senior 100 OTHER Interventional Myocardial Drug: Eplerenone Infarction NHS Greater Glasgow and Clyde Phase IV Both Adult|Senior 100 OTHER Interventional Myocardial Drug: Eplerenone Infarction NHS Greater Glasgow and Clyde Phase IV Both Adult|Senior 100 OTHER Interventional Myocardial Drug: Eplerenone Infarction NHS Greater Glasgow and Clyde Phase IV Both Adult|Senior 100 OTHER Interventional Myocardial Drug: Eplerenone Infarction NHS Greater Glasgow and Clyde Phase IV Both Adult|Senior 100 OTHER Interventional Myocardial Drug: Eplerenone Infarction NHS Greater Glasgow and Clyde Phase IV Both Adult|Senior 100 OTHER Interventional Myocardial Drug: Eplerenone Infarction NHS Greater Glasgow and Clyde Phase IV Both Adult|Senior 100 OTHER Interventional Myocardial Drug: Eplerenone Infarction NHS Greater Glasgow and Clyde Phase IV Both Adult|Senior 100 OTHER Interventional Myocardial Drug: Eplerenone Infarction NHS Greater Glasgow and Clyde Phase IV Both Adult|Senior 100 OTHER Interventional Myocardial Drug: Eplerenone Infarction NHS Greater Glasgow and Clyde Phase IV Both Adult|Senior 100 OTHER Interventional Myocardial Drug: Eplerenone Infarction NHS Greater Glasgow and Clyde Phase IV Both Adult|Senior 100 OTHER Interventional Myocardial Drug: Eplerenone Infarction NHS Greater Glasgow and Clyde Phase IV Both Adult|Senior 100 OTHER Interventional Myocardial Drug: Eplerenone Infarction NHS Greater Glasgow and Clyde Phase IV Both Adult|Senior 100 OTHER Interventional Myocardial Drug: Eplerenone Infarction NHS Greater Glasgow and Clyde Phase IV Both Adult|Senior 100 OTHER Interventional Myocardial Drug: Eplerenone Infarction NHS Greater Glasgow and Clyde Phase IV Both Adult|Senior 100 OTHER Interventional Myocardial Drug: Eplerenone Infarction NHS Greater Glasgow and Clyde Phase IV Both Adult|Senior 100 OTHER Interventional

Cohort|Prospective CP-04/06 15-Nov-06 7-May 10-Aug 3-Aug-09 9-Aug 9-Dec Cohort|Prospective CP-04/06 15-Nov-06 7-May 10-Aug 3-Aug-09 9-Aug 9-Dec Cohort|Prospective CP-04/06 15-Nov-06 7-May 10-Aug 3-Aug-09 9-Aug 9-Dec Cohort|Prospective CP-04/06 15-Nov-06 7-May 10-Aug 3-Aug-09 9-Aug 9-Dec Cohort|Prospective CP-04/06 15-Nov-06 7-May 10-Aug 3-Aug-09 9-Aug 9-Dec Cohort|Prospective CP-04/06 15-Nov-06 7-May 10-Aug 3-Aug-09 9-Aug 9-Dec Cohort|Prospective CP-04/06 15-Nov-06 7-May 10-Aug 3-Aug-09 9-Aug 9-Dec Cohort|Prospective CP-04/06 15-Nov-06 7-May 10-Aug 3-Aug-09 9-Aug 9-Dec Cohort|Prospective CP-04/06 15-Nov-06 7-May 10-Aug 3-Aug-09 9-Aug 9-Dec Cohort|Prospective CP-04/06 15-Nov-06 7-May 10-Aug 3-Aug-09 9-Aug 9-Dec Cohort|Prospective CP-04/06 15-Nov-06 7-May 10-Aug 3-Aug-09 9-Aug 9-Dec Cohort|Prospective CP-04/06 15-Nov-06 7-May 10-Aug 3-Aug-09 9-Aug 9-Dec Cohort|Prospective CP-04/06 15-Nov-06 7-May 10-Aug 3-Aug-09 9-Aug 9-Dec Cohort|Prospective CP-04/06 15-Nov-06 7-May 10-Aug 3-Aug-09 9-Aug 9-Dec Cohort|Prospective CP-04/06 15-Nov-06 7-May 10-Aug 3-Aug-09 9-Aug 9-Dec Cohort|Prospective CP-04/06 15-Nov-06 7-May 10-Aug 3-Aug-09 9-Aug 9-Dec Cohort|Prospective CP-04/06 15-Nov-06 7-May 10-Aug 3-Aug-09 9-Aug 9-Dec Cohort|Prospective CP-04/06 15-Nov-06 7-May 10-Aug 3-Aug-09 9-Aug 9-Dec Treatment|Non-Randomized|Open Label|Uncontrolled|Single Group Assignment|Pharmacodynamics Study MHI 06-890|D2454L00003 6-Nov 15-Nov-06 9-Jul-09 9-Jul Treatment|Non-Randomized|Open Label|Uncontrolled|Single Group Assignment|Pharmacodynamics Study MHI 06-890|D2454L00003 6-Nov 15-Nov-06 9-Jul-09 9-Jul Treatment|Non-Randomized|Open Label|Uncontrolled|Single Group Assignment|Pharmacodynamics Study MHI 06-890|D2454L00003 6-Nov 15-Nov-06 9-Jul-09 9-Jul Treatment|Non-Randomized|Open Label|Uncontrolled|Single Group Assignment|Pharmacodynamics Study MHI 06-890|D2454L00003 6-Nov 15-Nov-06 9-Jul-09 9-Jul Treatment|Non-Randomized|Open Label|Uncontrolled|Single Group Assignment|Pharmacodynamics Study MHI 06-890|D2454L00003 6-Nov 15-Nov-06 9-Jul-09 9-Jul Treatment|Non-Randomized|Open Label|Uncontrolled|Single Group Assignment|Pharmacodynamics Study MHI 06-890|D2454L00003 6-Nov 15-Nov-06 9-Jul-09 9-Jul Treatment|Non-Randomized|Open Label|Uncontrolled|Single Group Assignment|Pharmacodynamics Study MHI 06-890|D2454L00003 6-Nov 15-Nov-06 9-Jul-09 9-Jul Treatment|Non-Randomized|Open Label|Uncontrolled|Single Group Assignment|Pharmacodynamics Study MHI 06-890|D2454L00003 6-Nov 15-Nov-06 9-Jul-09 9-Jul Treatment|Non-Randomized|Open Label|Uncontrolled|Single Group Assignment|Pharmacodynamics Study MHI 06-890|D2454L00003 6-Nov 15-Nov-06 9-Jul-09 9-Jul Treatment|Non-Randomized|Open Label|Uncontrolled|Single Group Assignment|Pharmacodynamics Study MHI 06-890|D2454L00003 6-Nov 15-Nov-06 9-Jul-09 9-Jul Treatment|Non-Randomized|Open Label|Uncontrolled|Single Group Assignment|Pharmacodynamics Study MHI 06-890|D2454L00003 6-Nov 15-Nov-06 9-Jul-09 9-Jul Treatment|Non-Randomized|Open Label|Uncontrolled|Single Group Assignment|Pharmacodynamics Study MHI 06-890|D2454L00003 6-Nov 15-Nov-06 9-Jul-09 9-Jul Treatment|Non-Randomized|Open Label|Uncontrolled|Single Group Assignment|Pharmacodynamics Study MHI 06-890|D2454L00003 6-Nov 15-Nov-06 9-Jul-09 9-Jul Treatment|Non-Randomized|Open Label|Uncontrolled|Single Group Assignment|Pharmacodynamics Study MHI 06-890|D2454L00003 6-Nov 15-Nov-06 9-Jul-09 9-Jul Treatment|Non-Randomized|Open Label|Uncontrolled|Single Group Assignment|Pharmacodynamics Study MHI 06-890|D2454L00003 6-Nov 15-Nov-06 9-Jul-09 9-Jul Treatment|Non-Randomized|Open Label|Uncontrolled|Single Group Assignment|Pharmacodynamics Study MHI 06-890|D2454L00003 6-Nov 15-Nov-06 9-Jul-09 9-Jul Treatment|Non-Randomized|Open Label|Uncontrolled|Single Group Assignment|Pharmacodynamics Study MHI 06-890|D2454L00003 6-Nov 15-Nov-06 9-Jul-09 9-Jul Treatment|Non-Randomized|Open Label|Uncontrolled|Single Group Assignment|Pharmacodynamics Study MHI 06-890|D2454L00003 6-Nov 15-Nov-06 9-Jul-09 9-Jul Treatment|Non-Randomized|Open Label|Uncontrolled|Single Group Assignment|Pharmacodynamics Study MHI 06-890|D2454L00003 6-Nov 15-Nov-06 9-Jul-09 9-Jul Treatment|Non-Randomized|Open Label|Uncontrolled|Single Group Assignment|Pharmacodynamics Study MHI 06-890|D2454L00003 6-Nov 15-Nov-06 9-Jul-09 9-Jul Diagnostic|Randomized|Double-Blind|Placebo Control|Parallel Assignment|Efficacy Study 17 24-Nov-06 2-Sep 6-Jul 16-Apr-09 9-Apr Diagnostic|Randomized|Double-Blind|Placebo Control|Parallel Assignment|Efficacy Study 17 24-Nov-06 2-Sep 6-Jul 16-Apr-09 9-Apr Diagnostic|Randomized|Double-Blind|Placebo Control|Parallel Assignment|Efficacy Study 17 24-Nov-06 2-Sep 6-Jul 16-Apr-09 9-Apr Diagnostic|Randomized|Double-Blind|Placebo Control|Parallel Assignment|Efficacy Study 17 24-Nov-06 2-Sep 6-Jul 16-Apr-09 9-Apr Diagnostic|Randomized|Double-Blind|Placebo Control|Parallel Assignment|Efficacy Study 17 24-Nov-06 2-Sep 6-Jul 16-Apr-09 9-Apr

Diagnostic|Randomized|Double-Blind|Placebo Control|Parallel Assignment|Efficacy Study 17 24-Nov-06 2-Sep 6-Jul 16-Apr-09 9-Apr Diagnostic|Randomized|Double-Blind|Placebo Control|Parallel Assignment|Efficacy Study 17 24-Nov-06 2-Sep 6-Jul 16-Apr-09 9-Apr Diagnostic|Randomized|Double-Blind|Placebo Control|Parallel Assignment|Efficacy Study 17 24-Nov-06 2-Sep 6-Jul 16-Apr-09 9-Apr Diagnostic|Randomized|Double-Blind|Placebo Control|Parallel Assignment|Efficacy Study 17 24-Nov-06 2-Sep 6-Jul 16-Apr-09 9-Apr Diagnostic|Randomized|Double-Blind|Placebo Control|Parallel Assignment|Efficacy Study 17 24-Nov-06 2-Sep 6-Jul 16-Apr-09 9-Apr Diagnostic|Randomized|Double-Blind|Placebo Control|Parallel Assignment|Efficacy Study 17 24-Nov-06 2-Sep 6-Jul 16-Apr-09 9-Apr Diagnostic|Randomized|Double-Blind|Placebo Control|Parallel Assignment|Efficacy Study 17 24-Nov-06 2-Sep 6-Jul 16-Apr-09 9-Apr Diagnostic|Randomized|Double-Blind|Placebo Control|Parallel Assignment|Efficacy Study 17 24-Nov-06 2-Sep 6-Jul 16-Apr-09 9-Apr Diagnostic|Randomized|Double-Blind|Placebo Control|Parallel Assignment|Efficacy Study 17 24-Nov-06 2-Sep 6-Jul 16-Apr-09 9-Apr Diagnostic|Randomized|Double-Blind|Placebo Control|Parallel Assignment|Efficacy Study 17 24-Nov-06 2-Sep 6-Jul 16-Apr-09 9-Apr Diagnostic|Randomized|Double-Blind|Placebo Control|Parallel Assignment|Efficacy Study 17 24-Nov-06 2-Sep 6-Jul 16-Apr-09 9-Apr Diagnostic|Randomized|Double-Blind|Placebo Control|Parallel Assignment|Efficacy Study 17 24-Nov-06 2-Sep 6-Jul 16-Apr-09 9-Apr Diagnostic|Randomized|Double-Blind|Placebo Control|Parallel Assignment|Efficacy Study 17 24-Nov-06 2-Sep 6-Jul 16-Apr-09 9-Apr Treatment|Non-Randomized|Open Label|Historical Control|Single Group Assignment|Safety/Efficacy Study 4273 2-Jan-07 7-Jan 8-Jan 3-Jan-07 6-Dec Treatment|Non-Randomized|Open Label|Historical Control|Single Group Assignment|Safety/Efficacy Study 4273 2-Jan-07 7-Jan 8-Jan 3-Jan-07 6-Dec Treatment|Non-Randomized|Open Label|Historical Control|Single Group Assignment|Safety/Efficacy Study 4273 2-Jan-07 7-Jan 8-Jan 3-Jan-07 6-Dec Treatment|Non-Randomized|Open Label|Historical Control|Single Group Assignment|Safety/Efficacy Study 4273 2-Jan-07 7-Jan 8-Jan 3-Jan-07 6-Dec Treatment|Non-Randomized|Open Label|Historical Control|Single Group Assignment|Safety/Efficacy Study 4273 2-Jan-07 7-Jan 8-Jan 3-Jan-07 6-Dec Treatment|Non-Randomized|Open Label|Historical Control|Single Group Assignment|Safety/Efficacy Study 4273 2-Jan-07 7-Jan 8-Jan 3-Jan-07 6-Dec Treatment|Non-Randomized|Open Label|Historical Control|Single Group Assignment|Safety/Efficacy Study 4273 2-Jan-07 7-Jan 8-Jan 3-Jan-07 6-Dec Treatment|Non-Randomized|Open Label|Historical Control|Single Group Assignment|Safety/Efficacy Study 4273 2-Jan-07 7-Jan 8-Jan 3-Jan-07 6-Dec Treatment|Non-Randomized|Open Label|Historical Control|Single Group Assignment|Safety/Efficacy Study 4273 2-Jan-07 7-Jan 8-Jan 3-Jan-07 6-Dec Treatment|Non-Randomized|Open Label|Historical Control|Single Group Assignment|Safety/Efficacy Study 4273 2-Jan-07 7-Jan 8-Jan 3-Jan-07 6-Dec Treatment|Non-Randomized|Open Label|Historical Control|Single Group Assignment|Safety/Efficacy Study 4273 2-Jan-07 7-Jan 8-Jan 3-Jan-07 6-Dec Treatment|Non-Randomized|Open Label|Historical Control|Single Group Assignment|Safety/Efficacy Study 4273 2-Jan-07 7-Jan 8-Jan 3-Jan-07 6-Dec Treatment|Randomized|Double Blind (Subject, Investigator, Outcomes Assessor)|Active Control|Crossover Assignment|Effic Um dnr 03-0324-Apr-07 3-Nov 8-Jun 8-Jan-08 8-Jan BIFF 8-Jun Treatment|Randomized|Double Blind (Subject, Investigator, Outcomes Assessor)|Active Control|Crossover Assignment|Effic Um dnr 03-0324-Apr-07 3-Nov 8-Jun 8-Jan-08 8-Jan BIFF 8-Jun Treatment|Randomized|Double Blind (Subject, Investigator, Outcomes Assessor)|Active Control|Crossover Assignment|Effic Um dnr 03-0324-Apr-07 3-Nov 8-Jun 8-Jan-08 8-Jan BIFF 8-Jun Treatment|Randomized|Double Blind (Subject, Investigator, Outcomes Assessor)|Active Control|Crossover Assignment|Effic Um dnr 03-0324-Apr-07 3-Nov 8-Jun 8-Jan-08 8-Jan BIFF 8-Jun Treatment|Randomized|Double Blind (Subject, Investigator, Outcomes Assessor)|Active Control|Crossover Assignment|Effic Um dnr 03-0324-Apr-07 3-Nov 8-Jun 8-Jan-08 8-Jan BIFF 8-Jun Treatment|Randomized|Double Blind (Subject, Investigator, Outcomes Assessor)|Active Control|Crossover Assignment|Effic Um dnr 03-0324-Apr-07 3-Nov 8-Jun 8-Jan-08 8-Jan BIFF 8-Jun Treatment|Randomized|Double Blind (Subject, Investigator, Outcomes Assessor)|Active Control|Crossover Assignment|Effic Um dnr 03-0324-Apr-07 3-Nov 8-Jun 8-Jan-08 8-Jan BIFF 8-Jun Treatment|Randomized|Double Blind (Subject, Investigator, Outcomes Assessor)|Active Control|Crossover Assignment|Effic Um dnr 03-0324-Apr-07 3-Nov 8-Jun 8-Jan-08 8-Jan BIFF 8-Jun Treatment|Randomized|Double Blind (Subject, Investigator, Outcomes Assessor)|Active Control|Crossover Assignment|Effic Um dnr 03-0324-Apr-07 3-Nov 8-Jun 8-Jan-08 8-Jan BIFF 8-Jun Treatment|Randomized|Double Blind (Subject, Investigator, Outcomes Assessor)|Active Control|Crossover Assignment|Effic Um dnr 03-0324-Apr-07 3-Nov 8-Jun 8-Jan-08 8-Jan BIFF 8-Jun Treatment|Randomized|Double Blind (Subject, Investigator, Outcomes Assessor)|Active Control|Crossover Assignment|Effic Um dnr 03-0324-Apr-07 3-Nov 8-Jun 8-Jan-08 8-Jan BIFF 8-Jun Treatment|Randomized|Double Blind (Subject, Investigator, Outcomes Assessor)|Active Control|Crossover Assignment|Effic Um dnr 03-0324-Apr-07 3-Nov 8-Jun 8-Jan-08 8-Jan BIFF 8-Jun Treatment|Randomized|Open Label|Active Control|Parallel Assignment|Efficacy Study 20061016-V2 29-May-07 7-Mar 12-Jan 6-Feb-09 9-Feb DOT-HF 12-Jan Treatment|Randomized|Open Label|Active Control|Parallel Assignment|Efficacy Study 20061016-V2 29-May-07 7-Mar 12-Jan 6-Feb-09 9-Feb DOT-HF 12-Jan Treatment|Randomized|Open Label|Active Control|Parallel Assignment|Efficacy Study 20061016-V2 29-May-07 7-Mar 12-Jan 6-Feb-09 9-Feb DOT-HF 12-Jan Treatment|Randomized|Open Label|Active Control|Parallel Assignment|Efficacy Study 20061016-V2 29-May-07 7-Mar 12-Jan 6-Feb-09 9-Feb DOT-HF 12-Jan Treatment|Randomized|Open Label|Active Control|Parallel Assignment|Efficacy Study 20061016-V2 29-May-07 7-Mar 12-Jan 6-Feb-09 9-Feb DOT-HF 12-Jan Treatment|Randomized|Open Label|Active Control|Parallel Assignment|Efficacy Study 20061016-V2 29-May-07 7-Mar 12-Jan 6-Feb-09 9-Feb DOT-HF 12-Jan Treatment|Randomized|Open Label|Active Control|Parallel Assignment|Efficacy Study 20061016-V2 29-May-07 7-Mar 12-Jan 6-Feb-09 9-Feb DOT-HF 12-Jan

Treatment|Randomized|Open Label|Active Control|Parallel Assignment|Efficacy Study 20061016-V2 29-May-07 7-Mar 12-Jan 6-Feb-09 9-Feb DOT-HF 12-Jan Treatment|Randomized|Open Label|Active Control|Parallel Assignment|Efficacy Study 20061016-V2 29-May-07 7-Mar 12-Jan 6-Feb-09 9-Feb DOT-HF 12-Jan Treatment|Randomized|Open Label|Active Control|Parallel Assignment|Efficacy Study 20061016-V2 29-May-07 7-Mar 12-Jan 6-Feb-09 9-Feb DOT-HF 12-Jan Treatment|Randomized|Open Label|Active Control|Parallel Assignment|Efficacy Study 20061016-V2 29-May-07 7-Mar 12-Jan 6-Feb-09 9-Feb DOT-HF 12-Jan Treatment|Randomized|Open Label|Active Control|Parallel Assignment|Efficacy Study 20061016-V2 29-May-07 7-Mar 12-Jan 6-Feb-09 9-Feb DOT-HF 12-Jan Treatment|Randomized|Open Label|Active Control|Parallel Assignment|Efficacy Study 20061016-V2 29-May-07 7-Mar 12-Jan 6-Feb-09 9-Feb DOT-HF 12-Jan Treatment|Randomized|Open Label|Active Control|Parallel Assignment|Efficacy Study 20061016-V2 29-May-07 7-Mar 12-Jan 6-Feb-09 9-Feb DOT-HF 12-Jan Treatment|Randomized|Open Label|Active Control|Parallel Assignment|Efficacy Study 20061016-V2 29-May-07 7-Mar 12-Jan 6-Feb-09 9-Feb DOT-HF 12-Jan Treatment|Randomized|Open Label|Active Control|Parallel Assignment|Efficacy Study 20061016-V2 29-May-07 7-Mar 12-Jan 6-Feb-09 9-Feb DOT-HF 12-Jan Treatment|Randomized|Open Label|Active Control|Parallel Assignment|Efficacy Study 20061016-V2 29-May-07 7-Mar 12-Jan 6-Feb-09 9-Feb DOT-HF 12-Jan Cohort|Prospective SCR 06 007|NAF (APE) : 851A 7-Jun 8-Apr-08 9-Dec 29-Sep-09 9-Aug BED 9-Jun Cohort|Prospective SCR 06 007|NAF (APE) : 851A 7-Jun 8-Apr-08 9-Dec 29-Sep-09 9-Aug BED 9-Jun Cohort|Prospective SCR 06 007|NAF (APE) : 851A 7-Jun 8-Apr-08 9-Dec 29-Sep-09 9-Aug BED 9-Jun Cohort|Prospective SCR 06 007|NAF (APE) : 851A 7-Jun 8-Apr-08 9-Dec 29-Sep-09 9-Aug BED 9-Jun Cohort|Prospective SCR 06 007|NAF (APE) : 851A 7-Jun 8-Apr-08 9-Dec 29-Sep-09 9-Aug BED 9-Jun Cohort|Prospective SCR 06 007|NAF (APE) : 851A 7-Jun 8-Apr-08 9-Dec 29-Sep-09 9-Aug BED 9-Jun Cohort|Prospective SCR 06 007|NAF (APE) : 851A 7-Jun 8-Apr-08 9-Dec 29-Sep-09 9-Aug BED 9-Jun Cohort|Prospective SCR 06 007|NAF (APE) : 851A 7-Jun 8-Apr-08 9-Dec 29-Sep-09 9-Aug BED 9-Jun Cohort|Prospective SCR 06 007|NAF (APE) : 851A 7-Jun 8-Apr-08 9-Dec 29-Sep-09 9-Aug BED 9-Jun Cohort|Prospective SCR 06 007|NAF (APE) : 851A 7-Jun 8-Apr-08 9-Dec 29-Sep-09 9-Aug BED 9-Jun Cohort|Prospective SCR 06 007|NAF (APE) : 851A 7-Jun 8-Apr-08 9-Dec 29-Sep-09 9-Aug BED 9-Jun Cohort|Prospective SCR 06 007|NAF (APE) : 851A 7-Jun 8-Apr-08 9-Dec 29-Sep-09 9-Aug BED 9-Jun Cohort|Prospective SCR 06 007|NAF (APE) : 851A 7-Jun 8-Apr-08 9-Dec 29-Sep-09 9-Aug BED 9-Jun Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Crossover Assignment|Efficacy S RESET 23-Apr-08 8-Jul 11-Jun 11-Dec-09 9-Dec RESET 11-Jun Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Crossover Assignment|Efficacy S RESET 23-Apr-08 8-Jul 11-Jun 11-Dec-09 9-Dec RESET 11-Jun Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Crossover Assignment|Efficacy S RESET 23-Apr-08 8-Jul 11-Jun 11-Dec-09 9-Dec RESET 11-Jun Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Crossover Assignment|Efficacy S RESET 23-Apr-08 8-Jul 11-Jun 11-Dec-09 9-Dec RESET 11-Jun Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Crossover Assignment|Efficacy S RESET 23-Apr-08 8-Jul 11-Jun 11-Dec-09 9-Dec RESET 11-Jun Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Crossover Assignment|Efficacy S RESET 23-Apr-08 8-Jul 11-Jun 11-Dec-09 9-Dec RESET 11-Jun Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Crossover Assignment|Efficacy S RESET 23-Apr-08 8-Jul 11-Jun 11-Dec-09 9-Dec RESET 11-Jun Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Crossover Assignment|Efficacy S RESET 23-Apr-08 8-Jul 11-Jun 11-Dec-09 9-Dec RESET 11-Jun Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Crossover Assignment|Efficacy S RESET 23-Apr-08 8-Jul 11-Jun 11-Dec-09 9-Dec RESET 11-Jun Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Crossover Assignment|Efficacy S RESET 23-Apr-08 8-Jul 11-Jun 11-Dec-09 9-Dec RESET 11-Jun Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Crossover Assignment|Efficacy S RESET 23-Apr-08 8-Jul 11-Jun 11-Dec-09 9-Dec RESET 11-Jun Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Crossover Assignment|Efficacy S RESET 23-Apr-08 8-Jul 11-Jun 11-Dec-09 9-Dec RESET 11-Jun Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Crossover Assignment|Efficacy S RESET 23-Apr-08 8-Jul 11-Jun 11-Dec-09 9-Dec RESET 11-Jun Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Crossover Assignment|Efficacy S RESET 23-Apr-08 8-Jul 11-Jun 11-Dec-09 9-Dec RESET 11-Jun Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Crossover Assignment|Efficacy S RESET 23-Apr-08 8-Jul 11-Jun 11-Dec-09 9-Dec RESET 11-Jun Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Crossover Assignment|Efficacy S RESET 23-Apr-08 8-Jul 11-Jun 11-Dec-09 9-Dec RESET 11-Jun Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Crossover Assignment|Efficacy S RESET 23-Apr-08 8-Jul 11-Jun 11-Dec-09 9-Dec RESET 11-Jun Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Crossover Assignment|Efficacy S RESET 23-Apr-08 8-Jul 11-Jun 11-Dec-09 9-Dec RESET 11-Jun Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Crossover Assignment|Efficacy S RESET 23-Apr-08 8-Jul 11-Jun 11-Dec-09 9-Dec RESET 11-Jun

Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Crossover Assignment|Efficacy S RESET 23-Apr-08 8-Jul 11-Jun 11-Dec-09 9-Dec RESET 11-Jun Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Crossover Assignment|Efficacy S RESET 23-Apr-08 8-Jul 11-Jun 11-Dec-09 9-Dec RESET 11-Jun Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Crossover Assignment|Efficacy S RESET 23-Apr-08 8-Jul 11-Jun 11-Dec-09 9-Dec RESET 11-Jun Treatment|Randomized|Open Label|Parallel Assignment 2012064|IRB# 00013639 22-Dec-07 5-May 8-Jul 8-Oct-08 8-Oct 8-Jul Treatment|Randomized|Open Label|Parallel Assignment 2012064|IRB# 00013639 22-Dec-07 5-May 8-Jul 8-Oct-08 8-Oct 8-Jul Treatment|Randomized|Open Label|Parallel Assignment 2012064|IRB# 00013639 22-Dec-07 5-May 8-Jul 8-Oct-08 8-Oct 8-Jul Treatment|Randomized|Open Label|Parallel Assignment 2012064|IRB# 00013639 22-Dec-07 5-May 8-Jul 8-Oct-08 8-Oct 8-Jul Treatment|Randomized|Open Label|Parallel Assignment 2012064|IRB# 00013639 22-Dec-07 5-May 8-Jul 8-Oct-08 8-Oct 8-Jul Treatment|Randomized|Open Label|Parallel Assignment 2012064|IRB# 00013639 22-Dec-07 5-May 8-Jul 8-Oct-08 8-Oct 8-Jul Treatment|Randomized|Open Label|Parallel Assignment 2012064|IRB# 00013639 22-Dec-07 5-May 8-Jul 8-Oct-08 8-Oct 8-Jul Treatment|Randomized|Open Label|Parallel Assignment 2012064|IRB# 00013639 22-Dec-07 5-May 8-Jul 8-Oct-08 8-Oct 8-Jul Treatment|Randomized|Open Label|Parallel Assignment 2012064|IRB# 00013639 22-Dec-07 5-May 8-Jul 8-Oct-08 8-Oct 8-Jul Treatment|Randomized|Open Label|Parallel Assignment 2012064|IRB# 00013639 22-Dec-07 5-May 8-Jul 8-Oct-08 8-Oct 8-Jul Treatment|Randomized|Open Label|Parallel Assignment 2012064|IRB# 00013639 22-Dec-07 5-May 8-Jul 8-Oct-08 8-Oct 8-Jul Treatment|Randomized|Open Label|Parallel Assignment 2012064|IRB# 00013639 22-Dec-07 5-May 8-Jul 8-Oct-08 8-Oct 8-Jul Treatment|Randomized|Open Label|Parallel Assignment 2012064|IRB# 00013639 22-Dec-07 5-May 8-Jul 8-Oct-08 8-Oct 8-Jul Treatment|Randomized|Open Label|Parallel Assignment 2012064|IRB# 00013639 22-Dec-07 5-May 8-Jul 8-Oct-08 8-Oct 8-Jul Treatment|Randomized|Open Label|Parallel Assignment 2012064|IRB# 00013639 22-Dec-07 5-May 8-Jul 8-Oct-08 8-Oct 8-Jul Treatment|Randomized|Open Label|Parallel Assignment 2012064|IRB# 00013639 22-Dec-07 5-May 8-Jul 8-Oct-08 8-Oct 8-Jul Treatment|Randomized|Open Label|Parallel Assignment 2012064|IRB# 00013639 22-Dec-07 5-May 8-Jul 8-Oct-08 8-Oct 8-Jul Treatment|Randomized|Open Label|Parallel Assignment 2012064|IRB# 00013639 22-Dec-07 5-May 8-Jul 8-Oct-08 8-Oct 8-Jul Treatment|Randomized|Open Label|Parallel Assignment 2012064|IRB# 00013639 22-Dec-07 5-May 8-Jul 8-Oct-08 8-Oct 8-Jul Treatment|Randomized|Open Label|Parallel Assignment 2012064|IRB# 00013639 22-Dec-07 5-May 8-Jul 8-Oct-08 8-Oct 8-Jul Treatment|Randomized|Open Label|Parallel Assignment 2012064|IRB# 00013639 22-Dec-07 5-May 8-Jul 8-Oct-08 8-Oct 8-Jul Treatment|Randomized|Open Label|Parallel Assignment 2012064|IRB# 00013639 22-Dec-07 5-May 8-Jul 8-Oct-08 8-Oct 8-Jul Treatment|Randomized|Open Label|Parallel Assignment 2012064|IRB# 00013639 22-Dec-07 5-May 8-Jul 8-Oct-08 8-Oct 8-Jul Treatment|Randomized|Open Label|Parallel Assignment 2012064|IRB# 00013639 22-Dec-07 5-May 8-Jul 8-Oct-08 8-Oct 8-Jul Treatment|Randomized|Open Label|Parallel Assignment 2012064|IRB# 00013639 22-Dec-07 5-May 8-Jul 8-Oct-08 8-Oct 8-Jul Cohort|Prospective ITAC07 20-Nov-08 8-Dec 7-Jul-09 9-Jul Cohort|Prospective ITAC07 20-Nov-08 8-Dec 7-Jul-09 9-Jul Cohort|Prospective ITAC07 20-Nov-08 8-Dec 7-Jul-09 9-Jul Cohort|Prospective ITAC07 20-Nov-08 8-Dec 7-Jul-09 9-Jul Cohort|Prospective ITAC07 20-Nov-08 8-Dec 7-Jul-09 9-Jul Cohort|Prospective ITAC07 20-Nov-08 8-Dec 7-Jul-09 9-Jul Cohort|Prospective ITAC07 20-Nov-08 8-Dec 7-Jul-09 9-Jul Cohort|Prospective ITAC07 20-Nov-08 8-Dec 7-Jul-09 9-Jul Cohort|Prospective ITAC07 20-Nov-08 8-Dec 7-Jul-09 9-Jul Cohort|Prospective ITAC07 20-Nov-08 8-Dec 7-Jul-09 9-Jul Cohort|Prospective ITAC07 20-Nov-08 8-Dec 7-Jul-09 9-Jul Cohort|Prospective ITAC07 20-Nov-08 8-Dec 7-Jul-09 9-Jul Cohort|Prospective ITAC07 20-Nov-08 8-Dec 7-Jul-09 9-Jul Cohort|Prospective ITAC07 20-Nov-08 8-Dec 7-Jul-09 9-Jul Cohort|Prospective ITAC07 20-Nov-08 8-Dec 7-Jul-09 9-Jul

Cohort|Prospective ITAC07 20-Nov-08 8-Dec 7-Jul-09 9-Jul Cohort|Prospective ITAC07 20-Nov-08 8-Dec 7-Jul-09 9-Jul Cohort|Prospective ITAC07 20-Nov-08 8-Dec 7-Jul-09 9-Jul Cohort|Prospective ITAC07 20-Nov-08 8-Dec 7-Jul-09 9-Jul Cohort|Prospective ITAC07 20-Nov-08 8-Dec 7-Jul-09 9-Jul Cohort|Prospective ITAC07 20-Nov-08 8-Dec 7-Jul-09 9-Jul Cohort|Prospective ITAC07 20-Nov-08 8-Dec 7-Jul-09 9-Jul Cohort|Prospective ITAC07 20-Nov-08 8-Dec 7-Jul-09 9-Jul Cohort|Prospective ITAC07 20-Nov-08 8-Dec 7-Jul-09 9-Jul Cohort|Prospective ITAC07 20-Nov-08 8-Dec 7-Jul-09 9-Jul Treatment|Randomized|Double Blind (Subject, Investigator)|Active Control|ParallelSELECT Select-B1B2 2-Dec-08 2-Sep 4-Dec 3-Dec-08 8-Dec Assignment|Pharmacokinetics/Dynamic 4-Dec Treatment|Randomized|Double Blind (Subject, Investigator)|Active Control|ParallelSELECT Select-B1B2 2-Dec-08 2-Sep 4-Dec 3-Dec-08 8-Dec Assignment|Pharmacokinetics/Dynamic 4-Dec Treatment|Randomized|Double Blind (Subject, Investigator)|Active Control|ParallelSELECT Select-B1B2 2-Dec-08 2-Sep 4-Dec 3-Dec-08 8-Dec Assignment|Pharmacokinetics/Dynamic 4-Dec Treatment|Randomized|Double Blind (Subject, Investigator)|Active Control|ParallelSELECT Select-B1B2 2-Dec-08 2-Sep 4-Dec 3-Dec-08 8-Dec Assignment|Pharmacokinetics/Dynamic 4-Dec Treatment|Randomized|Double Blind (Subject, Investigator)|Active Control|ParallelSELECT Select-B1B2 2-Dec-08 2-Sep 4-Dec 3-Dec-08 8-Dec Assignment|Pharmacokinetics/Dynamic 4-Dec Treatment|Randomized|Double Blind (Subject, Investigator)|Active Control|ParallelSELECT Select-B1B2 2-Dec-08 2-Sep 4-Dec 3-Dec-08 8-Dec Assignment|Pharmacokinetics/Dynamic 4-Dec Treatment|Randomized|Double Blind (Subject, Investigator)|Active Control|ParallelSELECT Select-B1B2 2-Dec-08 2-Sep 4-Dec 3-Dec-08 8-Dec Assignment|Pharmacokinetics/Dynamic 4-Dec Treatment|Randomized|Double Blind (Subject, Investigator)|Active Control|ParallelSELECT Select-B1B2 2-Dec-08 2-Sep 4-Dec 3-Dec-08 8-Dec Assignment|Pharmacokinetics/Dynamic 4-Dec Treatment|Randomized|Double Blind (Subject, Investigator)|Active Control|ParallelSELECT Select-B1B2 2-Dec-08 2-Sep 4-Dec 3-Dec-08 8-Dec Assignment|Pharmacokinetics/Dynamic 4-Dec Treatment|Randomized|Double Blind (Subject, Investigator)|Active Control|ParallelSELECT Select-B1B2 2-Dec-08 2-Sep 4-Dec 3-Dec-08 8-Dec Assignment|Pharmacokinetics/Dynamic 4-Dec Treatment|Randomized|Double Blind (Subject, Investigator)|Active Control|ParallelSELECT Select-B1B2 2-Dec-08 2-Sep 4-Dec 3-Dec-08 8-Dec Assignment|Pharmacokinetics/Dynamic 4-Dec Treatment|Randomized|Double Blind (Subject, Investigator)|Active Control|ParallelSELECT Select-B1B2 2-Dec-08 2-Sep 4-Dec 3-Dec-08 8-Dec Assignment|Pharmacokinetics/Dynamic 4-Dec Treatment|Randomized|Double Blind (Subject, Investigator)|Active Control|ParallelSELECT Select-B1B2 2-Dec-08 2-Sep 4-Dec 3-Dec-08 8-Dec Assignment|Pharmacokinetics/Dynamic 4-Dec Treatment|Randomized|Double Blind (Subject, Investigator)|Active Control|ParallelSELECT Select-B1B2 2-Dec-08 2-Sep 4-Dec 3-Dec-08 8-Dec Assignment|Pharmacokinetics/Dynamic 4-Dec Treatment|Randomized|Double Blind (Subject, Investigator)|Active Control|ParallelSELECT Select-B1B2 2-Dec-08 2-Sep 4-Dec 3-Dec-08 8-Dec Assignment|Pharmacokinetics/Dynamic 4-Dec Treatment|Randomized|Open Label|Parallel Assignment|Pharmacokinetics Study CY 1021 40009 40642 40010 40733 40764 Treatment|Randomized|Open Label|Parallel Assignment|Pharmacokinetics Study CY 1021 40009 40642 40010 40733 40764 Treatment|Randomized|Open Label|Parallel Assignment|Pharmacokinetics Study CY 1021 40009 40642 40010 40733 40764 Treatment|Randomized|Open Label|Parallel Assignment|Pharmacokinetics Study CY 1021 40009 40642 40010 40733 40764 Treatment|Randomized|Open Label|Parallel Assignment|Pharmacokinetics Study CY 1021 40009 40642 40010 40733 40764 Treatment|Randomized|Open Label|Parallel Assignment|Pharmacokinetics Study CY 1021 40009 40642 40010 40733 40764 Treatment|Randomized|Open Label|Parallel Assignment|Pharmacokinetics Study CY 1021 40009 40642 40010 40733 40764 Treatment|Randomized|Open Label|Parallel Assignment|Pharmacokinetics Study CY 1021 40009 40642 40010 40733 40764 Treatment|Randomized|Open Label|Parallel Assignment|Pharmacokinetics Study CY 1021 40009 40642 40010 40733 40764 Treatment|Randomized|Open Label|Parallel Assignment|Pharmacokinetics Study CY 1021 40009 40642 40010 40733 40764 Treatment|Randomized|Open Label|Parallel Assignment|Pharmacokinetics Study CY 1021 40009 40642 40010 40733 40764 Treatment|Randomized|Open Label|Parallel Assignment|Pharmacokinetics Study CY 1021 40009 40642 40010 40733 40764 Treatment|Randomized|Open Label|Parallel Assignment|Pharmacokinetics Study CY 1021 40009 40642 40010 40733 40764 Treatment|Randomized|Open Label|Parallel Assignment|Pharmacokinetics Study CY 1021 40009 40642 40010 40733 40764 Treatment|Randomized|Open Label|Parallel Assignment|Pharmacokinetics Study CY 1021 40009 40642 40010 40733 40764 Treatment|Randomized|Open Label|Parallel Assignment|Pharmacokinetics Study CY 1021 40009 40642 40010 40733 40764 Treatment|Randomized|Open Label|Parallel Assignment|Pharmacokinetics Study CY 1021 40009 40642 40010 40733 40764 Treatment|Randomized|Open Label|Parallel Assignment|Pharmacokinetics Study CY 1021 40009 40642 40010 40733 40764

Treatment|Randomized|Open Label|Parallel Assignment|Pharmacokinetics Study CY 1021 40009 40642 40010 40733 Treatment|Randomized|Open Label|Parallel Assignment|Pharmacokinetics Study CY 1021 40009 40642 40010 40733 Treatment|Randomized|Open Label|Parallel Assignment|Pharmacokinetics Study CY 1021 40009 40642 40010 40733 Treatment|Randomized|Open Label|Parallel Assignment|Pharmacokinetics Study CY 1021 40009 40642 40010 40733 Treatment|Randomized|Open Label|Parallel Assignment|Pharmacokinetics Study CY 1021 40009 40642 40010 40733 Treatment|Randomized|Open Label|Parallel Assignment|Pharmacokinetics Study CY 1021 40009 40642 40010 40733 Treatment|Randomized|Open Label|Parallel Assignment|Pharmacokinetics Study CY 1021 40009 40642 40010 40733 Treatment|Randomized|Open Label|Parallel Assignment|Pharmacokinetics Study CY 1021 40009 40642 40010 40733 Treatment|Randomized|Open Label|Parallel Assignment|Pharmacokinetics Study CY 1021 40009 40642 40010 40733 Treatment|Randomized|Open Label|Parallel Assignment|Pharmacokinetics Study CY 1021 40009 40642 40010 40733 Treatment|Randomized|Open Label|Parallel Assignment|Pharmacokinetics Study CY 1021 40009 40642 40010 40733 Treatment|Randomized|Open Label|Parallel Assignment|Pharmacokinetics Study CY 1021 40009 40642 40010 40733 Treatment|Randomized|Open Label|Parallel Assignment|Pharmacokinetics Study CY 1021 40009 40642 40010 40733 Treatment|Randomized|Open Label|Parallel Assignment|Pharmacokinetics Study CY 1021 40009 40642 40010 40733 Treatment|Randomized|Open Label|Parallel Assignment|Pharmacokinetics Study CY 1021 40009 40642 40010 40733 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764

40764 40764 40764 40764 40764 40764 40764 40764 40764 40764 40764 40764 40764 40764 40764

Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Case-Only|Prospective HN 3052 40030 40550 40030 40764 Treatment|Randomized|Open Label|Parallel Assignment|Safety/Efficacy Study CVAL489AAU01 39931 40672 39947 40672 VIPER-BP 40613 Treatment|Randomized|Open Label|Parallel Assignment|Safety/Efficacy Study CVAL489AAU01 39931 40672 39947 40672 VIPER-BP 40613 Treatment|Randomized|Open Label|Parallel Assignment|Safety/Efficacy Study CVAL489AAU01 39931 40672 39947 40672 VIPER-BP 40613 Treatment|Randomized|Open Label|Parallel Assignment|Safety/Efficacy Study CVAL489AAU01 39931 40672 39947 40672 VIPER-BP 40613 Treatment|Randomized|Open Label|Parallel Assignment|Safety/Efficacy Study CVAL489AAU01 39931 40672 39947 40672 VIPER-BP 40613 Treatment|Randomized|Open Label|Parallel Assignment|Safety/Efficacy Study CVAL489AAU01 39931 40672 39947 40672 VIPER-BP 40613 Treatment|Randomized|Open Label|Parallel Assignment|Safety/Efficacy Study CVAL489AAU01 39931 40672 39947 40672 VIPER-BP 40613 Treatment|Randomized|Open Label|Parallel Assignment|Safety/Efficacy Study CVAL489AAU01 39931 40672 39947 40672 VIPER-BP 40613 Treatment|Randomized|Open Label|Parallel Assignment|Safety/Efficacy Study CVAL489AAU01 39931 40672 39947 40672 VIPER-BP 40613 Treatment|Randomized|Open Label|Parallel Assignment|Safety/Efficacy Study CVAL489AAU01 39931 40672 39947 40672 VIPER-BP 40613 Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Placebo40702 A-657-BR-CT-202 39980 40793 40702 39981 40703 Control|Parallel Assignm Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Placebo40702 A-657-BR-CT-202 39980 40793 40702 39981 40703 Control|Parallel Assignm Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Placebo40702 A-657-BR-CT-202 39980 40793 40702 39981 40703 Control|Parallel Assignm Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Placebo40702 A-657-BR-CT-202 39980 40793 40702 39981 40703 Control|Parallel Assignm Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Placebo40702 A-657-BR-CT-202 39980 40793 40702 39981 40703 Control|Parallel Assignm Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Placebo40702 A-657-BR-CT-202 39980 40793 40702 39981 40703 Control|Parallel Assignm

Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Placebo40702 A-657-BR-CT-202 39980 40793 40702 39981 40703 Control|Parallel Assignm Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Placebo40702 A-657-BR-CT-202 39980 40793 40702 39981 40703 Control|Parallel Assignm Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Placebo40702 A-657-BR-CT-202 39980 40793 40702 39981 40703 Control|Parallel Assignm Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Placebo40702 A-657-BR-CT-202 39980 40793 40702 39981 40703 Control|Parallel Assignm Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Placebo40702 A-657-BR-CT-202 39980 40793 40702 39981 40703 Control|Parallel Assignm Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Placebo40702 A-657-BR-CT-202 39980 40793 40702 39981 40703 Control|Parallel Assignm Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Placebo40702 A-657-BR-CT-202 39980 40793 40702 39981 40703 Control|Parallel Assignm Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Placebo40702 A-657-BR-CT-202 39980 40793 40702 39981 40703 Control|Parallel Assignm Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Placebo40702 A-657-BR-CT-202 39980 40793 40702 39981 40703 Control|Parallel Assignm Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Placebo40702 A-657-BR-CT-202 39980 40793 40702 39981 40703 Control|Parallel Assignm Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Placebo40702 A-657-BR-CT-202 39980 40793 40702 39981 40703 Control|Parallel Assignm Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Placebo40702 A-657-BR-CT-202 39980 40793 40702 39981 40703 Control|Parallel Assignm Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Placebo40702 A-657-BR-CT-202 39980 40793 40702 39981 40703 Control|Parallel Assignm Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Placebo40702 A-657-BR-CT-202 39980 40793 40702 39981 40703 Control|Parallel Assignm Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Placebo40702 A-657-BR-CT-202 39980 40793 40702 39981 40703 Control|Parallel Assignm Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Placebo40702 A-657-BR-CT-202 39980 40793 40702 39981 40703 Control|Parallel Assignm Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Placebo40702 A-657-BR-CT-202 39980 40793 40702 39981 40703 Control|Parallel Assignm Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Placebo40702 A-657-BR-CT-202 39980 40793 40702 39981 40703 Control|Parallel Assignm Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Placebo40702 A-657-BR-CT-202 39980 40793 40702 39981 40703 Control|Parallel Assignm Treatment|Randomized|Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Placebo40702 A-657-BR-CT-202 39980 40793 40702 39981 40703 Control|Parallel Assignm Treatment|Randomized|Double-Blind|Placebo Control|Parallel Assignment|Efficacy Study WN04CA024|Eudract number 5-Apr 18-Aug-05 2004-004399-35 7-Apr-06 4-Nov Treatment|Randomized|Double-Blind|Placebo Control|Parallel Assignment|Efficacy Study WN04CA024|Eudract number 5-Apr 18-Aug-05 2004-004399-35 7-Apr-06 4-Nov Treatment|Randomized|Double-Blind|Placebo Control|Parallel Assignment|Efficacy Study WN04CA024|Eudract number 5-Apr 18-Aug-05 2004-004399-35 7-Apr-06 4-Nov Treatment|Randomized|Double-Blind|Placebo Control|Parallel Assignment|Efficacy Study WN04CA024|Eudract number 5-Apr 18-Aug-05 2004-004399-35 7-Apr-06 4-Nov Treatment|Randomized|Double-Blind|Placebo Control|Parallel Assignment|Efficacy Study WN04CA024|Eudract number 5-Apr 18-Aug-05 2004-004399-35 7-Apr-06 4-Nov Treatment|Randomized|Double-Blind|Placebo Control|Parallel Assignment|Efficacy Study WN04CA024|Eudract number 5-Apr 18-Aug-05 2004-004399-35 7-Apr-06 4-Nov Treatment|Randomized|Double-Blind|Placebo Control|Parallel Assignment|Efficacy Study WN04CA024|Eudract number 5-Apr 18-Aug-05 2004-004399-35 7-Apr-06 4-Nov Treatment|Randomized|Double-Blind|Placebo Control|Parallel Assignment|Efficacy Study WN04CA024|Eudract number 5-Apr 18-Aug-05 2004-004399-35 7-Apr-06 4-Nov Treatment|Randomized|Double-Blind|Placebo Control|Parallel Assignment|Efficacy Study WN04CA024|Eudract number 5-Apr 18-Aug-05 2004-004399-35 7-Apr-06 4-Nov Treatment|Randomized|Double-Blind|Placebo Control|Parallel Assignment|Efficacy Study WN04CA024|Eudract number 5-Apr 18-Aug-05 2004-004399-35 7-Apr-06 4-Nov Treatment|Randomized|Double-Blind|Placebo Control|Parallel Assignment|Efficacy Study WN04CA024|Eudract number 5-Apr 18-Aug-05 2004-004399-35 7-Apr-06 4-Nov Treatment|Randomized|Double-Blind|Placebo Control|Parallel Assignment|Efficacy Study WN04CA024|Eudract number 5-Apr 18-Aug-05 2004-004399-35 7-Apr-06 4-Nov Treatment|Randomized|Double-Blind|Placebo Control|Parallel Assignment|Efficacy Study WN04CA024|Eudract number 5-Apr 18-Aug-05 2004-004399-35 7-Apr-06 4-Nov Treatment|Randomized|Double-Blind|Placebo Control|Parallel Assignment|Efficacy Study WN04CA024|Eudract number 5-Apr 18-Aug-05 2004-004399-35 7-Apr-06 4-Nov Treatment|Randomized|Double-Blind|Placebo Control|Parallel Assignment|Efficacy Study WN04CA024|Eudract number 5-Apr 18-Aug-05 2004-004399-35 7-Apr-06 4-Nov Treatment|Randomized|Double-Blind|Placebo Control|Parallel Assignment|Efficacy Study WN04CA024|Eudract number 5-Apr 18-Aug-05 2004-004399-35 7-Apr-06 4-Nov Treatment|Randomized|Double-Blind|Placebo Control|Parallel Assignment|Efficacy Study WN04CA024|Eudract number 5-Apr 18-Aug-05 2004-004399-35 7-Apr-06 4-Nov Treatment|Randomized|Double-Blind|Placebo Control|Parallel Assignment|Efficacy Study WN04CA024|Eudract number 5-Apr 18-Aug-05 2004-004399-35 7-Apr-06 4-Nov Treatment|Randomized|Double-Blind|Placebo Control|Parallel Assignment|Efficacy Study WN04CA024|Eudract number 5-Apr 18-Aug-05 2004-004399-35 7-Apr-06 4-Nov Treatment|Randomized|Double-Blind|Placebo Control|Parallel Assignment|Efficacy Study WN04CA024|Eudract number 5-Apr 18-Aug-05 2004-004399-35 7-Apr-06 4-Nov

678938 678939 678940 678941 678942 678943 678944 678945 678946 678947 678948 678949 678950 678951 678952 678953 678954 678955 679370 679371 679372 679373 679374 679375 679376 679377 679378 679379 679380 679381 679382 679383 679384 679385 679386 679387 679388 679389 684458 684459 684460 684461 684462

Age >= 60 years Age age\Age Group\AGGP\C1114365 | 60\NUMERAL\\ | years\Temporal Concept\TMCO\C156 age >=60 years Have been insured with HBA for 12 monthsinsured\Intellectualfor 12 months or longer | with\\\ | hba\Biologica Diagnostic or Lab Results been insured with hba Product\INPR\C1548605 have\\\ | been\\\ | or longer have Subjects at high-risk Symptom and subjectsDisabled Group\PODG\C2349001 | at\\\ ofhigh\Quantitative Concept\Q Disease, of subjects\Patient or at high-risk of subsequent development | heart failure subsequentSign development of heart failure comprising Disease,onecomprising\Organic Chemical\ORCH\ | myocardial infarction (mi) withoutConcept\QNCO\C at least Symptom and comprising >= one of: prior >=\SYMBOL\\ | one\Quantitative known left ventr of: Prior myocardial infarction (MI) without known left ventricular (LV) dysfunction Sign Current active ischemiccurrent\Temporal Concept\TMCO\C1705970 | active\Functional Concept\FTCN\C2347179 Disease, Symptomdisease heart and current active ischemic heart disease Sign Prior Cerebrovascular Accidentand prior cerebrovascular accident (cva) Disease, Symptom (CVA) prior\History\\C0332152 | cerebrovascular accident\Disease or Syndrome\DSYN\C003845 Sign Known valvular heart disease without known LV dysfunction Disease, Symptom and known valvular heart disease without knownheart disease\Disease or Syndrome known\Qualitative Concept\QLCO\C0205309 | valvular lv dysfunction Sign Atrial fibrillation Disease, Symptom and atrial fibrillation Function\PATF\C1963067 | atrial fibrillation\Pathologic Sign Ventricular Disease, Symptom and arrhythmia\Pathologic Function\PATF\C1963277 | resulting in\Functional Conc arrhythmia ventricular ventricular arrhythmia resulting in syncope or pre-syncope resulting in Sign syncope or pre-syncope Treated hypertension, of at least 2treated hypertension, of >= 2 years duration Disease, Symptom and Sign duration treated\Therapeutic or Preventive Procedure\TOPP\C1522326 | hypertension\Disease or S years Treated Diabetes mellitus, of at least 2 years duration Disease, Symptom and treated diabetes mellitus, of >= 2 years duration | diabetes mellitus\Disease treated\Therapeutic or Preventive Procedure\TOPP\C1522326 Sign Estimated Glomerular or Lab Results (eGFR) <50ml/min filtration rate (egfr)glomerular filtration rate\Diagnostic P Diagnostic Filtration Rate estimated\Quantitative Concept\QNCO\C0750572 | <50 ml / min estimated glomerular Exclusion Criteria: Symptom and exclusion criteria: Disease, exclusion criteria\NO\\C0680251 | Sign Known systolic or diastolic heart failure systolic or diastolic heart failure Disease, Symptom and known Concept\QLCO\C0205309 | systolic\Temporal Concept\TMCO\C003915 known\Qualitative Sign Symptoms suggestive of current heart failure.suggestive of current heart failure. of\Functional Concept\FTCN\C0 Disease, Symptom and symptoms symptoms\Sign or Symptom\SOSY\C1457887 | suggestive Sign LV systolic or diastolic dysfunction lv systolic or diastolic dysfunction onsystolic\Temporal Concept\TMCO\C00391 Pharmaceutical Substance echocardiography or other objective imaging modality. other objective imag lv\Pharmacologic Substance\PHSU\C1881413 | echocardiography or on or Drug Medications for treatment of heart failure suchfor ACE inhibitors, angiotensinsuchfor\\\blockers (ARBs), beta block Pharmaceutical Substance or Drug as treatment of heart failure receptor |inhibitors, angiotensin re medications\Pharmacologic Substance\PHSU\C0013227 | as ace treatment\Therapeutic medications Use of suchDisease, Symptom and use indications such as hypertension, post-MI management (without known LV medications for approved of Concept\FTCN\C1947944 | such\\\ | medications\Pharmacologicpost-m use of\Functional such medications for approved indications such as hypertension, Substa Sign Ages Eligible for Study: ages\Age and older Age 18 Years Group\AGGP\C1114365 18 years and older ages eligible for study: | eligible\Idea or Concept\IDCN\C1548635 | for\\\ | stu Genders Eligible for Study: Both gendersAttribute\ORGA\C0079399 | eligible\Idea or Concept\IDCN\C1548635 | Gender genders\Organism eligible for study: both Accepts Healthy Volunteers: No of PatientConcept\QLCO\C1548601 | healthy volunteers\Healthy Population\\n Special Characteristic accepts healthy volunteers: no accepts\Qualitative Principal Inclusion Criteria: Male or female >Concept\QLCO\C0401925female > or = 18 years old. Age principal\Qualitative inclusionyears old. principal or = 18 criteria: male or | inclusion criteria\Qualitative Concept\QL Symptomatic CHF corresponding to NYHA class II-IV corresponding at least |class ii-iv symptoms for >= 4 weeks pri Disease Stage symptomatic\Functional Concept\FTCN\C0231220 4 chf\Disease or Syndrome\DSYN\C001 symptomatic chf symptoms for to nyha weeks prior randomization. LVEF < or = Diagnostic or Lab Results < or = 40% 40% lvef\Laboratory or Test Result\LBTR\C0428772 | <\SYMBOL\\ | or\\\ | =\SYMBOL\\ | 40\N lvef Treatment with an optimal and stable dose ofwithPreventivefor at stable dose ofpriorinhibitor for >=in the study. Therapy or Surgery treatment\Therapeutic ACEan optimalProcedure\TOPP\C1705169enrolment| 4 weeksoptim treatment or inhibitor and least 4 weeks ace to | with\\\ an\\\ | prior Principal Exclusion Criteria: Treatment with exclusion criteria: treatment exclusion criteria\NO\\C0680251to:\\\ | Therapy or Surgery principal\Qualitative an ARB within 8 weeks prior to randomization. 8 weeks prior | rando principal Concept\QLCO\C0401925 | with an arb within Known hypersensitivityknown\Qualitative hypersensitivity to arbs or ace inhibitors. Allergy to ARBs or known Concept\QLCO\C0205309 | hypersensitivity\Allergy\\C0520946 | to\\\ ACE inhibitors. Creatinine clearance < or Lab Results serum creatinine >< 30 ml / min or serum creatinine > 221 | 30\NUMERAL Diagnostic 30 ml/min clearance\Laboratory Procedure\LBPR\C0812399 | <\SYMBOL\\ creatinine or creatinine clearance 221 Current serum potassium > Substance or Drug a history of marked5.0 mmol /potassium\Laboratory Procedure\LB Pharmaceutical or = 5.0 mmol/L or potassium > or = ACE inhibitor or ARB induced hyperkalemia. current\Temporal Concept\TMCO\C1705970 | serum l or a history of marked ace inhibito current serum Known bilateral renal artery stenosis. Disease, Symptom and known bilateral renal artery stenosis. known\Qualitative Concept\QLCO\C0205309 | bilateral renal artery stenosis\Disease or Sy Sign Current symptomatic hypotension currentConcept\TMCO\C1705970 | symptomatic\Functional Concept\FTCN\C0 Disease Stage current\Temporal systolic B.P hypotension and / or systolic b. p and/or symptomatic < 90 mmHg. iagnostic or Lab Results| 90\NUMERAL\\ | mmhg.\UNIT\\C0439475 | D <\SYMBOL\\ 90 mmhg. < Decompensated heart failure described as hospitalizationfailure described as hospitalization or i. v or Syndrome Disease Stage decompensated\Qualitative heart or I.V decompensated Concept\QLCO\C0205434 | heart failure\Disease administration of medication in emergency room of medication in emergency 4 weeks heartin\\\ | emergency ro Disease, Symptom and administration or heart failure Activity\HLCA\C0150270 | failure clinic within 4 administration of medication\Health Care clinic within room or Sign Stroke, acute coronary stroke\Disease within thecoronary syndrome, pci within the coronary syndrome\Disease or Disease, Symptom and PCI or Syndrome\DSYN\C0038454 randomization. 4 weeks before randomiza syndrome, stroke, acute last 4 weeks before | ,\\\ | acute last Sign Connective Disease, Symptom and tissue disease\Disease or Syndrome\DSYN\C0009782 | or\\\ | chronic\Tempor tissue disease or chronic inflammatory conditionor chronic inflammatory condition connective connective tissue disease Sign Acute inflammatory Symptom andas an infection or gout attacksuch aslast infection or goutSymptom\SOSY\C0333 Disease, process such acuteConcept\TMCO\C1547295the an 2 weeks. acute\Temporal inflammatory process in | inflammatory\Sign or attack in the last 2 wee Sign Pregnant orPregancy Related Activities of childbearing potential who | or\\\ |protected from pregnancy arean ac lactating women or women Function\ORGF\C0549206 are notchildbearing potential who by not p pregnant\Organism or lactating women or women of lactating\Organism Function\ORGF pregnant Age <18 and >80 Age age\Age Group\AGGP\C1114365 | <\SYMBOL\\ | 18\NUMERAL\\ | and\\\ | >\SYMBOL\\ | age <18 and >80 Serum creatinine level or2.5 mg per deciliter Diagnostic > Lab Results serum creatinine level\Laboratory > 2.5 mg per deciliter serum creatinine level or Test Result\LBTR\C0600061 | >\SYMBOL\\ | 2.5\NUM Serum potassium levelor 5.0 mmolserumlevel\Laboratory > 5.0 mmol per liter Diagnostic serumResults liter > Lab potassium potassium level Procedure\LBPR\C0302353 | >\SYMBOL\\ | 5.0\NUMER per Valvular heart disease amenable toSign Disease, Symptom and valvular heart disease Syndrome\DSYN\C1963123 | amenable\\\ | to\\\ | surgi valvular heart disease\Disease or amenable to surgical treatment surgical treatment Congenital heart disease Disease, Symptom andheart disease\Disease or Syndrome\DSYN\C0152021 | congenital congenital heart disease Sign

684463 684464 684465 684466 684467 684468 684469 684470 684471 684472 684473 684474 684475 705728 705729 705730 705731 705732 705733 705734 705735 705736 705737 705738 705739 765653 765654 765655 765656 765657 765658 765659 765660 765661 765662 765663 765664 799597 799598 799599 799600 799601 799602 799603

Unstable angina and/or acute myocardial infarction and/or acute myocardial infarctionprocedureacute myocardia Disease, Symptom and unstable angina Syndrome\DSYN\C0002965 | and\\\ and / or|coronary revascu unstable angina\Disease or and / or coronary revascularization | or\\\ within three mo Sign IntravenousPharmaceutical Substance or Drug therapymonths before enrolment three months before enrolmen therapy with inotropicintravenous three withPreventivedrugs within intravenous drugs within therapy\Therapeutic or inotropic Procedure\TOPP\C0455142 | with\\\ | ino History of resuscitated history of\History\\C2004062 | resuscitated\Finding\FNDG\C2587207hours of these occur Disease, Symptom and fibrillationresuscitated ventricular fibrillation or tachycardia, unless an acute m ventricular history of or tachycardia, unless these occurred within 24 | ventricular fibrillat Sign Chronic active hepatitischronic and chronic active hepatitis Syndrome\DSYN\C0520463 | or\\\ | cirrhosis\Disease o Disease, Symptom active hepatitis\Disease or or cirrhosis or cirrhosisSign Malignant neoplasm ormalignant neoplasm\Neoplastic Process\NEOP\C1547218 | cardiac any\\\ | life threatenin Neoplasm Statuslife threatening non cardiacor any life threatening non or\\\ | disease any malignant neoplasm disease History of hypersensitivity to studyhistory of hypersensitivity to study drug Allergy history of\History\\C2004062 | hypersensitivity\Allergy\\C0520946 | to\\\ | study\Resear drug Pregnancy or lactating or childbearing age women who are not protectedage an accepted method protected by an Pregancy Related Activities pregnancy\Organism Function\ORGF\C0032961 | or\\\ | lactating\Organism Function\ORG pregnancy or lactating or childbearing by women who are not of contraceptio History of drug abuseBehavior of\History\\C2004062alcohol abuse Addictive or alcohol abuse of drug or | drug\Pharmacologic Substance\PHSU\C1254351 | or\\\ | a history history Legal incapacity and/orlegal\Idea or Concept\IDCN\C1550727 | incapacity\Capacity\\ |the nature, scope and poss Capacity other circumstances rending theor otherunable to understand and\\\ | or\\\ | other\Qua legal incapacity and / patient circumstances rending the patient unable to und Evidence ofDisease, Symptom and evidence of Concept\FTCN\C0332120 | uncooperative\Individual Behavior\INB uncooperative attitudeSign evidence of\Functional uncooperative attitude Any condition other Symptom | failure that does not permit an optimal participation to permit anConcept\QLCO\C Disease, than heartand any condition other than heart failure that|does not the trial optimal participa any\\\ condition\Sign or Symptom\SOSY\C1705253 other\Qualitative Sign Participation to other RCTs during the last 3 months Disease, Symptom and participationBehavior\INBE\C0679823 | to\\\ | other\Qualitative Concept\QLC participation\Individual to other rcts during the last 3 months Sign Treatment with: Lithium salts, Potassium Drug or diuretics,salts,positive inotropic drugs or any investigational dru Pharmaceutical Substance or sparing Preventive Procedure\TOPP\C1705169 | with\\\ | :\\\ | inotropi treatment\Therapeutic treatment with: lithium oral potassium sparing diuretics, oral positive lithium Ages Eligible for Study: ages\Age and older Age 18 Years Group\AGGP\C1114365 18 years and older ages eligible for study: | eligible\Idea or Concept\IDCN\C1548635 | for\\\ | stu Genders Eligible for Study: Both gendersAttribute\ORGA\C0079399 | eligible\Idea or Concept\IDCN\C1548635 | Gender genders\Organism eligible for study: both Accepts Healthy Volunteers: No of PatientConcept\QLCO\C1548601 | healthy volunteers\Healthy Population\\n Special Characteristic accepts healthy volunteers: no accepts\Qualitative Inclusion Criteria: Symptom and inclusion criteria: Concept\QLCO\C1512693 | Disease, inclusion criteria\Qualitative Sign Ischemic heart disease ischemic heart disease\Disease or Syndrome\DSYN\C0151744 | Disease, Symptom and ischemic heart disease Sign Systolic lv dysfunction systolic\Temporal Drug Pharmaceutical Substance or Concept\TMCO\C0039155 | lv\Pharmacologic Substance\PHSU\C18814 systolic lv dysfunction Mild anemia isease, Symptom and mild anemia D mild anemia\Finding\FNDG\C1858586 | Sign Normal renal function normal and normal renal function Disease, Symptom renal function\Finding\FNDG\C0232805 | Sign Stable condition Disease, Symptom and stable condition stable\Qualitative Concept\QLCO\C1547311 | condition\Sign or Symptom\SOSY\C1705253 Sign Exclusion Criteria: Symptom and exclusion criteria: Disease, exclusion criteria\NO\\C0680251 | Sign Pregnancy Pregancy Related Activities pregnancy\Organism Function\ORGF\C0032961 | pregnancy Unstable condition Symptom and unstable condition Disease, unstable\Phenomenon or Process\PHPR\C1883468 | condition\Sign or Symptom\SOSY\C1 Sign Ages Eligible for Study: ages\Age toages eligible for study: 18 years to 80 or Concept\IDCN\C1548635 | for\\\ | stu Age 18 Years Group\AGGP\C1114365 | eligible\Idea years 80 Years Genders Eligible for Study: Both gendersAttribute\ORGA\C0079399 | eligible\Idea or Concept\IDCN\C1548635 | Gender genders\Organism eligible for study: both Accepts Healthy Volunteers: No of PatientConcept\QLCO\C1548601 | healthy volunteers\Healthy Population\\n Special Characteristic accepts healthy volunteers: no accepts\Qualitative Inclusion Criteria: Symptom and inclusion criteria: Concept\QLCO\C1512693 | Disease, inclusion criteria\Qualitative Sign Heart failure NYHA III-IV Disease Stage heart failure\Disease or Syndrome\DSYN\C0018801 | nyha\Classification\CLAS\ | iii\Classi heart failure nyha iii-iv LVEF<35% Diagnostic or Lab Results or Test Result\LBTR\C0428772 | <\SYMBOL\\ | 35\NUMERAL\\ | %\UNIT\ lvef\Laboratory lvef<35% QRS duration>150 ms qrs duration\Organism Attribute\ORGA\C0429025 | >\SYMBOL\\ | 150\NUMERAL\\ | ms\ Gender qrs duration>150 ms Chronic atrial fibrillation. Disease, Symptom and chronic atrial fibrillation.Syndrome\DSYN\C0694539 | chronic atrial fibrillation\Disease or Sign Exclusion Criteria: Symptom and exclusion criteria: Disease, exclusion criteria\NO\\C0680251 | Sign Heart failure not related to systolicheart failure Syndrome\DSYN\C0018801 | not related\Idea or Concept\IDCN\C Disease, Symptom and Sign heart failure\Disease or not related to systolic function function Unstable angina pectoris, AMI,and unstable angina 2 month Syndrome\DSYN\C0002965 | ,\\\ | ami\Disease or Syn Disease, Symptom PCI Sign pectoris\Disease or ami, pci or cabg within 2 month unstable angina or CABG within pectoris, Inclusion in Enrollment inclusion\Qualitative in other studies other studies other studies in inclusion Concept\QLCO\C1512693 | in\\\ | other studies\Other Study\\null | Ages Eligible for Study: ages\Age and older Age 18 Years Group\AGGP\C1114365 18 years and older ages eligible for study: | eligible\Idea or Concept\IDCN\C1548635 | for\\\ | stu Genders Eligible for Study: Both gendersAttribute\ORGA\C0079399 | eligible\Idea or Concept\IDCN\C1548635 | Gender genders\Organism eligible for study: both Accepts Healthy Volunteers: No of PatientConcept\QLCO\C1548601 | healthy volunteers\Healthy Population\\n Special Characteristic accepts healthy volunteers: no accepts\Qualitative Inclusion Criteria: Symptom and inclusion criteria: Concept\QLCO\C1512693 | Disease, inclusion criteria\Qualitative Sign Subjects of Diagnostic or Lab Results severe HF as defined as NHYA Class II to IV whodefined as nhya class ii to iv d both genders with mildsubjectsDisabledgenders with mild to severe hf as| both\Quantitative Concept\w subjects\Patient or of both Group\PODG\C2349001 | of\\\ also have an indication for to Exclusion Criteria: Symptom and exclusion criteria: Disease, exclusion criteria\NO\\C0680251 | Sign Subject is post heartor Surgery or activelyDisabled Group\PODG\C2349001 | listed|on probability (as defined reaso Therapy transplant subject is poston the transplant or actively is\\\ post\Temporal Concept\TMC subject\Patient or listed heart transplant list and reasonable the transplant list and by in

799604 799605 799606 799607 799608 799609 799610 799611 799612 799613 1070066 1070067 1070068 1070069 1070070 1070071 1070072 1070073 1070074 1070075 1070076 1070077 1070078 1088513 1088514 1088515 1088516 1088517 1088518 1088519 1088520 1088521 1088522 1088523 1088524 1088525 1088526 1088527 1088528 1088529 1088530 1088531

Subject received a coronary artery subjectDisabled valve surgery in last 90 days Therapy or Surgery subject\Patient or graft or Group\PODG\C2349001 |graft or valve surgery Concept\QLCO bypass received a coronary artery bypass received\Qualitative in last 90 days Subject with a myocardial infarction (MI) in the a myocardial infarction (mi) inwith\\\ |40 days. Disease, Symptom and subjectDisabled Group\PODG\C2349001 | the last a\\\ | myocardial infarctio subject\Patient or with last 40 days. Sign Subject's life expectancy is less than oneor Disabled Group\PODG\C2349001 | life expectancy\Group Attribute\GR Life Expectancy subjects\Patient year inexpectancy is < the physician opinion of the physician subject's life the opinion of one year in the Subject has Disease, Symptom and subjectDisabled Group\PODG\C2349001 | has\Qualitative(copd),documented i severe Chronic Obstructiveor has severe chronic obstructive pulmonary disease Concept\QLCO\C234 subject\Patient Pulmonary Disease (COPD), as determined by physician and as determine Sign Subject is listed for valve Lab Results or Disabled for valve replacement / valve repair Diagnostic or replacement/valve listed Group\PODG\C2349001 | is\\\ | listed\Conceptual Entity\CNC subject\Patient subject is repair Subject has Disease,primary pulmonaryor Disabled Group\PODG\C2349001 | has\Qualitative Concept\QLCO\C234 severe, Symptom and subject has severe,as determined by physician and documented in medical reco subject\Patient hypertension primary pulmonary hypertension as determined by physicia Sign Subject with serum creatinine 2.5 mg/dLwith serumwithin 14 days2.5 mg /|enrolmentserum creatinine\Laborato Diagnostic or Lab Results or Disabled Group\PODG\C2349001 dl measured within 14 days prior to e subject\Patient subject measured creatinine >= prior to with\\\ | Subject on chronic renal dialysis subjectDisabled Group\PODG\C2349001 | on\\\ | chronic\Temporal Concept\T Therapy or Surgery subject\Patient or on chronic renal dialysis Subject on continuous or uninterrupted ( onstable Group\PODG\C2349001 | on\\\ | continuous\Idea or Concept\ Therapy or Surgery subject\Patient or Disabled infusionsuninterrupted (>= 2 (inotropic) therapy for HF infusio subject 2 continuous or per week) infusion stable infusions per week) Subject has Disease, Symptom and subjectDisabled Group\PODG\C2349001 | has\Qualitative Concept\QLCO\C234 complex and uncorrected Congenital Heart and uncorrected congenital heart disease subject\Patient or has complex Disease Sign Ages Eligible for Study: ages\Age and older Age 80 Years Group\AGGP\C1114365 80 years and older ages eligible for study: | eligible\Idea or Concept\IDCN\C1548635 | for\\\ | stu Genders Eligible for Study: Both gendersAttribute\ORGA\C0079399 | eligible\Idea or Concept\IDCN\C1548635 | Gender genders\Organism eligible for study: both Accepts Healthy Volunteers: No of PatientConcept\QLCO\C1548601 | healthy volunteers\Healthy Population\\n Special Characteristic accepts healthy volunteers: no accepts\Qualitative Sampling Method: Non-Probabilitysampling method: Product\INPR\C0815259 | :\\\ | non\Functional Concept\FT Disease, Symptom and Sign sampling method\Intellectual non-probability sample Sample Study Population Characteristic of Patient Special study population\Population Group\POPG\C2348561 | study population Defined populationCharacteristic of population\Population Group\POPG\C1257890 | Special defined\\\ | Patientpopulation defined Inclusion Criteria: Symptom and inclusion criteria: Concept\QLCO\C1512693 | Disease, inclusion criteria\Qualitative Sign acute dyspnea Disease, Symptom and acuteConcept\TMCO\C1547295 | dyspnea\Sign or Symptom\SOSY\C0013404 | acute\Temporal dyspnea Sign crackles on Diagnostic or Lab Results or Symptom\SOSY\C0034642 | on\\\ | lung\Body Part Organ or Organ Comp lung auscultation, crackles\Sign crackles on lung auscultation, hypoxemia,Disease, Symptom and hypoxemia, hypoxemia\Finding\FNDG\C0700292 | Sign right-sided signs. Symptom andSubstance\BDSU\C1552823 | -\SYMBOL\\ | sided\Spatial Concept\SPCO\C0441 Disease, right\Body right-sided signs. Sign Exclusion Criteria: Symptom and exclusion criteria: Disease, exclusion criteria\NO\\C0680251 | Sign no exclusion criteria Symptom and no exclusion criteria Disease, no\NO\\C1549444 | exclusion criteria\NO\\C0680251 | Sign Ages Eligible for Study: ages\Age and older Age 18 Years Group\AGGP\C1114365 18 years and older ages eligible for study: | eligible\Idea or Concept\IDCN\C1548635 | for\\\ | stu Genders Eligible for Study: Both gendersAttribute\ORGA\C0079399 | eligible\Idea or Concept\IDCN\C1548635 | Gender genders\Organism eligible for study: both Accepts Healthy Volunteers: No of PatientConcept\QLCO\C1548601 | healthy volunteers\Healthy Population\\n Special Characteristic accepts healthy volunteers: no accepts\Qualitative Inclusion Criteria: Symptom and inclusion criteria: Concept\QLCO\C1512693 | Disease, inclusion criteria\Qualitative Sign Patients who are in sinus rhythm patientsDisabled Group\PODG\C1705908 | who\\\ | are\\\ | in\\\ | sinus rhyth Organ or Tissue Status patients\Patient or who are in sinus rhythm Patients who are on or Surgery Therapy stable medical therapywho are Group\PODG\C1705908 | who\\\ | are\\\ | on\\\ | stable\Qu patients\Patient or Disabled on stable medical therapy patients Patients who exhibit signs and symptoms of heart failure, NYHA Class II or III ofwho\\\ | exhibit\Intellectual Produ Disease Stage patients\Patient or Disabled Group\PODG\C1705908 | heart failure, nyha class ii or iii patients who exhibit signs and symptoms Patients who have experienced a hospitalizationhave experienced a hospitalization for|decompensated heart failu Disease, Symptom and patientsDisabled Group\PODG\C1705908 | who\\\ have\\\ | experienced\Me patients\Patient or who for decompensated heart failure Sign treatment for pulmonary congestion or volume overload congestion or volume overload Disease, Symptom and treatment for pulmonary Procedure\TOPP\C1705169 | for\\\ | pulmonary con treatment\Therapeutic or Preventive Sign chronic treatment withchronic\Temporal Drug Pharmaceutical Substance or Concept\TMCO\C1555457 | treatment\Therapeutic or Preventive Proce a loop diuretic chronic treatment with a loop diuretic or a BNP > 125 ng/l. or Lab|Results bnp\Gene orng / l. Diagnostic or\\\ a\\\ or a bnp > 125 Genome\GNGM\C1417808 | >\SYMBOL\\ | 125\NUMERAL\\ | | Left ventricular ejection fraction left ejection fraction\Laboratory >= 50% Result\LBTR\C0428772 | \\\ | 50\ Diagnostic or Lab Results ventricular ejection fraction or Test left ventricular 50% Exclusion Criteria: Symptom and exclusion criteria: Disease, exclusion criteria\NO\\C0680251 | Sign Patients with persistent atrial fibrillationor Disabled Group\PODG\C1705908 | atrial flutter Disease, Symptom and patients with persistent atrial fibrillation or with\\\ | persistent atrial fibrillatio patients\Patient or atrial flutter Sign Patients who are in complete heartSign or Disabled Group\PODG\C1705908 | who\\\ | are\\\ | in\\\ | complete Disease, Symptom and patients who are in complete heart block patients\Patient block Patients who have experienced a recentor Disabled Group\PODG\C1705908 | or have | have\\\ angina or require Disease, Symptom and patients who have experienced a recent mi who\\\ unstableor other procedure patients\Patient MI or have unstable angina or require cardiac surgery | experienced\Me Sign Patients who have severe heart valve disease or have severe heart valve disease or valve replacement Disease, Symptom and patientsDisabled Group\PODG\C1705908 | who\\\ | have\\\ | severe\Qualitat patients\Patient or who valve replacement Sign Patients with a contraindication for a pacemakerasystem Device patients\Patient or Disabled Group\PODG\C1705908 | with\\\ | a\\\ | contraindication\Q patients with contraindication for a pacemaker system Patients who have a neuromuscular, orthopedic have a neuromuscular, orthopedic or other non-cardiac neuromu Exercise patients\Patient or Disabled other non-cardiac condition that prevents patient from exercis patients who or Group\PODG\C1705908 | who\\\ | have\\\ | a\\\ | condition

1088532 1088533 1088534 1237959 1237960 1237961 1237962 1237963 1237964 1237965 1237966 1237967 1237968 1237969 1237970 1237971 1237972 1237973 1237974 1237975 1237976 1237977 1237978 1237979 1237980 1237981 1237982 1237983 1278885 1278886 1278887 1278888 1278889 1278890 1278891 1278892 1278893 1278894 1278895 1278896 1278897 1278898 1278899

Patients who have infiltrative or hypertrophic cardiomyopathy or hypertrophic cardiomyopathy infiltrative\Sign Disease, Symptom and patientsDisabled Group\PODG\C1705908 | who\\\ | have\\\ | patients\Patient or who have infiltrative Sign Patients who have known severe pulmonary disease known severe pulmonary disease have\\\ | known\Qualitat Disease, Symptom and patientsDisabled Group\PODG\C1705908 | who\\\ | patients\Patient or who have Sign Patients with uncontrolled diabetes or blood pressure (SBP > 160 mmHg or DBPpressure (sbp > 160 mmhg or dbp Disease, Symptom and patientsDisabled Group\PODG\C1705908 | with\\\mmHg) patients\Patient or with uncontrolled diabetes or blood > 95 | uncontrolled\Qualitative Sign Ages Eligible for Study: ages\Age toages eligible for study: 18 years to 85 or Concept\IDCN\C1548635 | for\\\ | stu Age 18 Years Group\AGGP\C1114365 | eligible\Idea years 85 Years Genders Eligible for Study: Both gendersAttribute\ORGA\C0079399 | eligible\Idea or Concept\IDCN\C1548635 | Gender genders\Organism eligible for study: both Accepts Healthy Volunteers: No of PatientConcept\QLCO\C1548601 | healthy volunteers\Healthy Population\\n Special Characteristic accepts healthy volunteers: no accepts\Qualitative Inclusion Criteria: Symptom and inclusion criteria: Concept\QLCO\C1512693 | Disease, inclusion criteria\Qualitative Sign Age of 18 to 85 years age\Age Group\AGGP\C1114365 | of\\\ | 18\NUMERAL\\ | to\\\ | 85\NUMERAL\\ | years Age age of 18 to 85 years Symptomatic heart Stage NYHA class I to III Concept\FTCN\C0231220to heart failure\Disease or Syndrome\DS Disease failure, symptomatic\Functional heart failure, nyha class i | iii symptomatic Left ventricular ejection fraction < left ejection fraction\Laboratory < 0.40 Result\LBTR\C0428772 | <\SYMBOL\\ Diagnostic or Lab Results ventricular ejection fraction or Test left ventricular 0.40 Give written informed consent Consent give\Functional Concept\FTCN\C1947972 | written\Finding\FNDG\C2584304 | informed c give written informed consent Exclusion Criteria: Symptom and exclusion criteria: Disease, exclusion criteria\NO\\C0680251 | Sign Pregnant orPregancy Related Activities lactating women pregnant\Organism Function\ORGF\C0549206 | or\\\ | lactating\Organism Function\ORGF pregnant or lactating women Women in reproductive yearsActivities an active form of years mustin\\\(oral active form of contraception (oral c Pregancy Related must have in reproductive contraception |an contraceptives, IUD, diaphragm, co women\Population Group\POPG\C1555916 | have reproductive\Organism Function\ORG women Heart failure as the results offailure\Disease or Syndrome\DSYN\C0018801following conditions: active myocarditi Disease, Symptomany of the following conditions: of any of the | as\\\ | the\\\ | results\Functional Co heart and heart failure as the results active myocarditis Sign congenital heart disease Disease, Symptom andheart disease\Disease or Syndrome\DSYN\C0152021 | congenital congenital heart disease Sign uncorrected, hemodynamically significant stenotic valvular disease Disease, Symptom and uncorrected, hemodynamically significant stenotic valvular disease uncorrected\\\ | ,\\\ | hemodynamically\Organ or Tissue Function\ORTF\ | significant\Qu Sign NYHA functional class IV symptoms Disease Stage nyha\Classification\CLAS\ | class iv symptoms nyha functional functional\Functional Concept\FTCN\C0542341 | class iv\Intel Current or previous treatment and currentConcept\TMCO\C1705970 | a concentrations with plasma 130 mg/dL and Disease, Symptom with a statin Patients with plasma with or\\\ | previous\Temporal Concept\TMCO\ current\Temporal or previous treatment LDL-C statin patients higher than ldl-c concentr Sign Ischemic cardiomyopathy Disease, Symptom and ischemic cardiomyopathy Syndrome\DSYN\C0349782 | ischemic cardiomyopathy\Disease or Sign Previous cardiovascular event (CVA, ACS event) Therapy or Surgery previous\Temporal Concept\TMCO\C1552607 | cardiovascular event\Finding\FNDG\C132 previous cardiovascular event (cva, acs event) Known coronary arteryknown\Qualitative coronary artery disease | coronary artery disease\Disease or Syndrom Disease, Symptom and known Concept\QLCO\C0205309 disease Sign Unstable angina Disease, Symptom and unstable angina Syndrome\DSYN\C0002965 | unstable angina\Disease or Sign Presence ofDisease, Symptom and presence of anywould be expected toprogressive\Functional expected to impac any progressive systemic disease that progressive any\\\ | disease the patient's outcome over the ti presence of\Finding\FNDG\C0392148 | systemic impact that would be Concept\FTCN\C0 Sign Uncorrected endocrineuncorrected\\\ | endocrine disorders\Disease or Syndrome\DSYN\C0014130 |pheochromo Neoplasm Status disorders including primary aldosteronism, pheochromocytoma, hyperthyroidism, hypoth uncorrected endocrine disorders including primary aldosteronism, including\F Inherited disorders of lipid metabolism Disease, Symptom and inherited Concept\FTCN\C0439660 | disorders of lipid metabolism\Disease or S inherited\Functional disorders of lipid metabolism Sign Evidence ofDiagnostic or Labdisease (serum of Concept\FTCN\C0332120 | significant\Qualitative Concept\QLCO\C significant renal Results evidence of\Functional significant2.5 mg/dl), or hepatic creatinine > 2.5 mg / dl), or hepatic evidence creatinine > renal disease (serum disease (transaminase levels > thre Inability or unwillingness to cooperate withor unwillingness to cooperate with study or giveto\\\ | cooperate\Acti Consent inability\Clinical Attribute\CLNA\ |written informed consent inability study or give or\\\ | unwillingness\Willing\\ | written informed cons Ages Eligible for Study: ages\Age and older Age 18 Years Group\AGGP\C1114365 18 years and older ages eligible for study: | eligible\Idea or Concept\IDCN\C1548635 | for\\\ | stu Genders Eligible for Study: Both gendersAttribute\ORGA\C0079399 | eligible\Idea or Concept\IDCN\C1548635 | Gender genders\Organism eligible for study: both Accepts Healthy Volunteers: No of PatientConcept\QLCO\C1548601 | healthy volunteers\Healthy Population\\n Special Characteristic accepts healthy volunteers: no accepts\Qualitative Sampling Method: Non-Probabilitysampling method: Product\INPR\C0815259 | :\\\ | non\Functional Concept\FT Disease, Symptom and Sign sampling method\Intellectual non-probability sample Sample Study Population Characteristic of Patient Special study population\Population Group\POPG\C2348561 | study population Heart failure patients needing CRT heart failure Syndrome\DSYN\C0018801 | patients\Patient or Disabled Group\P Disease, Symptom and Sign heart failure\Disease or patients needing crt therapy therapy Inclusion Criteria: Symptom and inclusion criteria: Concept\QLCO\C1512693 | Disease, inclusion criteria\Qualitative Sign NYHA Class Disease Stage class iii\Classification\CLAS\C1882086 | iv\Classification\CLAS\C1706303 | III/IV nyha nyha class iii / iv Stable medical regimenstable\Qualitative medical regimen Therapy or Surgery stable Concept\QLCO\C1547311 | medical\Professional or Occupational Group QRS greater than or Symptom|and qrs > or = | or\\\ | =\SYMBOL\\ | 130\NUMERAL\\ | ms\Disease or Syndrome\ Disease, equal to 130 ms qrs\\\ >\SYMBOL\\ 130 ms Sign LVEF less than or equallvef\Laboratory < or = 35% Diagnostic or Lab Results or Test Result\LBTR\C0428772 | <\SYMBOL\\ | or\\\ | =\SYMBOL\\ | 35\N to 35% lvef Exclusion Criteria: Symptom and exclusion criteria: Disease, exclusion criteria\NO\\C0680251 | Sign VT of transient or reversible causes Patient Special Characteristic of Function\PATF\C0042537causes | transient\Population Group\POPG\C1550 vt\Pathologic of transient or reversible | of\\\ vt Incessant VT isease, Symptom and incessant vt D incessant\\\Sign | vt\Pathologic Function\PATF\C0042537 | Currently implanted or Surgery positioned Concept\TMCO\C0521116 |(unlessthrough the coronary sinus (unless i Therapy with a lead currentlythrough thewith a lead positioned it is the SITUS OTW LV lead) Pro currently\Temporal implanted coronary sinus implanted\Therapeutic or Preventive

1278900 1278901 1278902 1278903 1278904 1278906 1278907 1278908 1278909 1278910

Cardiac revascularization or angioplasty within the Organ Component\\C1522601the last month Therapy or Surgery cardiac\Body Part Organ or last month angioplasty within | revascularization\Therapeutic cardiac revascularization or Heart failure due to correctable valve disease Syndrome\DSYN\C0018801 | due to\Functional Concept\FTCN\C0 Disease, Symptom and heart failure due to correctable valve disease heart failure\Disease or Sign Chronic, medially refractory AT chronic, medially refractory at Disease, Symptom and Sign Concept\TMCO\C1555457 | ,\\\ | medially\\\ | refractory\Functional Co chronic\Temporal Enrolled in another clinical study that may confound the resultsclinical study\Research Activity\RESA\C0008972 | Enrollment enrolled studies in other in another\Other Study\\null | of this study confound the results of this study enrolled in another clinical study that may Life expectancy Expectancyexpectancy\Group Attribute\GRPA\C0023671 | <\SYMBOL\\ | 6\NUMERAL\\ | months Life less than 6 monthslife expectancy < 6 months life Inability or refusal to provide informed consent Consent inability\Clinical Attribute\CLNA\provide | refusal\Idea or Concept\IDCN\C1569452 | to\\\ inability or refusal to | or\\\ informed consent UnavailableTherapy or Surgery for scheduled follow-up with the implanting practice unavailable\Functional Concept\FTCN\C0686905 | for\\\implanting practice Care Activity\ unavailable for scheduled follow-up with the | scheduled\Health Sensitivity to 1 mg dexamethasonesensitivity to 1 mg dexamethasone sodium | mg\UNIT\\C2348270 | dexametha Allergy sensitivity\Allergy\\C2349185 | to\\\ | 1\NUMERAL\\ phosphate sodium phosphate Less than 18 years of age Age <\SYMBOL\\ | 18\NUMERAL\\ | years\Temporal Concept\TMCO\C1561544 | of\\\ | age\A < 18 years of age Pregnancy Pregancy Related Activities pregnancy\Organism Function\ORGF\C0032961 | pregnancy

Inclusion Inclusion Inclusion Inclusion Inclusion Inclusion Inclusion Inclusion Inclusion Inclusion Inclusion Inclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion NoInEx Age NoInEx Gender NoInEx Healthy Inclusion Inclusion Inclusion Inclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion

http://ClinicalTrials.gov/show/NCT00400257Evaluation ofNo Results Available Heart Failure (SCREEN 47941 NCT00400257 Screening Recruiting the Evolution of New Heart Failure http://ClinicalTrials.gov/show/NCT00400257Evaluation ofNo Results Available Heart Failure (SCREEN 47941 NCT00400257 Screening Recruiting the Evolution of New Heart Failure http://ClinicalTrials.gov/show/NCT00400257Evaluation ofNo Results Available Heart Failure (SCREEN 47941 NCT00400257 Screening Recruiting the Evolution of New Heart Failure http://ClinicalTrials.gov/show/NCT00400257Evaluation ofNo Results Available Heart Failure (SCREEN 47941 NCT00400257 Screening Recruiting the Evolution of New Heart Failure http://ClinicalTrials.gov/show/NCT00400257Evaluation ofNo Results Available Heart Failure (SCREEN 47941 NCT00400257 Screening Recruiting the Evolution of New Heart Failure http://ClinicalTrials.gov/show/NCT00400257Evaluation ofNo Results Available Heart Failure (SCREEN 47941 NCT00400257 Screening Recruiting the Evolution of New Heart Failure http://ClinicalTrials.gov/show/NCT00400257Evaluation ofNo Results Available Heart Failure (SCREEN 47941 NCT00400257 Screening Recruiting the Evolution of New Heart Failure http://ClinicalTrials.gov/show/NCT00400257Evaluation ofNo Results Available Heart Failure (SCREEN 47941 NCT00400257 Screening Recruiting the Evolution of New Heart Failure http://ClinicalTrials.gov/show/NCT00400257Evaluation ofNo Results Available Heart Failure (SCREEN 47941 NCT00400257 Screening Recruiting the Evolution of New Heart Failure http://ClinicalTrials.gov/show/NCT00400257Evaluation ofNo Results Available Heart Failure (SCREEN 47941 NCT00400257 Screening Recruiting the Evolution of New Heart Failure http://ClinicalTrials.gov/show/NCT00400257Evaluation ofNo Results Available Heart Failure (SCREEN 47941 NCT00400257 Screening Recruiting the Evolution of New Heart Failure http://ClinicalTrials.gov/show/NCT00400257Evaluation ofNo Results Available Heart Failure (SCREEN 47941 NCT00400257 Screening Recruiting the Evolution of New Heart Failure http://ClinicalTrials.gov/show/NCT00400257Evaluation ofNo Results Available Heart Failure (SCREEN 47941 NCT00400257 Screening Recruiting the Evolution of New Heart Failure http://ClinicalTrials.gov/show/NCT00400257Evaluation ofNo Results Available Heart Failure (SCREEN 47941 NCT00400257 Screening Recruiting the Evolution of New Heart Failure http://ClinicalTrials.gov/show/NCT00400257Evaluation ofNo Results Available Heart Failure (SCREEN 47941 NCT00400257 Screening Recruiting the Evolution of New Heart Failure http://ClinicalTrials.gov/show/NCT00400257Evaluation ofNo Results Available Heart Failure (SCREEN 47941 NCT00400257 Screening Recruiting the Evolution of New Heart Failure http://ClinicalTrials.gov/show/NCT00400257Evaluation ofNo Results Available Heart Failure (SCREEN 47941 NCT00400257 Screening Recruiting the Evolution of New Heart Failure http://ClinicalTrials.gov/show/NCT00400257Evaluation ofNo Results Available Heart Failure (SCREEN 47941 NCT00400257 Screening Recruiting the Evolution of New Heart Failure http://ClinicalTrials.gov/show/NCT00400582 RecruitingStudyResults Availablein Heart Failure 68820 NCT00400582 A Pharmacogenomic No of Candesartan Heart Failure http://ClinicalTrials.gov/show/NCT00400582 RecruitingStudyResults Availablein Heart Failure 68820 NCT00400582 A Pharmacogenomic No of Candesartan Heart Failure http://ClinicalTrials.gov/show/NCT00400582 RecruitingStudyResults Availablein Heart Failure 68820 NCT00400582 A Pharmacogenomic No of Candesartan Heart Failure http://ClinicalTrials.gov/show/NCT00400582 RecruitingStudyResults Availablein Heart Failure 68820 NCT00400582 A Pharmacogenomic No of Candesartan Heart Failure http://ClinicalTrials.gov/show/NCT00400582 RecruitingStudyResults Availablein Heart Failure 68820 NCT00400582 A Pharmacogenomic No of Candesartan Heart Failure http://ClinicalTrials.gov/show/NCT00400582 RecruitingStudyResults Availablein Heart Failure 68820 NCT00400582 A Pharmacogenomic No of Candesartan Heart Failure http://ClinicalTrials.gov/show/NCT00400582 RecruitingStudyResults Availablein Heart Failure 68820 NCT00400582 A Pharmacogenomic No of Candesartan Heart Failure http://ClinicalTrials.gov/show/NCT00400582 RecruitingStudyResults Availablein Heart Failure 68820 NCT00400582 A Pharmacogenomic No of Candesartan Heart Failure http://ClinicalTrials.gov/show/NCT00400582 RecruitingStudyResults Availablein Heart Failure 68820 NCT00400582 A Pharmacogenomic No of Candesartan Heart Failure http://ClinicalTrials.gov/show/NCT00400582 RecruitingStudyResults Availablein Heart Failure 68820 NCT00400582 A Pharmacogenomic No of Candesartan Heart Failure http://ClinicalTrials.gov/show/NCT00400582 RecruitingStudyResults Availablein Heart Failure 68820 NCT00400582 A Pharmacogenomic No of Candesartan Heart Failure http://ClinicalTrials.gov/show/NCT00400582 RecruitingStudyResults Availablein Heart Failure 68820 NCT00400582 A Pharmacogenomic No of Candesartan Heart Failure http://ClinicalTrials.gov/show/NCT00400582 RecruitingStudyResults Availablein Heart Failure 68820 NCT00400582 A Pharmacogenomic No of Candesartan Heart Failure http://ClinicalTrials.gov/show/NCT00400582 RecruitingStudyResults Availablein Heart Failure 68820 NCT00400582 A Pharmacogenomic No of Candesartan Heart Failure http://ClinicalTrials.gov/show/NCT00400582 RecruitingStudyResults Availablein Heart Failure 68820 NCT00400582 A Pharmacogenomic No of Candesartan Heart Failure http://ClinicalTrials.gov/show/NCT00400582 RecruitingStudyResults Availablein Heart Failure 68820 NCT00400582 A Pharmacogenomic No of Candesartan Heart Failure http://ClinicalTrials.gov/show/NCT00400582 RecruitingStudyResults Availablein Heart Failure 68820 NCT00400582 A Pharmacogenomic No of Candesartan Heart Failure http://ClinicalTrials.gov/show/NCT00400582 RecruitingStudyResults Availablein Heart Failure 68820 NCT00400582 A Pharmacogenomic No of Candesartan Heart Failure http://ClinicalTrials.gov/show/NCT00400582 RecruitingStudyResults Availablein Heart Failure 68820 NCT00400582 A Pharmacogenomic No of Candesartan Heart Failure http://ClinicalTrials.gov/show/NCT00400582 RecruitingStudyResults Availablein Heart Failure 68820 NCT00400582 A Pharmacogenomic No of Candesartan Heart Failure http://ClinicalTrials.gov/show/NCT00403910 CompletedOf Aldosterone Receptors Blockade With Can 8691 NCT00403910 Antiremodeling Effect No Results Available Heart Failure http://ClinicalTrials.gov/show/NCT00403910 CompletedOf Aldosterone Receptors Blockade With Can 8691 NCT00403910 Antiremodeling Effect No Results Available Heart Failure http://ClinicalTrials.gov/show/NCT00403910 CompletedOf Aldosterone Receptors Blockade With Can 8691 NCT00403910 Antiremodeling Effect No Results Available Heart Failure http://ClinicalTrials.gov/show/NCT00403910 CompletedOf Aldosterone Receptors Blockade With Can 8691 NCT00403910 Antiremodeling Effect No Results Available Heart Failure http://ClinicalTrials.gov/show/NCT00403910 CompletedOf Aldosterone Receptors Blockade With Can 8691 NCT00403910 Antiremodeling Effect No Results Available Heart Failure

Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion NoInEx NoInEx NoInEx Inclusion Inclusion Inclusion Inclusion Inclusion Inclusion Exclusion Exclusion Exclusion NoInEx NoInEx NoInEx Inclusion Inclusion Inclusion Inclusion Inclusion Exclusion Exclusion Exclusion Exclusion NoInEx NoInEx NoInEx Inclusion Exclusion Exclusion Exclusion

Age Gender Healthy

Age Gender Healthy

Age Gender Healthy

http://ClinicalTrials.gov/show/NCT00403910 CompletedOf Aldosterone Receptors Blockade With Can 8691 NCT00403910 Antiremodeling Effect No Results Available Heart Failure http://ClinicalTrials.gov/show/NCT00403910 CompletedOf Aldosterone Receptors Blockade With Can 8691 NCT00403910 Antiremodeling Effect No Results Available Heart Failure http://ClinicalTrials.gov/show/NCT00403910 CompletedOf Aldosterone Receptors Blockade With Can 8691 NCT00403910 Antiremodeling Effect No Results Available Heart Failure http://ClinicalTrials.gov/show/NCT00403910 CompletedOf Aldosterone Receptors Blockade With Can 8691 NCT00403910 Antiremodeling Effect No Results Available Heart Failure http://ClinicalTrials.gov/show/NCT00403910 CompletedOf Aldosterone Receptors Blockade With Can 8691 NCT00403910 Antiremodeling Effect No Results Available Heart Failure http://ClinicalTrials.gov/show/NCT00403910 CompletedOf Aldosterone Receptors Blockade With Can 8691 NCT00403910 Antiremodeling Effect No Results Available Heart Failure http://ClinicalTrials.gov/show/NCT00403910 CompletedOf Aldosterone Receptors Blockade With Can 8691 NCT00403910 Antiremodeling Effect No Results Available Heart Failure http://ClinicalTrials.gov/show/NCT00403910 CompletedOf Aldosterone Receptors Blockade With Can 8691 NCT00403910 Antiremodeling Effect No Results Available Heart Failure http://ClinicalTrials.gov/show/NCT00403910 CompletedOf Aldosterone Receptors Blockade With Can 8691 NCT00403910 Antiremodeling Effect No Results Available Heart Failure http://ClinicalTrials.gov/show/NCT00403910 CompletedOf Aldosterone Receptors Blockade With Can 8691 NCT00403910 Antiremodeling Effect No Results Available Heart Failure http://ClinicalTrials.gov/show/NCT00403910 CompletedOf Aldosterone Receptors Blockade With Can 8691 NCT00403910 Antiremodeling Effect No Results Available Heart Failure http://ClinicalTrials.gov/show/NCT00403910 CompletedOf Aldosterone Receptors Blockade With Can 8691 NCT00403910 Antiremodeling Effect No Results Available Heart Failure http://ClinicalTrials.gov/show/NCT00403910 CompletedOf Aldosterone Receptors Blockade With Can 8691 NCT00403910 Antiremodeling Effect No Results Available Heart Failure http://ClinicalTrials.gov/show/NCT00418119 NotTreatment in Patients With Systolic Left Ventricular D 16211 NCT00418119 Erythropoietin yet recruiting No Results Available Heart Failure http://ClinicalTrials.gov/show/NCT00418119 NotTreatment in Patients With Systolic Left Ventricular D 16211 NCT00418119 Erythropoietin yet recruiting No Results Available Heart Failure http://ClinicalTrials.gov/show/NCT00418119 NotTreatment in Patients With Systolic Left Ventricular D 16211 NCT00418119 Erythropoietin yet recruiting No Results Available Heart Failure http://ClinicalTrials.gov/show/NCT00418119 NotTreatment in Patients With Systolic Left Ventricular D 16211 NCT00418119 Erythropoietin yet recruiting No Results Available Heart Failure http://ClinicalTrials.gov/show/NCT00418119 NotTreatment in Patients With Systolic Left Ventricular D 16211 NCT00418119 Erythropoietin yet recruiting No Results Available Heart Failure http://ClinicalTrials.gov/show/NCT00418119 NotTreatment in Patients With Systolic Left Ventricular D 16211 NCT00418119 Erythropoietin yet recruiting No Results Available Heart Failure http://ClinicalTrials.gov/show/NCT00418119 NotTreatment in Patients With Systolic Left Ventricular D 16211 NCT00418119 Erythropoietin yet recruiting No Results Available Heart Failure http://ClinicalTrials.gov/show/NCT00418119 NotTreatment in Patients With Systolic Left Ventricular D 16211 NCT00418119 Erythropoietin yet recruiting No Results Available Heart Failure http://ClinicalTrials.gov/show/NCT00418119 NotTreatment in Patients With Systolic Left Ventricular D 16211 NCT00418119 Erythropoietin yet recruiting No Results Available Heart Failure http://ClinicalTrials.gov/show/NCT00418119 NotTreatment in Patients With Systolic Left Ventricular D 16211 NCT00418119 Erythropoietin yet recruiting No Results Available Heart Failure http://ClinicalTrials.gov/show/NCT00418119 NotTreatment in Patients With Systolic Left Ventricular D 16211 NCT00418119 Erythropoietin yet recruiting No Results Available Heart Failure http://ClinicalTrials.gov/show/NCT00418119 NotTreatment in Patients With Systolic Left Ventricular D 16211 NCT00418119 Erythropoietin yet recruiting No Results Available Heart Failure http://ClinicalTrials.gov/show/NCT00457834 Active, not recruitingWith Atrial Fibrillation and Heart Fa 28757 NCT00457834 Bi-Ventricular Pacing inNo Results Available Patients Heart Failure http://ClinicalTrials.gov/show/NCT00457834 Active, not recruitingWith Atrial Fibrillation and Heart Fa 28757 NCT00457834 Bi-Ventricular Pacing inNo Results Available Patients Heart Failure http://ClinicalTrials.gov/show/NCT00457834 Active, not recruitingWith Atrial Fibrillation and Heart Fa 28757 NCT00457834 Bi-Ventricular Pacing inNo Results Available Patients Heart Failure http://ClinicalTrials.gov/show/NCT00457834 Active, not recruitingWith Atrial Fibrillation and Heart Fa 28757 NCT00457834 Bi-Ventricular Pacing inNo Results Available Patients Heart Failure http://ClinicalTrials.gov/show/NCT00457834 Active, not recruitingWith Atrial Fibrillation and Heart Fa 28757 NCT00457834 Bi-Ventricular Pacing inNo Results Available Patients Heart Failure http://ClinicalTrials.gov/show/NCT00457834 Active, not recruitingWith Atrial Fibrillation and Heart Fa 28757 NCT00457834 Bi-Ventricular Pacing inNo Results Available Patients Heart Failure http://ClinicalTrials.gov/show/NCT00457834 Active, not recruitingWith Atrial Fibrillation and Heart Fa 28757 NCT00457834 Bi-Ventricular Pacing inNo Results Available Patients Heart Failure http://ClinicalTrials.gov/show/NCT00457834 Active, not recruitingWith Atrial Fibrillation and Heart Fa 28757 NCT00457834 Bi-Ventricular Pacing inNo Results Available Patients Heart Failure http://ClinicalTrials.gov/show/NCT00457834 Active, not recruitingWith Atrial Fibrillation and Heart Fa 28757 NCT00457834 Bi-Ventricular Pacing inNo Results Available Patients Heart Failure http://ClinicalTrials.gov/show/NCT00457834 Active, not recruitingWith Atrial Fibrillation and Heart Fa 28757 NCT00457834 Bi-Ventricular Pacing inNo Results Available Patients Heart Failure http://ClinicalTrials.gov/show/NCT00457834 Active, not recruitingWith Atrial Fibrillation and Heart Fa 28757 NCT00457834 Bi-Ventricular Pacing inNo Results Available Patients Heart Failure http://ClinicalTrials.gov/show/NCT00457834 Active, not recruitingWith Atrial Fibrillation and Heart Fa 28757 NCT00457834 Bi-Ventricular Pacing inNo Results Available Patients Heart Failure http://ClinicalTrials.gov/show/NCT00480077 Outcome Trial in Heart Available 64702 NCT00480077 Diagnostic Active, not recruiting FailureFailure Trial) No Results Heart (DOT-HF http://ClinicalTrials.gov/show/NCT00480077 Outcome Trial in Heart Available 64702 NCT00480077 Diagnostic Active, not recruiting FailureFailure Trial) No Results Heart (DOT-HF http://ClinicalTrials.gov/show/NCT00480077 Outcome Trial in Heart Available 64702 NCT00480077 Diagnostic Active, not recruiting FailureFailure Trial) No Results Heart (DOT-HF http://ClinicalTrials.gov/show/NCT00480077 Outcome Trial in Heart Available 64702 NCT00480077 Diagnostic Active, not recruiting FailureFailure Trial) No Results Heart (DOT-HF http://ClinicalTrials.gov/show/NCT00480077 Outcome Trial in Heart Available 64702 NCT00480077 Diagnostic Active, not recruiting FailureFailure Trial) No Results Heart (DOT-HF http://ClinicalTrials.gov/show/NCT00480077 Outcome Trial in Heart Available 64702 NCT00480077 Diagnostic Active, not recruiting FailureFailure Trial) No Results Heart (DOT-HF http://ClinicalTrials.gov/show/NCT00480077 Outcome Trial in Heart Available 64702 NCT00480077 Diagnostic Active, not recruiting FailureFailure Trial) No Results Heart (DOT-HF

Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion NoInEx NoInEx NoInEx NoInEx NoInEx NoInEx Inclusion Inclusion Inclusion Inclusion Inclusion Exclusion Exclusion NoInEx NoInEx NoInEx Inclusion Inclusion Inclusion Inclusion Inclusion Inclusion Inclusion Inclusion Inclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion

Age Gender Healthy

Age Gender Healthy

http://ClinicalTrials.gov/show/NCT00480077 Outcome Trial in Heart Available 64702 NCT00480077 Diagnostic Active, not recruiting FailureFailure Trial) No Results Heart (DOT-HF http://ClinicalTrials.gov/show/NCT00480077 Outcome Trial in Heart Available 64702 NCT00480077 Diagnostic Active, not recruiting FailureFailure Trial) No Results Heart (DOT-HF http://ClinicalTrials.gov/show/NCT00480077 Outcome Trial in Heart Available 64702 NCT00480077 Diagnostic Active, not recruiting FailureFailure Trial) No Results Heart (DOT-HF http://ClinicalTrials.gov/show/NCT00480077 Outcome Trial in Heart Available 64702 NCT00480077 Diagnostic Active, not recruiting FailureFailure Trial) No Results Heart (DOT-HF http://ClinicalTrials.gov/show/NCT00480077 Outcome Trial in Heart Available 64702 NCT00480077 Diagnostic Active, not recruiting FailureFailure Trial) No Results Heart (DOT-HF http://ClinicalTrials.gov/show/NCT00480077 Outcome Trial in Heart Available 64702 NCT00480077 Diagnostic Active, not recruiting FailureFailure Trial) No Results Heart (DOT-HF http://ClinicalTrials.gov/show/NCT00480077 Outcome Trial in Heart Available 64702 NCT00480077 Diagnostic Active, not recruiting FailureFailure Trial) No Results Heart (DOT-HF http://ClinicalTrials.gov/show/NCT00480077 Outcome Trial in Heart Available 64702 NCT00480077 Diagnostic Active, not recruiting FailureFailure Trial) No Results Heart (DOT-HF http://ClinicalTrials.gov/show/NCT00480077 Outcome Trial in Heart Available 64702 NCT00480077 Diagnostic Active, not recruiting FailureFailure Trial) No Results Heart (DOT-HF http://ClinicalTrials.gov/show/NCT00480077 Outcome Trial in Heart Available 64702 NCT00480077 Diagnostic Active, not recruiting FailureFailure Trial) No Results Heart (DOT-HF http://ClinicalTrials.gov/show/NCT00658216 Recruiting No(BNP) Usefulness In Elderly Dyspneic Patie 13900 NCT00658216 Natriuretic Peptide Results Available Brain Heart Failure http://ClinicalTrials.gov/show/NCT00658216 Recruiting No(BNP) Usefulness In Elderly Dyspneic Patie 13900 NCT00658216 Natriuretic Peptide Results Available Brain Heart Failure http://ClinicalTrials.gov/show/NCT00658216 Recruiting No(BNP) Usefulness In Elderly Dyspneic Patie 13900 NCT00658216 Natriuretic Peptide Results Available Brain Heart Failure http://ClinicalTrials.gov/show/NCT00658216 Recruiting No(BNP) Usefulness In Elderly Dyspneic Patie 13900 NCT00658216 Natriuretic Peptide Results Available Brain Heart Failure http://ClinicalTrials.gov/show/NCT00658216 Recruiting No(BNP) Usefulness In Elderly Dyspneic Patie 13900 NCT00658216 Natriuretic Peptide Results Available Brain Heart Failure http://ClinicalTrials.gov/show/NCT00658216 Recruiting No(BNP) Usefulness In Elderly Dyspneic Patie 13900 NCT00658216 Natriuretic Peptide Results Available Brain Heart Failure http://ClinicalTrials.gov/show/NCT00658216 Recruiting No(BNP) Usefulness In Elderly Dyspneic Patie 13900 NCT00658216 Natriuretic Peptide Results Available Brain Heart Failure http://ClinicalTrials.gov/show/NCT00658216 Recruiting No(BNP) Usefulness In Elderly Dyspneic Patie 13900 NCT00658216 Natriuretic Peptide Results Available Brain Heart Failure http://ClinicalTrials.gov/show/NCT00658216 Recruiting No(BNP) Usefulness In Elderly Dyspneic Patie 13900 NCT00658216 Natriuretic Peptide Results Available Brain Heart Failure http://ClinicalTrials.gov/show/NCT00658216 Recruiting No(BNP) Usefulness In Elderly Dyspneic Patie 13900 NCT00658216 Natriuretic Peptide Results Available Brain Heart Failure http://ClinicalTrials.gov/show/NCT00658216 Recruiting No(BNP) Usefulness In Elderly Dyspneic Patie 13900 NCT00658216 Natriuretic Peptide Results Available Brain Heart Failure http://ClinicalTrials.gov/show/NCT00658216 Recruiting No(BNP) Usefulness In Elderly Dyspneic Patie 13900 NCT00658216 Natriuretic Peptide Results Available Brain Heart Failure http://ClinicalTrials.gov/show/NCT00658216 Recruiting No(BNP) Usefulness In Elderly Dyspneic Patie 13900 NCT00658216 Natriuretic Peptide Results Available Brain Heart Failure http://ClinicalTrials.gov/show/NCT00670111 Recruiting No Results Available Heart Failure Patients W 9726 NCT00670111 Restoration of Chronotropic Competence in Heart Failure http://ClinicalTrials.gov/show/NCT00670111 Recruiting No Results Available Heart Failure Patients W 9726 NCT00670111 Restoration of Chronotropic Competence in Heart Failure http://ClinicalTrials.gov/show/NCT00670111 Recruiting No Results Available Heart Failure Patients W 9726 NCT00670111 Restoration of Chronotropic Competence in Heart Failure http://ClinicalTrials.gov/show/NCT00670111 Recruiting No Results Available Heart Failure Patients W 9726 NCT00670111 Restoration of Chronotropic Competence in Heart Failure http://ClinicalTrials.gov/show/NCT00670111 Recruiting No Results Available Heart Failure Patients W 9726 NCT00670111 Restoration of Chronotropic Competence in Heart Failure http://ClinicalTrials.gov/show/NCT00670111 Recruiting No Results Available Heart Failure Patients W 9726 NCT00670111 Restoration of Chronotropic Competence in Heart Failure http://ClinicalTrials.gov/show/NCT00670111 Recruiting No Results Available Heart Failure Patients W 9726 NCT00670111 Restoration of Chronotropic Competence in Heart Failure http://ClinicalTrials.gov/show/NCT00670111 Recruiting No Results Available Heart Failure Patients W 9726 NCT00670111 Restoration of Chronotropic Competence in Heart Failure http://ClinicalTrials.gov/show/NCT00670111 Recruiting No Results Available Heart Failure Patients W 9726 NCT00670111 Restoration of Chronotropic Competence in Heart Failure http://ClinicalTrials.gov/show/NCT00670111 Recruiting No Results Available Heart Failure Patients W 9726 NCT00670111 Restoration of Chronotropic Competence in Heart Failure http://ClinicalTrials.gov/show/NCT00670111 Recruiting No Results Available Heart Failure Patients W 9726 NCT00670111 Restoration of Chronotropic Competence in Heart Failure http://ClinicalTrials.gov/show/NCT00670111 Recruiting No Results Available Heart Failure Patients W 9726 NCT00670111 Restoration of Chronotropic Competence in Heart Failure http://ClinicalTrials.gov/show/NCT00670111 Recruiting No Results Available Heart Failure Patients W 9726 NCT00670111 Restoration of Chronotropic Competence in Heart Failure http://ClinicalTrials.gov/show/NCT00670111 Recruiting No Results Available Heart Failure Patients W 9726 NCT00670111 Restoration of Chronotropic Competence in Heart Failure http://ClinicalTrials.gov/show/NCT00670111 Recruiting No Results Available Heart Failure Patients W 9726 NCT00670111 Restoration of Chronotropic Competence in Heart Failure http://ClinicalTrials.gov/show/NCT00670111 Recruiting No Results Available Heart Failure Patients W 9726 NCT00670111 Restoration of Chronotropic Competence in Heart Failure http://ClinicalTrials.gov/show/NCT00670111 Recruiting No Results Available Heart Failure Patients W 9726 NCT00670111 Restoration of Chronotropic Competence in Heart Failure http://ClinicalTrials.gov/show/NCT00670111 Recruiting No Results Available Heart Failure Patients W 9726 NCT00670111 Restoration of Chronotropic Competence in Heart Failure http://ClinicalTrials.gov/show/NCT00670111 Recruiting No Results Available Heart Failure Patients W 9726 NCT00670111 Restoration of Chronotropic Competence in Heart Failure

Exclusion Exclusion Exclusion NoInEx NoInEx NoInEx Inclusion Inclusion Inclusion Inclusion Inclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion NoInEx NoInEx NoInEx NoInEx NoInEx NoInEx Inclusion Inclusion Inclusion Inclusion Inclusion Exclusion Exclusion Exclusion Exclusion

Age Gender Healthy

Age Gender Healthy

http://ClinicalTrials.gov/show/NCT00670111 Recruiting No Results Available Heart Failure Patients W 9726 NCT00670111 Restoration of Chronotropic Competence in Heart Failure http://ClinicalTrials.gov/show/NCT00670111 Recruiting No Results Available Heart Failure Patients W 9726 NCT00670111 Restoration of Chronotropic Competence in Heart Failure http://ClinicalTrials.gov/show/NCT00670111 Recruiting No Results Available Heart Failure Patients W 9726 NCT00670111 Restoration of Chronotropic Competence in Heart Failure http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on theFailure 8969 NCT00769210 Effect Completed No Results Available The Heart Expression of Procoagulan http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on theFailure 8969 NCT00769210 Effect Completed No Results Available The Heart Expression of Procoagulan http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on theFailure 8969 NCT00769210 Effect Completed No Results Available The Heart Expression of Procoagulan http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on theFailure 8969 NCT00769210 Effect Completed No Results Available The Heart Expression of Procoagulan http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on theFailure 8969 NCT00769210 Effect Completed No Results Available The Heart Expression of Procoagulan http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on theFailure 8969 NCT00769210 Effect Completed No Results Available The Heart Expression of Procoagulan http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on theFailure 8969 NCT00769210 Effect Completed No Results Available The Heart Expression of Procoagulan http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on theFailure 8969 NCT00769210 Effect Completed No Results Available The Heart Expression of Procoagulan http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on theFailure 8969 NCT00769210 Effect Completed No Results Available The Heart Expression of Procoagulan http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on theFailure 8969 NCT00769210 Effect Completed No Results Available The Heart Expression of Procoagulan http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on theFailure 8969 NCT00769210 Effect Completed No Results Available The Heart Expression of Procoagulan http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on theFailure 8969 NCT00769210 Effect Completed No Results Available The Heart Expression of Procoagulan http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on theFailure 8969 NCT00769210 Effect Completed No Results Available The Heart Expression of Procoagulan http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on theFailure 8969 NCT00769210 Effect Completed No Results Available The Heart Expression of Procoagulan http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on theFailure 8969 NCT00769210 Effect Completed No Results Available The Heart Expression of Procoagulan http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on theFailure 8969 NCT00769210 Effect Completed No Results Available The Heart Expression of Procoagulan http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on theFailure 8969 NCT00769210 Effect Completed No Results Available The Heart Expression of Procoagulan http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on theFailure 8969 NCT00769210 Effect Completed No Results Available The Heart Expression of Procoagulan http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on theFailure 8969 NCT00769210 Effect Completed No Results Available The Heart Expression of Procoagulan http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on theFailure 8969 NCT00769210 Effect Completed No Results Available The Heart Expression of Procoagulan http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on theFailure 8969 NCT00769210 Effect Completed No Results Available The Heart Expression of Procoagulan http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on theFailure 8969 NCT00769210 Effect Completed No Results Available The Heart Expression of Procoagulan http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on theFailure 8969 NCT00769210 Effect Completed No Results Available The Heart Expression of Procoagulan http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on theFailure 8969 NCT00769210 Effect Completed No Results Available The Heart Expression of Procoagulan http://ClinicalTrials.gov/show/NCT00769210 of Simvastatin Therapy on theFailure 8969 NCT00769210 Effect Completed No Results Available The Heart Expression of Procoagulan http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Study Heart Failure http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Study Heart Failure http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Study Heart Failure http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Study Heart Failure http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Study Heart Failure http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Study Heart Failure http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Study Heart Failure http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Study Heart Failure http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Study Heart Failure http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Study Heart Failure http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Study Heart Failure http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Study Heart Failure http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Study Heart Failure http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Study Heart Failure http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Study Heart Failure

Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion Exclusion

http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Study Heart Failure http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Study Heart Failure http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Study Heart Failure http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Study Heart Failure http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Study Heart Failure http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Study Heart Failure http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Study Heart Failure http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Study Heart Failure http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Study Heart Failure http://ClinicalTrials.gov/show/NCT00795873 Recruiting No Results Available 61604 NCT00795873 OVATIO CRT and SITUS OTW LV Lead Post Approval Study Heart Failure

Behavioral: The Alfred|HBA of heart failure Early detection Both Adult|Senior Behavioral: The Alfred|HBA of heart failure Early detection Both Adult|Senior Behavioral: The Alfred|HBA of heart failure Early detection Both Adult|Senior Behavioral: The Alfred|HBA of heart failure Early detection Both Adult|Senior Behavioral: The Alfred|HBA of heart failure Early detection Both Adult|Senior Behavioral: The Alfred|HBA of heart failure Early detection Both Adult|Senior Behavioral: The Alfred|HBA of heart failure Early detection Both Adult|Senior Behavioral: The Alfred|HBA of heart failure Early detection Both Adult|Senior Behavioral: The Alfred|HBA of heart failure Early detection Both Adult|Senior Behavioral: The Alfred|HBA of heart failure Early detection Both Adult|Senior Behavioral: The Alfred|HBA of heart failure Early detection Both Adult|Senior Behavioral: The Alfred|HBA of heart failure Early detection Both Adult|Senior Behavioral: The Alfred|HBA of heart failure Early detection Both Adult|Senior Behavioral: The Alfred|HBA of heart failure Early detection Both Adult|Senior Behavioral: The Alfred|HBA of heart failure Early detection Both Adult|Senior Behavioral: The Alfred|HBA of heart failure Early detection Both Adult|Senior Behavioral: The Alfred|HBA of heart failure Early detection Both Adult|Senior Behavioral: The Alfred|HBA of heart failure Early detection Both Adult|Senior Drug: Candesartan upHeart Institute|AstraZeneca IV Montreal to 32 mg daily Both Adult|Senior Phase Drug: Candesartan upHeart Institute|AstraZeneca IV Montreal to 32 mg daily Both Adult|Senior Phase Drug: Candesartan upHeart Institute|AstraZeneca IV Montreal to 32 mg daily Both Adult|Senior Phase Drug: Candesartan upHeart Institute|AstraZeneca IV Montreal to 32 mg daily Both Adult|Senior Phase Drug: Candesartan upHeart Institute|AstraZeneca IV Montreal to 32 mg daily Both Adult|Senior Phase Drug: Candesartan upHeart Institute|AstraZeneca IV Montreal to 32 mg daily Both Adult|Senior Phase Drug: Candesartan upHeart Institute|AstraZeneca IV Montreal to 32 mg daily Both Adult|Senior Phase Drug: Candesartan upHeart Institute|AstraZeneca IV Montreal to 32 mg daily Both Adult|Senior Phase Drug: Candesartan upHeart Institute|AstraZeneca IV Montreal to 32 mg daily Both Adult|Senior Phase Drug: Candesartan upHeart Institute|AstraZeneca IV Montreal to 32 mg daily Both Adult|Senior Phase Drug: Candesartan upHeart Institute|AstraZeneca IV Montreal to 32 mg daily Both Adult|Senior Phase Drug: Candesartan upHeart Institute|AstraZeneca IV Montreal to 32 mg daily Both Adult|Senior Phase Drug: Candesartan upHeart Institute|AstraZeneca IV Montreal to 32 mg daily Both Adult|Senior Phase Drug: Candesartan upHeart Institute|AstraZeneca IV Montreal to 32 mg daily Both Adult|Senior Phase Drug: Candesartan upHeart Institute|AstraZeneca IV Montreal to 32 mg daily Both Adult|Senior Phase Drug: Candesartan upHeart Institute|AstraZeneca IV Montreal to 32 mg daily Both Adult|Senior Phase Drug: Candesartan upHeart Institute|AstraZeneca IV Montreal to 32 mg daily Both Adult|Senior Phase Drug: Candesartan upHeart Institute|AstraZeneca IV Montreal to 32 mg daily Both Adult|Senior Phase Drug: Candesartan upHeart Institute|AstraZeneca IV Montreal to 32 mg daily Both Adult|Senior Phase Drug: Candesartan upHeart Institute|AstraZeneca IV Montreal to 32 mg daily Both Adult|Senior Phase Drug: Canrenone Care Foundation Adult|Senior Heart Both Phase III Drug: Canrenone Care Foundation Adult|Senior Heart Both Phase III Drug: Canrenone Care Foundation Adult|Senior Heart Both Phase III Drug: Canrenone Care Foundation Adult|Senior Heart Both Phase III Drug: Canrenone Care Foundation Adult|Senior Heart Both Phase III

3500 3500 3500 3500 3500 3500 3500 3500 3500 3500 3500 3500 3500 3500 3500 3500 3500 3500 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 300 500 500 500 500 500

OTHER|UNKNOWN Cohort|Prospective Observational OTHER|UNKNOWN Cohort|Prospective Observational OTHER|UNKNOWN Cohort|Prospective Observational OTHER|UNKNOWN Cohort|Prospective Observational OTHER|UNKNOWN Cohort|Prospective Observational OTHER|UNKNOWN Cohort|Prospective Observational OTHER|UNKNOWN Cohort|Prospective Observational OTHER|UNKNOWN Cohort|Prospective Observational OTHER|UNKNOWN Cohort|Prospective Observational OTHER|UNKNOWN Cohort|Prospective Observational OTHER|UNKNOWN Cohort|Prospective Observational OTHER|UNKNOWN Cohort|Prospective Observational OTHER|UNKNOWN Cohort|Prospective Observational OTHER|UNKNOWN Cohort|Prospective Observational OTHER|UNKNOWN Cohort|Prospective Observational OTHER|UNKNOWN Cohort|Prospective Observational OTHER|UNKNOWN Cohort|Prospective Observational OTHER|UNKNOWN Cohort|Prospective Observational OTHER|INDUSTRY Interventional Treatment|Non-Randomized|Op OTHER|INDUSTRY Interventional Treatment|Non-Randomized|Op OTHER|INDUSTRY Interventional Treatment|Non-Randomized|Op OTHER|INDUSTRY Interventional Treatment|Non-Randomized|Op OTHER|INDUSTRY Interventional Treatment|Non-Randomized|Op OTHER|INDUSTRY Interventional Treatment|Non-Randomized|Op OTHER|INDUSTRY Interventional Treatment|Non-Randomized|Op OTHER|INDUSTRY Interventional Treatment|Non-Randomized|Op OTHER|INDUSTRY Interventional Treatment|Non-Randomized|Op OTHER|INDUSTRY Interventional Treatment|Non-Randomized|Op OTHER|INDUSTRY Interventional Treatment|Non-Randomized|Op OTHER|INDUSTRY Interventional Treatment|Non-Randomized|Op OTHER|INDUSTRY Interventional Treatment|Non-Randomized|Op OTHER|INDUSTRY Interventional Treatment|Non-Randomized|Op OTHER|INDUSTRY Interventional Treatment|Non-Randomized|Op OTHER|INDUSTRY Interventional Treatment|Non-Randomized|Op OTHER|INDUSTRY Interventional Treatment|Non-Randomized|Op OTHER|INDUSTRY Interventional Treatment|Non-Randomized|Op OTHER|INDUSTRY Interventional Treatment|Non-Randomized|Op OTHER|INDUSTRY Interventional Treatment|Non-Randomized|Op OTHER Interventional Diagnostic|Randomized|DoubleOTHER Interventional Diagnostic|Randomized|DoubleOTHER Interventional Diagnostic|Randomized|DoubleOTHER Interventional Diagnostic|Randomized|DoubleOTHER Interventional Diagnostic|Randomized|Double-

Drug: Canrenone Care Foundation Adult|Senior Heart Both Phase III 500 OTHER Drug: Canrenone Care Foundation Adult|Senior Heart Both Phase III 500 OTHER Drug: Canrenone Care Foundation Adult|Senior Heart Both Phase III 500 OTHER Drug: Canrenone Care Foundation Adult|Senior Heart Both Phase III 500 OTHER Drug: Canrenone Care Foundation Adult|Senior Heart Both Phase III 500 OTHER Drug: Canrenone Care Foundation Adult|Senior Heart Both Phase III 500 OTHER Drug: Canrenone Care Foundation Adult|Senior Heart Both Phase III 500 OTHER Drug: Canrenone Care Foundation Adult|Senior Heart Both Phase III 500 OTHER Drug: Canrenone Care Foundation Adult|Senior Heart Both Phase III 500 OTHER Drug: Canrenone Care Foundation Adult|Senior Heart Both Phase III 500 OTHER Drug: Canrenone Care Foundation Adult|Senior Heart Both Phase III 500 OTHER Drug: Canrenone Care Foundation Adult|Senior Heart Both Phase III 500 OTHER Drug: Canrenone Care Foundation Adult|Senior Heart Both Phase III 500 OTHER Drug: erythropoietin Both Rabin Medical Center Adult|Senior Phase IV 10 OTHER Drug: erythropoietin Both Rabin Medical Center Adult|Senior Phase IV 10 OTHER Drug: erythropoietin Both Rabin Medical Center Adult|Senior Phase IV 10 OTHER Drug: erythropoietin Both Rabin Medical Center Adult|Senior Phase IV 10 OTHER Drug: erythropoietin Both Rabin Medical Center Adult|Senior Phase IV 10 OTHER Drug: erythropoietin Both Rabin Medical Center Adult|Senior Phase IV 10 OTHER Drug: erythropoietin Both Rabin Medical Center Adult|Senior Phase IV 10 OTHER Drug: erythropoietin Both Rabin Medical Center Adult|Senior Phase IV 10 OTHER Drug: erythropoietin Both Rabin Medical Center Adult|Senior Phase IV 10 OTHER Drug: erythropoietin Both Rabin Medical Center Adult|Senior Phase IV 10 OTHER Drug: erythropoietin Both Rabin Medical Center Adult|Senior Phase IV 10 OTHER Drug: erythropoietin Both Rabin Medical Center Adult|Senior Phase IV 10 OTHER Device: InSync III University Ume Both Adult|Senior Phase II 40 OTHER Device: InSync III University Ume Both Adult|Senior Phase II 40 OTHER Device: InSync III University Ume Both Adult|Senior Phase II 40 OTHER Device: InSync III University Ume Both Adult|Senior Phase II 40 OTHER Device: InSync III University Ume Both Adult|Senior Phase II 40 OTHER Device: InSync III University Ume Both Adult|Senior Phase II 40 OTHER Device: InSync III University Ume Both Adult|Senior Phase II 40 OTHER Device: InSync III University Ume Both Adult|Senior Phase II 40 OTHER Device: InSync III University Ume Both Adult|Senior Phase II 40 OTHER Device: InSync III University Ume Both Adult|Senior Phase II 40 OTHER Device: InSync III University Ume Both Adult|Senior Phase II 40 OTHER Device: InSync III University Ume Both Adult|Senior Phase II 40 OTHER Device: Programming (CRT-D, CRT,Adult|Senior and Cardiac Compass ) Medtronic Bakken ResearchOptiVol III Both ICD Center Phase 2300 INDUSTRY Device: Programming (CRT-D, CRT,Adult|Senior and Cardiac Compass ) Medtronic Bakken ResearchOptiVol III Both ICD Center Phase 2300 INDUSTRY Device: Programming (CRT-D, CRT,Adult|Senior and Cardiac Compass ) Medtronic Bakken ResearchOptiVol III Both ICD Center Phase 2300 INDUSTRY Device: Programming (CRT-D, CRT,Adult|Senior and Cardiac Compass ) Medtronic Bakken ResearchOptiVol III Both ICD Center Phase 2300 INDUSTRY Device: Programming (CRT-D, CRT,Adult|Senior and Cardiac Compass ) Medtronic Bakken ResearchOptiVol III Both ICD Center Phase 2300 INDUSTRY Device: Programming (CRT-D, CRT,Adult|Senior and Cardiac Compass ) Medtronic Bakken ResearchOptiVol III Both ICD Center Phase 2300 INDUSTRY Device: Programming (CRT-D, CRT,Adult|Senior and Cardiac Compass ) Medtronic Bakken ResearchOptiVol III Both ICD Center Phase 2300 INDUSTRY

Interventional Diagnostic|Randomized|DoubleInterventional Diagnostic|Randomized|DoubleInterventional Diagnostic|Randomized|DoubleInterventional Diagnostic|Randomized|DoubleInterventional Diagnostic|Randomized|DoubleInterventional Diagnostic|Randomized|DoubleInterventional Diagnostic|Randomized|DoubleInterventional Diagnostic|Randomized|DoubleInterventional Diagnostic|Randomized|DoubleInterventional Diagnostic|Randomized|DoubleInterventional Diagnostic|Randomized|DoubleInterventional Diagnostic|Randomized|DoubleInterventional Diagnostic|Randomized|DoubleInterventional Treatment|Non-Randomized|Op Interventional Treatment|Non-Randomized|Op Interventional Treatment|Non-Randomized|Op Interventional Treatment|Non-Randomized|Op Interventional Treatment|Non-Randomized|Op Interventional Treatment|Non-Randomized|Op Interventional Treatment|Non-Randomized|Op Interventional Treatment|Non-Randomized|Op Interventional Treatment|Non-Randomized|Op Interventional Treatment|Non-Randomized|Op Interventional Treatment|Non-Randomized|Op Interventional Treatment|Non-Randomized|Op Interventional Treatment|Randomized|Double Interventional Treatment|Randomized|Double Interventional Treatment|Randomized|Double Interventional Treatment|Randomized|Double Interventional Treatment|Randomized|Double Interventional Treatment|Randomized|Double Interventional Treatment|Randomized|Double Interventional Treatment|Randomized|Double Interventional Treatment|Randomized|Double Interventional Treatment|Randomized|Double Interventional Treatment|Randomized|Double Interventional Treatment|Randomized|Double Interventional Treatment|Randomized|Open La Interventional Treatment|Randomized|Open La Interventional Treatment|Randomized|Open La Interventional Treatment|Randomized|Open La Interventional Treatment|Randomized|Open La Interventional Treatment|Randomized|Open La Interventional Treatment|Randomized|Open La

Device: Programming (CRT-D, CRT,Adult|Senior and Cardiac Compass ) Medtronic Bakken ResearchOptiVol III Both ICD Center Phase 2300 INDUSTRY Device: Programming (CRT-D, CRT,Adult|Senior and Cardiac Compass ) Medtronic Bakken ResearchOptiVol III Both ICD Center Phase 2300 INDUSTRY Device: Programming (CRT-D, CRT,Adult|Senior and Cardiac Compass ) Medtronic Bakken ResearchOptiVol III Both ICD Center Phase 2300 INDUSTRY Device: Programming (CRT-D, CRT,Adult|Senior and Cardiac Compass ) Medtronic Bakken ResearchOptiVol III Both ICD Center Phase 2300 INDUSTRY Device: Programming (CRT-D, CRT,Adult|Senior and Cardiac Compass ) Medtronic Bakken ResearchOptiVol III Both ICD Center Phase 2300 INDUSTRY Device: Programming (CRT-D, CRT,Adult|Senior and Cardiac Compass ) Medtronic Bakken ResearchOptiVol III Both ICD Center Phase 2300 INDUSTRY Device: Programming (CRT-D, CRT,Adult|Senior and Cardiac Compass ) Medtronic Bakken ResearchOptiVol III Both ICD Center Phase 2300 INDUSTRY Device: Programming (CRT-D, CRT,Adult|Senior and Cardiac Compass ) Medtronic Bakken ResearchOptiVol III Both ICD Center Phase 2300 INDUSTRY Device: Programming (CRT-D, CRT,Adult|Senior and Cardiac Compass ) Medtronic Bakken ResearchOptiVol III Both ICD Center Phase 2300 INDUSTRY Device: Programming (CRT-D, CRT,Adult|Senior and Cardiac Compass ) Medtronic Bakken ResearchOptiVol III Both ICD Center Phase 2300 INDUSTRY Heart Failure Assistance Publique - Hpitaux de Paris Both Senior 300 OTHER Heart Failure Assistance Publique - Hpitaux de Paris Both Senior 300 OTHER Heart Failure Assistance Publique - Hpitaux de Paris Both Senior 300 OTHER Heart Failure Assistance Publique - Hpitaux de Paris Both Senior 300 OTHER Heart Failure Assistance Publique - Hpitaux de Paris Both Senior 300 OTHER Heart Failure Assistance Publique - Hpitaux de Paris Both Senior 300 OTHER Heart Failure Assistance Publique - Hpitaux de Paris Both Senior 300 OTHER Heart Failure Assistance Publique - Hpitaux de Paris Both Senior 300 OTHER Heart Failure Assistance Publique - Hpitaux de Paris Both Senior 300 OTHER Heart Failure Assistance Publique - Hpitaux de Paris Both Senior 300 OTHER Heart Failure Assistance Publique - Hpitaux de Paris Both Senior 300 OTHER Heart Failure Assistance Publique - Hpitaux de Paris Both Senior 300 OTHER Heart Failure Assistance Publique - Hpitaux de Paris Both Senior 300 OTHER Device: Insignia Plus / Ultra (Guidant/Boston Scientific) Boston Scientific Corporation Both Adult|Senior 400 INDUSTRY Device: Insignia Plus / Ultra (Guidant/Boston Scientific) Boston Scientific Corporation Both Adult|Senior 400 INDUSTRY Device: Insignia Plus / Ultra (Guidant/Boston Scientific) Boston Scientific Corporation Both Adult|Senior 400 INDUSTRY Device: Insignia Plus / Ultra (Guidant/Boston Scientific) Boston Scientific Corporation Both Adult|Senior 400 INDUSTRY Device: Insignia Plus / Ultra (Guidant/Boston Scientific) Boston Scientific Corporation Both Adult|Senior 400 INDUSTRY Device: Insignia Plus / Ultra (Guidant/Boston Scientific) Boston Scientific Corporation Both Adult|Senior 400 INDUSTRY Device: Insignia Plus / Ultra (Guidant/Boston Scientific) Boston Scientific Corporation Both Adult|Senior 400 INDUSTRY Device: Insignia Plus / Ultra (Guidant/Boston Scientific) Boston Scientific Corporation Both Adult|Senior 400 INDUSTRY Device: Insignia Plus / Ultra (Guidant/Boston Scientific) Boston Scientific Corporation Both Adult|Senior 400 INDUSTRY Device: Insignia Plus / Ultra (Guidant/Boston Scientific) Boston Scientific Corporation Both Adult|Senior 400 INDUSTRY Device: Insignia Plus / Ultra (Guidant/Boston Scientific) Boston Scientific Corporation Both Adult|Senior 400 INDUSTRY Device: Insignia Plus / Ultra (Guidant/Boston Scientific) Boston Scientific Corporation Both Adult|Senior 400 INDUSTRY Device: Insignia Plus / Ultra (Guidant/Boston Scientific) Boston Scientific Corporation Both Adult|Senior 400 INDUSTRY Device: Insignia Plus / Ultra (Guidant/Boston Scientific) Boston Scientific Corporation Both Adult|Senior 400 INDUSTRY Device: Insignia Plus / Ultra (Guidant/Boston Scientific) Boston Scientific Corporation Both Adult|Senior 400 INDUSTRY Device: Insignia Plus / Ultra (Guidant/Boston Scientific) Boston Scientific Corporation Both Adult|Senior 400 INDUSTRY Device: Insignia Plus / Ultra (Guidant/Boston Scientific) Boston Scientific Corporation Both Adult|Senior 400 INDUSTRY Device: Insignia Plus / Ultra (Guidant/Boston Scientific) Boston Scientific Corporation Both Adult|Senior 400 INDUSTRY Device: Insignia Plus / Ultra (Guidant/Boston Scientific) Boston Scientific Corporation Both Adult|Senior 400 INDUSTRY

Interventional Treatment|Randomized|Open La Interventional Treatment|Randomized|Open La Interventional Treatment|Randomized|Open La Interventional Treatment|Randomized|Open La Interventional Treatment|Randomized|Open La Interventional Treatment|Randomized|Open La Interventional Treatment|Randomized|Open La Interventional Treatment|Randomized|Open La Interventional Treatment|Randomized|Open La Interventional Treatment|Randomized|Open La Observational Cohort|Prospective Observational Cohort|Prospective Observational Cohort|Prospective Observational Cohort|Prospective Observational Cohort|Prospective Observational Cohort|Prospective Observational Cohort|Prospective Observational Cohort|Prospective Observational Cohort|Prospective Observational Cohort|Prospective Observational Cohort|Prospective Observational Cohort|Prospective Observational Cohort|Prospective Interventional Treatment|Randomized|Double Interventional Treatment|Randomized|Double Interventional Treatment|Randomized|Double Interventional Treatment|Randomized|Double Interventional Treatment|Randomized|Double Interventional Treatment|Randomized|Double Interventional Treatment|Randomized|Double Interventional Treatment|Randomized|Double Interventional Treatment|Randomized|Double Interventional Treatment|Randomized|Double Interventional Treatment|Randomized|Double Interventional Treatment|Randomized|Double Interventional Treatment|Randomized|Double Interventional Treatment|Randomized|Double Interventional Treatment|Randomized|Double Interventional Treatment|Randomized|Double Interventional Treatment|Randomized|Double Interventional Treatment|Randomized|Double Interventional Treatment|Randomized|Double

Device: Insignia Plus / Ultra (Guidant/Boston Scientific) Boston Scientific Corporation Both Adult|Senior Device: Insignia Plus / Ultra (Guidant/Boston Scientific) Boston Scientific Corporation Both Adult|Senior Device: Insignia Plus / Ultra (Guidant/Boston Scientific) Boston Scientific Corporation Both Adult|Senior Drug: Simvastatin University of Utah Both Adult|Senior Drug: Simvastatin University of Utah Both Adult|Senior Drug: Simvastatin University of Utah Both Adult|Senior Drug: Simvastatin University of Utah Both Adult|Senior Drug: Simvastatin University of Utah Both Adult|Senior Drug: Simvastatin University of Utah Both Adult|Senior Drug: Simvastatin University of Utah Both Adult|Senior Drug: Simvastatin University of Utah Both Adult|Senior Drug: Simvastatin University of Utah Both Adult|Senior Drug: Simvastatin University of Utah Both Adult|Senior Drug: Simvastatin University of Utah Both Adult|Senior Drug: Simvastatin University of Utah Both Adult|Senior Drug: Simvastatin University of Utah Both Adult|Senior Drug: Simvastatin University of Utah Both Adult|Senior Drug: Simvastatin University of Utah Both Adult|Senior Drug: Simvastatin University of Utah Both Adult|Senior Drug: Simvastatin University of Utah Both Adult|Senior Drug: Simvastatin University of Utah Both Adult|Senior Drug: Simvastatin University of Utah Both Adult|Senior Drug: Simvastatin University of Utah Both Adult|Senior Drug: Simvastatin University of Utah Both Adult|Senior Drug: Simvastatin University of Utah Both Adult|Senior Drug: Simvastatin University of Utah Both Adult|Senior Drug: Simvastatin University of Utah Both Adult|Senior Drug: Simvastatin University of Utah Both Adult|Senior Heart Failure ELA Medical, Inc. Both Adult|Senior Heart Failure ELA Medical, Inc. Both Adult|Senior Heart Failure ELA Medical, Inc. Both Adult|Senior Heart Failure ELA Medical, Inc. Both Adult|Senior Heart Failure ELA Medical, Inc. Both Adult|Senior Heart Failure ELA Medical, Inc. Both Adult|Senior Heart Failure ELA Medical, Inc. Both Adult|Senior Heart Failure ELA Medical, Inc. Both Adult|Senior Heart Failure ELA Medical, Inc. Both Adult|Senior Heart Failure ELA Medical, Inc. Both Adult|Senior Heart Failure ELA Medical, Inc. Both Adult|Senior Heart Failure ELA Medical, Inc. Both Adult|Senior Heart Failure ELA Medical, Inc. Both Adult|Senior Heart Failure ELA Medical, Inc. Both Adult|Senior Heart Failure ELA Medical, Inc. Both Adult|Senior

400 400 400 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 12 2260 2260 2260 2260 2260 2260 2260 2260 2260 2260 2260 2260 2260 2260 2260

INDUSTRY INDUSTRY INDUSTRY OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER OTHER INDUSTRY INDUSTRY INDUSTRY INDUSTRY INDUSTRY INDUSTRY INDUSTRY INDUSTRY INDUSTRY INDUSTRY INDUSTRY INDUSTRY INDUSTRY INDUSTRY INDUSTRY

Interventional Treatment|Randomized|Double Interventional Treatment|Randomized|Double Interventional Treatment|Randomized|Double Interventional Treatment|Randomized|Open La Interventional Treatment|Randomized|Open La Interventional Treatment|Randomized|Open La Interventional Treatment|Randomized|Open La Interventional Treatment|Randomized|Open La Interventional Treatment|Randomized|Open La Interventional Treatment|Randomized|Open La Interventional Treatment|Randomized|Open La Interventional Treatment|Randomized|Open La Interventional Treatment|Randomized|Open La Interventional Treatment|Randomized|Open La Interventional Treatment|Randomized|Open La Interventional Treatment|Randomized|Open La Interventional Treatment|Randomized|Open La Interventional Treatment|Randomized|Open La Interventional Treatment|Randomized|Open La Interventional Treatment|Randomized|Open La Interventional Treatment|Randomized|Open La Interventional Treatment|Randomized|Open La Interventional Treatment|Randomized|Open La Interventional Treatment|Randomized|Open La Interventional Treatment|Randomized|Open La Interventional Treatment|Randomized|Open La Interventional Treatment|Randomized|Open La Interventional Treatment|Randomized|Open La Observational Cohort|Prospective Observational Cohort|Prospective Observational Cohort|Prospective Observational Cohort|Prospective Observational Cohort|Prospective Observational Cohort|Prospective Observational Cohort|Prospective Observational Cohort|Prospective Observational Cohort|Prospective Observational Cohort|Prospective Observational Cohort|Prospective Observational Cohort|Prospective Observational Cohort|Prospective Observational Cohort|Prospective Observational Cohort|Prospective

Heart Failure Heart Failure Heart Failure Heart Failure Heart Failure Heart Failure Heart Failure Heart Failure Heart Failure Heart Failure

ELA Medical, Inc. Both ELA Medical, Inc. Both ELA Medical, Inc. Both ELA Medical, Inc. Both ELA Medical, Inc. Both ELA Medical, Inc. Both ELA Medical, Inc. Both ELA Medical, Inc. Both ELA Medical, Inc. Both ELA Medical, Inc. Both

Adult|Senior Adult|Senior Adult|Senior Adult|Senior Adult|Senior Adult|Senior Adult|Senior Adult|Senior Adult|Senior Adult|Senior

2260 2260 2260 2260 2260 2260 2260 2260 2260 2260

INDUSTRY INDUSTRY INDUSTRY INDUSTRY INDUSTRY INDUSTRY INDUSTRY INDUSTRY INDUSTRY INDUSTRY

Observational Cohort|Prospective Observational Cohort|Prospective Observational Cohort|Prospective Observational Cohort|Prospective Observational Cohort|Prospective Observational Cohort|Prospective Observational Cohort|Prospective Observational Cohort|Prospective Observational Cohort|Prospective Observational Cohort|Prospective

CP-04/06 15-Nov-06 7-May CP-04/06 15-Nov-06 7-May CP-04/06 15-Nov-06 7-May CP-04/06 15-Nov-06 7-May CP-04/06 15-Nov-06 7-May CP-04/06 15-Nov-06 7-May CP-04/06 15-Nov-06 7-May CP-04/06 15-Nov-06 7-May CP-04/06 15-Nov-06 7-May CP-04/06 15-Nov-06 7-May CP-04/06 15-Nov-06 7-May CP-04/06 15-Nov-06 7-May CP-04/06 15-Nov-06 7-May CP-04/06 15-Nov-06 7-May CP-04/06 15-Nov-06 7-May CP-04/06 15-Nov-06 7-May CP-04/06 15-Nov-06 7-May CP-04/06 15-Nov-06 7-May MHI 06-890|D2454L00003 6-Nov 15-Nov-06 MHI 06-890|D2454L00003 6-Nov 15-Nov-06 MHI 06-890|D2454L00003 6-Nov 15-Nov-06 MHI 06-890|D2454L00003 6-Nov 15-Nov-06 MHI 06-890|D2454L00003 6-Nov 15-Nov-06 MHI 06-890|D2454L00003 6-Nov 15-Nov-06 MHI 06-890|D2454L00003 6-Nov 15-Nov-06 MHI 06-890|D2454L00003 6-Nov 15-Nov-06 MHI 06-890|D2454L00003 6-Nov 15-Nov-06 MHI 06-890|D2454L00003 6-Nov 15-Nov-06 MHI 06-890|D2454L00003 6-Nov 15-Nov-06 MHI 06-890|D2454L00003 6-Nov 15-Nov-06 MHI 06-890|D2454L00003 6-Nov 15-Nov-06 MHI 06-890|D2454L00003 6-Nov 15-Nov-06 MHI 06-890|D2454L00003 6-Nov 15-Nov-06 MHI 06-890|D2454L00003 6-Nov 15-Nov-06 MHI 06-890|D2454L00003 6-Nov 15-Nov-06 MHI 06-890|D2454L00003 6-Nov 15-Nov-06 MHI 06-890|D2454L00003 6-Nov 15-Nov-06 MHI 06-890|D2454L00003 6-Nov 15-Nov-06 17 24-Nov-06 2-Sep 17 24-Nov-06 2-Sep 17 24-Nov-06 2-Sep 17 24-Nov-06 2-Sep 17 24-Nov-06 2-Sep

10-Aug 10-Aug 10-Aug 10-Aug 10-Aug 10-Aug 10-Aug 10-Aug 10-Aug 10-Aug 10-Aug 10-Aug 10-Aug 10-Aug 10-Aug 10-Aug 10-Aug 10-Aug

6-Jul 6-Jul 6-Jul 6-Jul 6-Jul

3-Aug-09 3-Aug-09 3-Aug-09 3-Aug-09 3-Aug-09 3-Aug-09 3-Aug-09 3-Aug-09 3-Aug-09 3-Aug-09 3-Aug-09 3-Aug-09 3-Aug-09 3-Aug-09 3-Aug-09 3-Aug-09 3-Aug-09 3-Aug-09 9-Jul-09 9-Jul-09 9-Jul-09 9-Jul-09 9-Jul-09 9-Jul-09 9-Jul-09 9-Jul-09 9-Jul-09 9-Jul-09 9-Jul-09 9-Jul-09 9-Jul-09 9-Jul-09 9-Jul-09 9-Jul-09 9-Jul-09 9-Jul-09 9-Jul-09 9-Jul-09 16-Apr-09 16-Apr-09 16-Apr-09 16-Apr-09 16-Apr-09

9-Aug 9-Aug 9-Aug 9-Aug 9-Aug 9-Aug 9-Aug 9-Aug 9-Aug 9-Aug 9-Aug 9-Aug 9-Aug 9-Aug 9-Aug 9-Aug 9-Aug 9-Aug 9-Jul 9-Jul 9-Jul 9-Jul 9-Jul 9-Jul 9-Jul 9-Jul 9-Jul 9-Jul 9-Jul 9-Jul 9-Jul 9-Jul 9-Jul 9-Jul 9-Jul 9-Jul 9-Jul 9-Jul 9-Apr 9-Apr 9-Apr 9-Apr 9-Apr

9-Dec 9-Dec 9-Dec 9-Dec 9-Dec 9-Dec 9-Dec 9-Dec 9-Dec 9-Dec 9-Dec 9-Dec 9-Dec 9-Dec 9-Dec 9-Dec 9-Dec 9-Dec

17 24-Nov-06 17 24-Nov-06 17 24-Nov-06 17 24-Nov-06 17 24-Nov-06 17 24-Nov-06 17 24-Nov-06 17 24-Nov-06 17 24-Nov-06 17 24-Nov-06 17 24-Nov-06 17 24-Nov-06 17 24-Nov-06 4273 2-Jan-07 4273 2-Jan-07 4273 2-Jan-07 4273 2-Jan-07 4273 2-Jan-07 4273 2-Jan-07 4273 2-Jan-07 4273 2-Jan-07 4273 2-Jan-07 4273 2-Jan-07 4273 2-Jan-07 4273 2-Jan-07 Um dnr 03-032 4-Apr-07 Um dnr 03-032 4-Apr-07 Um dnr 03-032 4-Apr-07 Um dnr 03-032 4-Apr-07 Um dnr 03-032 4-Apr-07 Um dnr 03-032 4-Apr-07 Um dnr 03-032 4-Apr-07 Um dnr 03-032 4-Apr-07 Um dnr 03-032 4-Apr-07 Um dnr 03-032 4-Apr-07 Um dnr 03-032 4-Apr-07 Um dnr 03-032 4-Apr-07 20061016-V2####### # 20061016-V2####### # 20061016-V2####### # 20061016-V2####### # 20061016-V2####### # 20061016-V2####### # 20061016-V2####### #

2-Sep 2-Sep 2-Sep 2-Sep 2-Sep 2-Sep 2-Sep 2-Sep 2-Sep 2-Sep 2-Sep 2-Sep 2-Sep 7-Jan 7-Jan 7-Jan 7-Jan 7-Jan 7-Jan 7-Jan 7-Jan 7-Jan 7-Jan 7-Jan 7-Jan 3-Nov 3-Nov 3-Nov 3-Nov 3-Nov 3-Nov 3-Nov 3-Nov 3-Nov 3-Nov 3-Nov 3-Nov 7-Mar 7-Mar 7-Mar 7-Mar 7-Mar 7-Mar 7-Mar

6-Jul 6-Jul 6-Jul 6-Jul 6-Jul 6-Jul 6-Jul 6-Jul 6-Jul 6-Jul 6-Jul 6-Jul 6-Jul 8-Jan 8-Jan 8-Jan 8-Jan 8-Jan 8-Jan 8-Jan 8-Jan 8-Jan 8-Jan 8-Jan 8-Jan 8-Jun 8-Jun 8-Jun 8-Jun 8-Jun 8-Jun 8-Jun 8-Jun 8-Jun 8-Jun 8-Jun 8-Jun 12-Jan 12-Jan 12-Jan 12-Jan 12-Jan 12-Jan 12-Jan

16-Apr-09 16-Apr-09 16-Apr-09 16-Apr-09 16-Apr-09 16-Apr-09 16-Apr-09 16-Apr-09 16-Apr-09 16-Apr-09 16-Apr-09 16-Apr-09 16-Apr-09 3-Jan-07 3-Jan-07 3-Jan-07 3-Jan-07 3-Jan-07 3-Jan-07 3-Jan-07 3-Jan-07 3-Jan-07 3-Jan-07 3-Jan-07 3-Jan-07 8-Jan-08 8-Jan-08 8-Jan-08 8-Jan-08 8-Jan-08 8-Jan-08 8-Jan-08 8-Jan-08 8-Jan-08 8-Jan-08 8-Jan-08 8-Jan-08 6-Feb-09 6-Feb-09 6-Feb-09 6-Feb-09 6-Feb-09 6-Feb-09 6-Feb-09

9-Apr 9-Apr 9-Apr 9-Apr 9-Apr 9-Apr 9-Apr 9-Apr 9-Apr 9-Apr 9-Apr 9-Apr 9-Apr 6-Dec 6-Dec 6-Dec 6-Dec 6-Dec 6-Dec 6-Dec 6-Dec 6-Dec 6-Dec 6-Dec 6-Dec 8-Jan 8-Jan 8-Jan 8-Jan 8-Jan 8-Jan 8-Jan 8-Jan 8-Jan 8-Jan 8-Jan 8-Jan 9-Feb 9-Feb 9-Feb 9-Feb 9-Feb 9-Feb 9-Feb

BIFF BIFF BIFF BIFF BIFF BIFF BIFF BIFF BIFF BIFF BIFF BIFF DOT-HF DOT-HF DOT-HF DOT-HF DOT-HF DOT-HF DOT-HF

8-Jun 8-Jun 8-Jun 8-Jun 8-Jun 8-Jun 8-Jun 8-Jun 8-Jun 8-Jun 8-Jun 8-Jun 12-Jan 12-Jan 12-Jan 12-Jan 12-Jan 12-Jan 12-Jan

20061016-V2####### # 7-Mar 20061016-V2####### # 7-Mar 20061016-V2####### # 7-Mar 20061016-V2####### # 7-Mar 20061016-V2####### # 7-Mar 20061016-V2####### # 7-Mar 20061016-V2####### # 7-Mar 20061016-V2####### # 7-Mar 20061016-V2####### # 7-Mar 20061016-V2####### # 7-Mar SCR 06 007|NAF (APE) : 851A 8-Apr-08 7-Jun SCR 06 007|NAF (APE) : 851A 8-Apr-08 7-Jun SCR 06 007|NAF (APE) : 851A 8-Apr-08 7-Jun SCR 06 007|NAF (APE) : 851A 8-Apr-08 7-Jun SCR 06 007|NAF (APE) : 851A 8-Apr-08 7-Jun SCR 06 007|NAF (APE) : 851A 8-Apr-08 7-Jun SCR 06 007|NAF (APE) : 851A 8-Apr-08 7-Jun SCR 06 007|NAF (APE) : 851A 8-Apr-08 7-Jun SCR 06 007|NAF (APE) : 851A 8-Apr-08 7-Jun SCR 06 007|NAF (APE) : 851A 8-Apr-08 7-Jun SCR 06 007|NAF (APE) : 851A 8-Apr-08 7-Jun SCR 06 007|NAF (APE) : 851A 8-Apr-08 7-Jun SCR 06 007|NAF (APE) : 851A 8-Apr-08 7-Jun RESET 23-Apr-08 8-Jul RESET 23-Apr-08 8-Jul RESET 23-Apr-08 8-Jul RESET 23-Apr-08 8-Jul RESET 23-Apr-08 8-Jul RESET 23-Apr-08 8-Jul RESET 23-Apr-08 8-Jul RESET 23-Apr-08 8-Jul RESET 23-Apr-08 8-Jul RESET 23-Apr-08 8-Jul RESET 23-Apr-08 8-Jul RESET 23-Apr-08 8-Jul RESET 23-Apr-08 8-Jul RESET 23-Apr-08 8-Jul RESET 23-Apr-08 8-Jul RESET 23-Apr-08 8-Jul RESET 23-Apr-08 8-Jul RESET 23-Apr-08 8-Jul RESET 23-Apr-08 8-Jul

12-Jan 12-Jan 12-Jan 12-Jan 12-Jan 12-Jan 12-Jan 12-Jan 12-Jan 12-Jan 9-Dec 9-Dec 9-Dec 9-Dec 9-Dec 9-Dec 9-Dec 9-Dec 9-Dec 9-Dec 9-Dec 9-Dec 9-Dec 11-Jun 11-Jun 11-Jun 11-Jun 11-Jun 11-Jun 11-Jun 11-Jun 11-Jun 11-Jun 11-Jun 11-Jun 11-Jun 11-Jun 11-Jun 11-Jun 11-Jun 11-Jun 11-Jun

6-Feb-09 6-Feb-09 6-Feb-09 6-Feb-09 6-Feb-09 6-Feb-09 6-Feb-09 6-Feb-09 6-Feb-09 6-Feb-09 29-Sep-09 29-Sep-09 29-Sep-09 29-Sep-09 29-Sep-09 29-Sep-09 29-Sep-09 29-Sep-09 29-Sep-09 29-Sep-09 29-Sep-09 29-Sep-09 29-Sep-09 11-Dec-09 11-Dec-09 11-Dec-09 11-Dec-09 11-Dec-09 11-Dec-09 11-Dec-09 11-Dec-09 11-Dec-09 11-Dec-09 11-Dec-09 11-Dec-09 11-Dec-09 11-Dec-09 11-Dec-09 11-Dec-09 11-Dec-09 11-Dec-09 11-Dec-09

9-Feb 9-Feb 9-Feb 9-Feb 9-Feb 9-Feb 9-Feb 9-Feb 9-Feb 9-Feb 9-Aug 9-Aug 9-Aug 9-Aug 9-Aug 9-Aug 9-Aug 9-Aug 9-Aug 9-Aug 9-Aug 9-Aug 9-Aug 9-Dec 9-Dec 9-Dec 9-Dec 9-Dec 9-Dec 9-Dec 9-Dec 9-Dec 9-Dec 9-Dec 9-Dec 9-Dec 9-Dec 9-Dec 9-Dec 9-Dec 9-Dec 9-Dec

DOT-HF DOT-HF DOT-HF DOT-HF DOT-HF DOT-HF DOT-HF DOT-HF DOT-HF DOT-HF BED BED BED BED BED BED BED BED BED BED BED BED BED RESET RESET RESET RESET RESET RESET RESET RESET RESET RESET RESET RESET RESET RESET RESET RESET RESET RESET RESET

12-Jan 12-Jan 12-Jan 12-Jan 12-Jan 12-Jan 12-Jan 12-Jan 12-Jan 12-Jan 9-Jun 9-Jun 9-Jun 9-Jun 9-Jun 9-Jun 9-Jun 9-Jun 9-Jun 9-Jun 9-Jun 9-Jun 9-Jun 11-Jun 11-Jun 11-Jun 11-Jun 11-Jun 11-Jun 11-Jun 11-Jun 11-Jun 11-Jun 11-Jun 11-Jun 11-Jun 11-Jun 11-Jun 11-Jun 11-Jun 11-Jun 11-Jun

RESET 23-Apr-08 RESET 23-Apr-08 RESET 23-Apr-08 2012064|IRB# 00013639 22-Dec-07 2012064|IRB# 00013639 22-Dec-07 2012064|IRB# 00013639 22-Dec-07 2012064|IRB# 00013639 22-Dec-07 2012064|IRB# 00013639 22-Dec-07 2012064|IRB# 00013639 22-Dec-07 2012064|IRB# 00013639 22-Dec-07 2012064|IRB# 00013639 22-Dec-07 2012064|IRB# 00013639 22-Dec-07 2012064|IRB# 00013639 22-Dec-07 2012064|IRB# 00013639 22-Dec-07 2012064|IRB# 00013639 22-Dec-07 2012064|IRB# 00013639 22-Dec-07 2012064|IRB# 00013639 22-Dec-07 2012064|IRB# 00013639 22-Dec-07 2012064|IRB# 00013639 22-Dec-07 2012064|IRB# 00013639 22-Dec-07 2012064|IRB# 00013639 22-Dec-07 2012064|IRB# 00013639 22-Dec-07 2012064|IRB# 00013639 22-Dec-07 2012064|IRB# 00013639 22-Dec-07 2012064|IRB# 00013639 22-Dec-07 2012064|IRB# 00013639 22-Dec-07 2012064|IRB# 00013639 22-Dec-07 2012064|IRB# 00013639 22-Dec-07 ITAC07 20-Nov-08 ITAC07 20-Nov-08 ITAC07 20-Nov-08 ITAC07 20-Nov-08 ITAC07 20-Nov-08 ITAC07 20-Nov-08 ITAC07 20-Nov-08 ITAC07 20-Nov-08 ITAC07 20-Nov-08 ITAC07 20-Nov-08 ITAC07 20-Nov-08 ITAC07 20-Nov-08 ITAC07 20-Nov-08 ITAC07 20-Nov-08 ITAC07 20-Nov-08

8-Jul 8-Jul 8-Jul 5-May 5-May 5-May 5-May 5-May 5-May 5-May 5-May 5-May 5-May 5-May 5-May 5-May 5-May 5-May 5-May 5-May 5-May 5-May 5-May 5-May 5-May 5-May 5-May 5-May 8-Dec 8-Dec 8-Dec 8-Dec 8-Dec 8-Dec 8-Dec 8-Dec 8-Dec 8-Dec 8-Dec 8-Dec 8-Dec 8-Dec 8-Dec

11-Jun 11-Dec-09 11-Jun 11-Dec-09 11-Jun 11-Dec-09 8-Jul 8-Oct-08 8-Jul 8-Oct-08 8-Jul 8-Oct-08 8-Jul 8-Oct-08 8-Jul 8-Oct-08 8-Jul 8-Oct-08 8-Jul 8-Oct-08 8-Jul 8-Oct-08 8-Jul 8-Oct-08 8-Jul 8-Oct-08 8-Jul 8-Oct-08 8-Jul 8-Oct-08 8-Jul 8-Oct-08 8-Jul 8-Oct-08 8-Jul 8-Oct-08 8-Jul 8-Oct-08 8-Jul 8-Oct-08 8-Jul 8-Oct-08 8-Jul 8-Oct-08 8-Jul 8-Oct-08 8-Jul 8-Oct-08 8-Jul 8-Oct-08 8-Jul 8-Oct-08 8-Jul 8-Oct-08 8-Jul 8-Oct-08 7-Jul-09 7-Jul-09 7-Jul-09 7-Jul-09 7-Jul-09 7-Jul-09 7-Jul-09 7-Jul-09 7-Jul-09 7-Jul-09 7-Jul-09 7-Jul-09 7-Jul-09 7-Jul-09 7-Jul-09

9-Dec RESET 9-Dec RESET 9-Dec RESET 8-Oct 8-Oct 8-Oct 8-Oct 8-Oct 8-Oct 8-Oct 8-Oct 8-Oct 8-Oct 8-Oct 8-Oct 8-Oct 8-Oct 8-Oct 8-Oct 8-Oct 8-Oct 8-Oct 8-Oct 8-Oct 8-Oct 8-Oct 8-Oct 8-Oct 9-Jul 9-Jul 9-Jul 9-Jul 9-Jul 9-Jul 9-Jul 9-Jul 9-Jul 9-Jul 9-Jul 9-Jul 9-Jul 9-Jul 9-Jul

11-Jun 11-Jun 11-Jun 8-Jul 8-Jul 8-Jul 8-Jul 8-Jul 8-Jul 8-Jul 8-Jul 8-Jul 8-Jul 8-Jul 8-Jul 8-Jul 8-Jul 8-Jul 8-Jul 8-Jul 8-Jul 8-Jul 8-Jul 8-Jul 8-Jul 8-Jul 8-Jul 8-Jul

ITAC07 ITAC07 ITAC07 ITAC07 ITAC07 ITAC07 ITAC07 ITAC07 ITAC07 ITAC07

20-Nov-08 20-Nov-08 20-Nov-08 20-Nov-08 20-Nov-08 20-Nov-08 20-Nov-08 20-Nov-08 20-Nov-08 20-Nov-08

8-Dec 8-Dec 8-Dec 8-Dec 8-Dec 8-Dec 8-Dec 8-Dec 8-Dec 8-Dec

7-Jul-09 7-Jul-09 7-Jul-09 7-Jul-09 7-Jul-09 7-Jul-09 7-Jul-09 7-Jul-09 7-Jul-09 7-Jul-09

9-Jul 9-Jul 9-Jul 9-Jul 9-Jul 9-Jul 9-Jul 9-Jul 9-Jul 9-Jul